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ABSTRACT 
 
In Western populations the incidence of oesophageal adenocarcinoma (OAC) is increasing 
greater than any other malignant disease. Increasing epidemiological and experimental 
evidence associates iron with OAC. Our understanding of iron physiology has increased 
enormously in recent years due to the elucidation of transport proteins and regulatory 
pathways. Haem scavenging and metabolism remains to be clearly characterised although 
candidate import proteins have been identified. This project aimed to characterise the 
iron transport machinery in the progression of OAC and the effects of iron exposure in-
vitro.  
Overexpression of iron and haem import proteins, with a repression of iron export, was 
identified in the progression of Barrett’s metaplasia to OAC suggesting a role for iron in 
disease progression. Interestingly expression of hepcidin, the hepatic peptide responsible 
for systemic control of iron, was identified in samples of OAC. Culturing OAC cells with 
iron or haem increased cell proliferation, migration and anchorage independent growth. 
These effects were inhibited by the addition of alginate, a naturally occurring chelator. 
Knockdown of LRP-1, the prime haem import candidate, confirmed the role of this 
transporter. 
Understanding the differential expression of these proteins between benign and 
malignant tissue may permit novel therapeutic strategies in the future.  
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CHAPTER 1: INTRODUCTION 
 
1.1 Oesophageal adenocarcinoma  
There are two histological forms of oesophageal cancer – stratified squamous 
carcinoma (SSC) and oesophageal adenocarcinoma (OAC). The incidence of OAC is 
increasing greater than any other malignant disease in Western populations[1] and is 
consequently the focus of intense research into disease aetiology and treatment[2]. 
Unfortunately the diagnosis is often made at a late stage when three quarters of 
patients cannot receive potentially curative treatment[1]. Of the minority that undergo 
surgery the 30 day mortality is 5-10% and less than 30% of this group or 10% of the 
total will survive five years[1] (Fig 1). Morbidity due to surgery is considerable with 
quality of life scores lower than pre-operative scores three years following surgery[3]. 
There have been improvements with overall 5-year survival improved from 3% 30 years 
ago to 10%-15% reported in recent series[4;5]. Advances in adjuvant therapies, in 
combination with potentially curative surgery, partly explain the slight improvement[1]. 
However the vast majority of patients still die from their disease and consequently it is 
of immense importance that the cellular events leading to progression of normal 
oesophageal mucosa to invasive adenocarcinoma are understood. It would be hoped 
that this would lead to novel therapeutic strategies where side effects, complications 
and mortality associated with existing forms of treatment can be avoided. 
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Figure 1. Medium term survival of patients with oesophageal adenocarcinoma (Park J 
R Coll Surg Ed; James IV lecture 2002[6]) 
Surgical resection offers the only chance of cure following a diagnosis of OAC. Patients 
with unresectable disease invariably die within three years of diagnosis although most 
within one year.  
 
 
1.2 Epidemiology 
The incidence of OAC is increasing at a rate greater than other malignant diseases in 
Western populations[7] (fig 2). This trend is a huge concern given the rate of increase, 
the poor prognosis and the lack of understanding behind this increase. The rising 
incidence contrasts with that of SSC which is decreasing in the same populations[8].  
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For the majority of the twentieth century OAC was a rare disease. Between 1926 and 
1976 three large surgical series reported that 0.8-3.7% of oesophageal tumours were 
adenocarcinomas[9-11]. During the last quarter of the twentieth century there was 
approximately a 350% increase in OAC incidence[8]. This contrasts with the experience 
in the Far East where no increase in OAC has been observed and SSC continues to be 
the more common histological type[12]. In Western populations recent publications 
demonstrate that 30-70% of all oesophageal carcinomas are adenocarcinoma (United 
States[13;14], United Kingdom[15] and Switzerland[16]) with white males 
predominantly at risk[17]. The current rise in incidence of OAC is centred on the UK (5–
8.7/100 000), over double that of the USA (3.7/100 0000). There are variations within 
Western populations with large rises in incidence, up to 30% per year, observed in 
West European white men, a rise not mirrored in Eastern Europe[18;19].  
 
Worldwide the incidence of SSC varies considerably and also, to some extent, among 
ethnic groups within a common area. Some of the highest rates occur in northern 
China[20] and northern Iran[21], where incidence exceeds 100 in 100,000 individuals. In 
the U.K. (where the rate is the highest of any Western country), the incidence is less 
than 10 per 100,000. An individual’s racial background appears important as SSC 
predominates in African Americans over Caucasians by a ratio of 6:1, and OAC has the 
opposite preponderance, occurring in Caucasians over African Americans at a ratio of 
4:1[7].  
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Figure 2. Change in the incidence of oesophageal adenocarcinoma relative to other 
malignant diseases (1975–2001) (adapted from Pohl et al. J Natl Cancer Inst 2005[22]).  
Data from the US National Cancer Institute. The baseline was the average incidence 
between 1973 and 1975.  
 
 
1.3 Risk factors for oesophageal tumours and the increasing incidence of oesophageal 
adenocarcinoma 
Tobacco and alcohol, which have a synergistic effect, are very strong risk factors for SSC 
and moderate risk factors for OAC[23]. Tobacco exposure has been linked to a tenfold 
higher risk for SSC in heavy smokers relative to non-smokers with the risk related to the 
duration of exposure[24;25]. In contrast, smoking has been linked to only a two- to 
threefold greater risk for OAC in smokers relative to nonsmokers[8;26]. The relative risk 
of OAC remains high up to 30 years after smoking cessation, however, this contrasts to 
the significant decline in risk of SSC within a decade of smoking cessation[27]. There is a 
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greater than additive effect between smoking and alcohol consumption in SSC whilst 
the effect is additive in for OAC[28]. The exception to this may be the consumption of 
hard liquor, which has been found to have a stronger association with OAC than with 
SSC[29].  
In Linxian, China, SSC is endemic and has been directly related to dietary nitrosamines 
and inversely related to consumption of riboflavin, nicotinic acid, magnesium, and 
zinc[30]. Nitrosamines are highly carcinogenic and are formed from certain food 
preservatives (nitrates and nitrites) widely used in the Far East. In the Western world 
there is less impact from dietary factors due to different food preservation 
techniques[30]. 
 
The most important epidemiological difference between SSC and OAC is the strong 
association between gastro-oesophageal reflux disease (GORD) and OAC[31]. The 
results of a population-based case controlled study suggest that symptomatic GORD is 
a risk factor for OAC[32]. The frequency, severity, and duration of reflux symptoms 
have been positively associated with increased risk of OAC[32-34].  
Long-standing GORD predisposes to Barrett’s metaplasia (BM)[31]. BM has been 
identified as the most significant risk factor for subsequent development of OAC[31].  
 
 
1.4 Barrett’s oesophagus and gastro-oesophageal reflux 
Norman Barrett described the condition that bears his name in 1950 believing the 
oesophagus to be congenitally short[35]. The squamous epithelium of the distal 
oesophagus undergoes metaplastic change to become an intestinal type epithelium 
  
6 
 
with goblet cells. The goblet cells are different from those found in the stomach and on 
histological examination stain differently, allowing differentiation between BM and 
normal gastric epithelia[36]. BM is the most significant risk factor for the development 
of OAC[37] with an individual's relative risk of developing OAC 30 to 120 times greater 
when compared with those without BM[32;38;39]. Dysplasia in BM represents an 
alteration of the epithelium that heralds progression to invasive OAC[40]. 
Although the link between BM and OAC is clear the actual risk to the patient with BM is 
not as dramatic as one might expect: OAC develops in 0.5-1% of patients with BM per 
year[41-43]. A recent meta-analysis of the larger longitudinal studies identified an 
annual risk of 0.5% progression to OAC per year[44]. The authors of this study believe 
that publication bias may artificially elevate cancer risk with small studies being 
published due to the reported, eye catching, high estimates of cancer incidence[44]. 
 
It is likely that the metaplasia that characterises Barrett’s oesophagus occurs in 
response to reflux of bile and acid into the oesophagus[32]. It is estimated that 5-15% 
of patients with GORD will have BM and that patients with long-standing GORD are at 
greatest risk for developing BM[32;45].  
 
Due to the rare nature of OAC there are no prospective cohort studies of reflux 
patients to assess cancer risk. However, three case-control studies have examined 
reflux symptoms as a risk factor for the development of OAC. In Sweden, Lagergren et 
al performed the largest of these studies - a population based case-control study 
examining the relationship between reflux symptoms and OAC[32]. Control subjects 
were age and sex matched by using a national registry. Case and control subjects were 
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questioned about the frequency and severity of any reflux symptoms they experienced 
within the previous five years. After multiple risk factors for cancer were controlled for, 
subjects with OAC were eight times as likely to report at least weekly symptoms of 
reflux or regurgitation than were control subjects (95% confidence interval [CI], 5.3-
11.4). Furthermore, a dose-response relationship existed. If an individual's reflux 
symptoms were long-term (>20 years) and severe (defined by a scale of frequency and 
severity of symptoms) the adjusted odds ratio (OR) for OAC was 43.5 (compared to 
subjects with short term and minor symptoms; 95% CI 18.3-103.5). As recall bias might 
explain the observed association between reflux symptoms and OAC a second group 
with SSC were also studied. No association was found between reflux symptoms and 
SSC risk[32].  
A second study compared 196 patients with OAC from 1986 to 1992 with controls 
matched for age and sex[45]. Medical records were reviewed for a documented history 
of reflux disease, hiatal hernia, oesophagitis, and dysphagia. After relevant risk factors 
were adjusted for, patients with OAC were at least twice as likely as control subjects to 
have documentation of one of these conditions. A third population-based case-control 
study using United States tumour registries studied 293 patients with OAC and 695 
control subjects[46]. This study also demonstrated a dose-response relationship 
between frequency of reflux symptoms and risk of OAC. The adjusted odds ratio (OR) 
for cancer of individuals experiencing at least daily reflux was 5.5 (95% CI, 3.2-9.3).  
Although these studies report eye-catching results for relative risk (RR), it is the 
absolute risk that more accurately describes any individual's chance of getting 
cancer[44]. The most common clinical manifestation of GORD is heartburn; 44% of 
adults in the United States experience heartburn at least once a month. 
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As the number of individuals with reflux symptoms is high and because the incidence of 
OAC is so low, by necessity the absolute risk to the average person with reflux is 
low[44]. In a review of GORD and Barrett’s disease Shaheen et al argues that this 
absolute risk is very low[44]. In the USA 14% of the over 50 population experience 
weekly symptoms of gastroesophageal reflux (approximately 10 million people)[47]. Of 
these 6500 will develop OAC per year and thus the annual cancer rate for patients aged 
over 50 is 0.00065. The cancer risk to any one given individual with reflux, therefore, 
would be very low[44]. 
Whilst the frequency of reflux symptoms relates to the development of OAC, 
conversely, a paucity of symptoms does not indicate lack of risk with many of those 
developing OAC never experiencing severe chronic reflux symptoms. In the study by 
Lagergren et al[32] 40% of those with OAC experienced reflux less frequently than once 
per week prior to development of cancer.  
 
 
1.5 Clinical aspects of the Barrett’s metaplasia – dysplasia – adenocarcinoma 
sequence 
OAC is similar to other intestinal adenocarcinomas in that progression from normal to 
malignant epithelium can be observed through increasingly dysplastic changes with the 
risk of malignant change proportional to the degree of dysplasia[48]. The most 
important predictor of cancer risk in patients with BM is the presence and degree of 
dysplasia. Biopsy specimens are graded as negative, indefinite for dysplasia, low-grade 
dysplasia (LGD), and high-grade dysplasia (HGD)[49]. The progression from BM to OAC 
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is thought to occur stepwise from metaplasia to dysplasia to OAC[50]. However, the 
time for progression through these stages has not been well characterised[48]. 
A low degree of interobserver agreement between pathologists makes the diagnosis of 
LGD difficult to reach, thus studies of the natural history of LGD are highly variable and 
difficult to interpret[33]. A proportion of patients will progress to develop HGD[33]. Up 
to three quarters of patients may have non-dysplastic epithelium upon subsequent 
endoscopy[40;51] reflecting the difficulty in accurately diagnosing LGD. 
The diagnosis of HGD upon histological assessment is more reliable[51]. In addition the 
natural history of HGD is more clear with progression to OAC a significant risk with up 
to one third of patients progressing to OAC within three years[51]. It has been 
identified that subclinical cancers may be present at the time of HGD diagnosis and 
missed by biopsy sampling error[52]. When these prevalent cases are excluded the 
proportion of patients with HGD who progress to OAC is lower. In support of this a 
recent large study of 1099 patients with BM reported a 16% progression from HGD to 
OAC over 7.3 years[52]. Management of patients with HGD is controversial. Some 
authors recommend prophylactic oesophagectomy due to the risk of disease 
progression and metastasis at an early stage[52]. As oeosphagectomy is associated 
with high morbidity and mortality[53;54] investigators have tried to identify subgroups 
of patients with HGD at particular risk. Positive indicators that HGD may rapidly 
progress to OAC include a high proportion of biopsy samples demonstrating 
HGD[51;55], nodular HGD[51],  increased expression of cell cycle regulators such as 
proliferating cell nuclear antigen and Ki-67, abnormalities in the DNA content of 
metaplastic cells, and a loss of tumour suppressor genes such as p53[40;56]. Finally the 
development of less invasive management strategies may render these arguments 
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obsolete. Endoscopic submucosal resection [57] and radiofrequency ablation[58] can 
be curative though long term follow up in these patients is lacking.  
 
1.6 A molecular and genetic basis for the evolution and progression of Barrett’s 
metaplasia to adenocarcinoma 
Accumulating molecular and genetic aberrations underlie the metaplastic change to 
specialised intestinal type epithelium that is characteristic of BM and subsequent 
dysplasia and adenocarcinoma formation. Pertinent aspects of the biochemical basis 
for the progression of BM to OAC are subsequently discussed. These changes are 
summarised diagrammatically (fig 3). 
 
 
Figure 3. Summary of the genetic basis for progression through the Barrett’s 
metaplasia-dysplasia-adenocarcinoma sequence 
LOH - loss of heterozygosity; Rb - retinoblastoma gene; Mdm - murine double minute; 
APC - adenomatous polyposis coli gene; Bcl - B cell lymphoma; VEGF - vascular 
endothelial growth factor; VEGFR - vascular endothelial growth factor receptor; EGF - 
epidermal growth factor; COX - cycloxygenase; iNOS - inducible nitric oxide synthase; k-
ras - Kirsten rat sarcoma  
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1.6.1 Control of the cell cycle and insensitivity to anti-growth signals in the 
progression of Barrett’s metaplsia to oesophageal adenocarcinoma 
Cell cycle progression is regulated by cyclin dependent kinases (CDK’s) which in turn are 
influenced by numerous cell cycle control proteins[59]. A feature common to diverse 
malignant tissue types is the loss of activity of these cell cycle proteins[60]. 
p16. Methylation of the p16 gene represents one of the earliest changes in the 
progression of Barrett’s metaplasia[61]. p16 is a CDK inhibitor and tumour suppressor 
gene. Increased expression of p16 reduces the proliferation of stem cells and acts as a 
protective mechanism against oncogene induced DNA replication providing a barrier to 
malignant progression[62]. p16 gene methylation has been demonstrated in 75% of 
BM[63] and 90% of dysplasia arising within BM[64]. Reid et al. consider p16 loss to be 
integral to the development and progression of BM[65]. It has been suggested that 
Barrett’s cells with p16 loss have a survival advantage and undergo clonal expansion so 
that subsequent Barrett’s mucosa is derived from the same population[65].  
Adenomatous polyposis coli (APC). APC forms a complex with axin and glycogen 
synthase kinase-3β which is essential to the canonical Wnt pathway[66]. Extracellular 
Wnt proteins bind to cell surface receptors intiating intracellular pathways which, via 
the APC-axin-GSK complex, phosphorylates β-catenin resulting in its destruction. Loss 
of APC function, by methylation or mutation of the APC gene, therefore results in 
accumulation of nuclear β-catenin[67]. Downstream effects include increased 
expression of the oncogenes c-myc and cyclin D1[67]. In addition the APC protein binds 
to the ends of microtubules that form the spindle apparatus during chromosome 
segregation and so APC defects may mediate chromosomal instability during 
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metaphase[61;68]. APC loss  occurs early in the metaplasia-dysplasia sequence[69;70] 
by methylation of the promoter region of its gene.  
Cyclin D1. Cyclin D1 regulates the cell cycle by promoting the progression of cells from 
the G1 to S phase by inactivating the retinoblastoma protein[71;72]. The cyclin D1 
proto-oncogene is overexpressed in 46% of Barrett’s cases[73] and is associated with 
an increased risk (6-7 times greater compared to Barrett’s patients without 
overexpression[74]) of progression to OAC.  
Retinoblastoma gene, Rb. The Rb tumour suppressor gene product inhibits cell cycle 
progression and linked to apoptotic pathways mediated via p53[75]. The Rb gene locus 
is aberrant in 36-48%[70;76-78] of OAC and detectable in Barrett’s epithelium[79]. 
p53. The p53 tumour suppressor protein halts cell cycle progression at G1 if a genetic 
abnormality is detected[80-83]. Efforts at repair are made, which if unsuccessful, leads 
to apoptosis[81]. p53 mutations occur in up to 60% of Barrett’s[80], 66% of dysplasia 
and up to 88% of adenocarcinomas[83].  An interesting observation is that p53 loss 
occurs after loss of p16 in almost all cases[84]. A second method of p53 inactivation is 
seen in adenocarcinomas overexpressing murine double minute-2 gene (Mdm2)[85]. 
Mdm2 stabilises wild type p53 inactivating its tumour suppressor function[85].  
P27. p27 is a further tumour suppressor that acts as a CDK inhibitor and thus helps 
control the cell cycle[86]. Repression of p27 is observed in 83% of OAC; in 50% of HGD 
the protein is relocalised to cellular locations where it is inactive[86]. 
K-ras. The K-ras oncogene encodes a highly conserved protein involved in signal 
transduction and promotes cell proliferation[87]; mutations have been detected in 40% 
of high grade dysplasias and 30% of adenocarcinomas[88]. These changes have not 
been detected in metaplastic tissue[89]. 
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1.6.2 Avoidance of apoptosis in the malignant progression of oesophageal 
adenocarcinoma 
Apoptosis or programmed cell death relies upon intact cellular control mechanisms. In 
early G1 p53 triggers a checkpoint halting cell cycle progression; damaged DNA 
undergoes attempts at repair prior to the cell entering S phase[82]. If the cell is 
committed to division p53 triggers programmed cell death[82]. Several other proteins 
controlling the cell cycle are dependent upon p53 or act upon it (fig 4). (The roles of 
MDM2, Cyclin D1 and Rb proteins in Barrett’s and OAC are described above).  
The Bcl2 oncogene inhibits apoptosis[90]. In all cases of LGD it is overexpressed but 
only in 20-40% of HGD cases or OAC suggesting that it plays role in the early 
progression of BM. Presumably OAC cells also avoid apoptosis by other mechanisms 
independent of Bcl2[91]. 
 
Figure 4. The role of p53 in cell cycle control (reproduced from Merola, 2006[82]) 
Passage from G1 to S phases of the cell cycle is controlled by p53. Following detection 
of DNA damage MDM2 inhibition results in accumulation of nuclear p53. 
Phosphorylation of the Rb gene product prevents cells from progressing through the 
restriction point late in G1[82].  
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1.6.3 Cell adhesion and signalling in the malignant progression of oesophageal 
adenocarcinoma 
Local and distant growth of tumours is partly dependent upon the ability to modify 
adhesion between cells, the extracellular matrix and other cells[92]. Cell-cell adhesion 
is maintained by the adherens junction comprising of calcium dependent 
transmembrane glycoproteins termed cadherins[93]. Cadherins are anchored to the 
axin cytoskeleton. Cadherins are important in maintaining cell-cell contact by mediating 
signal transduction and cellular polarity[94]. The function of cadherins is dependent 
upon interaction with catenins[95;96]. Loss of E-cadherin leads to invasive properties of 
cells grown in culture[97] and proposed to be an important contributor of invasion[98] 
in-vivo. There is progressive loss of cadherin expression through the progression of 
Barrett’s metaplasia to invasive OAC[92;99;100].  
Catenins are involved in cell-cell adhesion in conjunction with cadherins. Secondly they 
interact with the APC tumour suppressor gene. As described above (1.6.1) loss of APC 
function results in β-catenin accumulation and nuclear translocation where it acts as a 
transcription factor of growth-promoting genes[98]. These genes, including c-myc and 
cyclin D1, consequently drive cell cycle progression[101].  
The tyrosine kinase SRC has been reported to be overexpressed in BM[102]. This is 
implicated in deregulating cell adhesion[103] potentially by downstream activation of 
c-myc[103]. 
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1.6.4 Growth factors and receptors in the progression of esophageal adenocarcinoma 
Amplification of the epidermal growth factor gene is observed in the majority of 
OAC’s[113;114] and represents a late event being associated with lymph node 
metastasis[115]. The c-erbB-2 gene codes for a transmembrane growth factor 
receptor[104;105] with ligands including Neu-differentiating factor and 
heregulin[106;107]. Overexpression is associated with metastasis in human 
tumours[108]. Amplifications appear in OAC and are late changes in the dysplasia – 
carcinoma sequence[109-111] being associated with a poor prognosis[112].  
 
1.6.5 Immortalisation of cells in the progression of oesophageal adenocarcinoma 
Normal somatic cells have progressive telomere shortening throughout life. In 
immortal cells, such as germ cells, telomerase utilises its own RNA template for the 
addition of sequences to chromosome ends to maintain telomeric length[116]. 
Telomerase re-expression confers immortalisation to cells facilitating accumulation of 
genetic defects[117]. In a study of telomerase expression all OAC and HGD samples 
were strongly positive as were 70% of Barrett’s samples[116].  
 
1.6.6 Other genes involved in the malignant progression of BM to OAC 
Chronic inflammation of the lower oesophagus occurs due to repeated reflux of gastric 
acid and bile[32]. The resultant oxidative stress induces transcription of genes known 
to mediate malignant progression.      
Inducible nitric oxide synthase (iNOS). Overexpression of iNOS is reported in 76% of 
patients with BM and 80% of those with OAC[118]. Nitric oxide is a potent reactive 
oxygen species capable of inducing mutations in DNA[119].  
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COX2. COX2 expression occurs in samples of BM following exposure to bile[120]. 
Downstream effects include expression of the oncogene Bcl2 (above), inhibition of 
immune surveillance and promotion of angiogenesis[120]. Thus COX-2 inhibitors may 
be useful in the treatment of patients with Barrett’s oesophagus[121]. 
In the oesophagus accumulating genetic insults lead to dysplasia and finally a malignant 
epithelium. This is analogous to the colorectal adenoma-carcinoma sequence 
characterised by Fearon and Vogelstein[122]. Comparisons are made in fig5 and table1.   
 
 
 
Figure 5. Key genetic defects in the progression of colorectal and oesophageal tissue 
in the progression of normal epithelium to dysplasia and adenocarcinoma. 
APC - adenomatous polyposis coli gene; DCC - deleted in colorectal carcinoma; k-ras - 
Kirsten rat sarcoma  
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 Frequency % 
Mutation/  
aberration 
Colorectal Oesophageal 
Adenoma Carcinoma BM Dysplasia OAC 
APC/5q loss 27-29 36-56 
0-54 
[79;123] 
0[123]  
55-66 
[79;123] 
APC 
methylation 
59-82 52-60 
36-
85[69;1
24] 
66[69] 
42-
93[69;1
24] 
P53/17p 
loss 
14 71-75 
0 
[79;123] 
38- 
100[79;1
23]  
79-
100[79;
123;125
]  
P53 
mutation 
4-26 71-75 60[126] 
30-
66[83;12
7;128]  
40-
88[83;1
27;128]  
DCC/18q 
loss 
 
11-70 73 41[79]  57[79]  
β-catenin 
 
2-12 1-17 66[92]  60[92] 
k-ras 
 
12-59 35-41 
0-
25[89;1
29] 
25-
40[88;12
9] 
30-
40[88;1
29;130] 
 
 
Table 1: A comparison of genetic abnormalities between reported series of colonic 
adenomas/adenocarcinomas and oesophageal metaplasia, dysplasia and 
adenocarcinoma (colorectal data taken from the review by Leslie et al.[131]) 
 
APC - adenomatous polyposis coli gene; DCC - deleted in colorectal carcinoma; k-ras - 
Kirsten rat sarcoma 
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1.7 The role of dietary agents in the development of Barrett’s metaplasia and 
oesophageal adenocarcinoma 
Dietary habits of patients with BM and OAC have been studied to identify potential 
associations.  Subjects with BM have a higher intake of red meat, fried food and lower 
intake of fruit and vegetables than subjects matched with similar body mass index and 
GORD symptoms[132]. In this study the odds ratio that a ‘Western diet’ (high meat and 
fast food intake) was associated with BM was 2.3 (95% CI 1.26-4.21) whilst in those 
with a ‘health conscious diet’ (high in fruit, vegetables and low in meat) it was 0.35 
(95%CI 0.20-0.64; p<0.001)[132]. Other authors have observed that men and women 
with diets high in red meat have a greater risk of BM and OAC development[132-135]. 
Other studies have reviewed the potential role of antixodants. Dietary 
supplementation with vitamin C and beta carotene has been associated with a reduced 
incidence of BM (OR 0.48, 95%CI 0.26-0.90)[136]. The association of BM and OAC with 
diets low in antioxidants, fruit or vegetables has been made by others[26;137-139]. In 
support of this anti-inflammatory medication is associated with a protective effect 
against the development of BM and OAC. In a large population-based case-control 
study users of aspirin were at decreased risk of OAC (OR 0.37, 95%CI 0.24-0.58)[140]. 
Furthermore, aspirin use correlated with decreased rates of other upper GI 
malignancies (oesophageal squamous carcinoma: OR 0.49, 95%CI 0.28-0.87 and gastric 
adenocarcinoma: OR 0.46, 95%CI 0.31-0.68). Risk was similarly reduced among users of 
non-aspirin NSAIDs[140]. A meta-analysis reviewed 9 studies associating risk of OAC 
with aspirin use, all of which demonstrated a protective association[133;140-146].  
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1.8 The role of iron in oesophageal adenocarcinoma 
The observation that diets high in red meat are associated with the development of BM 
and OAC suggest a potential role for iron in OAC[132;135;136;138]. It has been 
suggested that the substantial increase in dietary iron intake over the past few decades 
mirrors the rise in incidence of oesophageal adenocarcinoma[134]. As GORD 
predisposes to BM and subsequent development of OAC in humans animal models 
have been developed to explore these issues further. There is experimental evidence 
linking iron with reflux and progression to OAC. In a rat model of reflux an oesophago-
duodenal anastomosis mimicks GORD[147]. In initial experiments using this model 
development of OAC was an infrequent event[147]. Furthermore, animals developed 
anaemia. This was corrected by administration of intra-peritoneal iron in subsequent 
experiments. It was then observed that animals receiving supplemental iron had a very 
high incidence of BM and OAC, 91% and 73% respectively, 31 weeks after surgery[148]. 
These animals demonstrated increasing deposition of iron within the lower 
oesophagus, cellular proliferation, hyperplasia and markers of oxidative damage 
(inducible nitric oxide synthase) when compared to animals not receiving supplemental 
iron[148].  
The authors went on to explore the role of iron supplementation in animals with and 
without GORD[149]. Animals were randomly assigned to the following: group A (n=43) 
had oesophagogastric anastomosis as did group B (n=41) with this latter group 
receiving intra-peritoneal iron supplementation; group C (n=10) were non-operated 
controls as were group D (n=10) but this group had intra-peritoneal iron 
supplementation. After 40 weeks the animals were killed and the oesophagus 
inspected. 23 (53%) of the group A animals developed BM compared with 32 (78%) of 
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those in group B. OAC was present in 11 (26%) of group A animals compared with 22 
(54%) of group B animals (all p<0.05). The tumour volume and degree of oesophagitis 
(measured histologically) were also greater in the group B animals. None of the 
controls developed metaplasia, dysplasia or adenocarcinoma. Iron staining of the 
oesophagus was assessed and found to be greatest in the animals with reflux and intra-
peritoneal iron supplementation. Staining was also seen in the other model of reflux, 
group A, but was less obvious and no staining was observed in either control model. 
The authors conclude that iron, in the presence of GORD, was driving oxidative stress 
and thus responsible for the enhanced rate of metaplasia, dysplasia and 
adenocarcinoma[149]. 
 
 
1.9 Oxidative damage and iron in the development of oesophageal adenocarcinoma 
Oxidative damage has been proposed to be closely related to reflux oesophagitis and a 
possible cause for BM[150]. In a study of oesophagitis reactive oxygen species 
increased with the grade of oesophagitis and were the highest in BM[151]. There are 
other sources of evidence to support this. Β-carotene, an anti-oxidant, can prevent and 
even reverse BM[152]. In epidemiological studies intake of β-carotene has been 
inversely associated with risk of OAC[153]. Smoking which is known to stimulate 
production of reactive oxygen species and deplete endogenous antioxidant defence 
mechanisms is associated with OAC[154]. 
In an animal model of reflux Chen et al explored the role of iron, inflammation and 
OAC[155]. Iron staining was found only to be present in areas of inflammation, BM and 
adjacent to tumours of animals that had received supplemental iron[155]. At these 
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sites oxidative damage was observed in lipids, protein and DNA. Immunohistochemistry 
was used to locate cells affected by oxidative damage by using two genes known to be 
expressed following oxidative damage (haem oxygenase 1, HO-1 and metallothionine, 
MT)[155]. Strong expression of HO-1 and MT was observed in both BM and OAC. Chen 
et al suggest that elevated serum iron levels in rats receiving supplemental iron 
allowed, at sites of inflammation via increased capillary permeability, iron to leak into 
tissues[155]. This appears plausible as iron is taken up by macrophages and therefore 
‘carried’ to sites of inflammation and deposited[156]. Chen et al argue this is the 
reason for extracellular iron being detected at sites of inflammation[155]. It was also 
noted that there was increased expression of transferrin receptor in BM, OAC and 
macrophages[155]. These cells are thus importing transferrin bound iron and this may 
present another mechanism of iron-related toxicity[157].  
 
In addition to this murine evidence there is evidence linking iron with OAC in humans. 
In a study of subjects with the iron overload condition hereditary haemochromatosis 
the standardised incidence ratio of OAC was 42.9 (the 95% CI was broad [4.8-154.9] 
due to low numbers of affected adults in the study) [158].  
 
 
1.10 Iron  
Iron is essential for almost all organisms and is the most abundant metal in humans 
with the average adult containing 4g[159]. The reason for this abundance is that iron 
redox chemistry is facile and two way[160] with electron transfer easily accomplished 
between ferric and ferrous iron. This property permits diverse enzymatic reactions: iron 
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containing proteins catalyse key reactions involving energy metabolism, oxygen 
transport and DNA synthesis[160]. Iron plays a key role in the cell cycle where it is 
required by various control mechanisms such as p53, GADD45 and WAF1/p21 and 
without iron cells are unable to proceed from the G1 to S phase[161;162]. 
The highly reactive nature of free iron, paradoxically, makes it a highly toxic compound. 
In the presence of oxidative stress ferrous iron can reduce oxygen to produce 
superoxide with subsequent hydroxyl radical formation (the classically described 
Fenton reaction, fig 6.). This hydroxyl free radical, possibly the most powerful oxidant 
encountered in organisms, can attack nucleic acids, proteins and initiate lipid 
peroxidation[160]. As a result any biological use of iron involves complexing iron with 
protein which allows access to the redox potential of iron but protects cells from free 
radical formation[163].  
 
 
Fe2+ + H2O2 → Fe
3+ + OH• + OH-  
 Fe3+ + H2O2 → Fe
2++ OOH• + HO+ 
 
Figure 6. The Fenton reactions 
In states of oxidative stress Fe2+ ferrous and Fe3+ ferric iron undergo electron transfer 
generating OH• hydroxyl and OOH• peroxide free radicals 
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1.11 Dietary iron  
As iron is utilised by plants and animals it is readily available in the diet. It exists in two 
main forms. Inorganic iron is derived mainly from fruit, cereals and vegetables whilst 
organic iron is derived from meat mainly in the form of haem iron which is released 
following digestion of haemoglobin and myoglobin[163]. Haem (ferrous protoporphyrin 
IX) is a protein complex with a central iron atom surrounded by a porphyrin ring (fig 7.). 
A chronic lack of dietary iron will result in iron deficiency anaemia[163]. The proteins 
involved in the absorption of iron and haem from the gut are demonstrated in fig 8. 
 
 
 
 
 
Figure 7. Haem - ferrous protoporphyrin IX 
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Figure 8. Cellular iron and haem transport proteins in the enterocyte 
Dietary inorganic iron (Fe3+) is reduced by a ferrireductase, duodenal cytochrome b (Dcytb), 
before transport into the enterocyte via the divalent metal transporter 1 (DMT1). Iron as haem 
is imported via the haem carrier protein (HCP) and metabolised by haem oxygenase (HO-1) 
releasing biliverdin, carbon monoxide and iron (Fe2+). Cellular iron can be utilised by the cell, 
stored within ferritin or exported by the basolateral transporter ferroportin. Hephestin, a 
ferrioxidase, oxidises the iron prior to transport throughout the circulation bound to transferrin 
(Fe3+). Transport of intact haem through the enterocyte into the circulation may occur. The 
feline leukaemic virus receptor (FLVCR) and ATP-binding cassette G2 (ABCG2) protein are the 
candidate haem export proteins responsible.  
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1.12 The structure, role and function of the cellular iron transport proteins  
The following is a summary of the cellular and systemic iron transport machinery 
followed by a detailed description of each transport protein. Absorption of iron occurs 
almost entirely within the duodenum[164]. The majority of inorganic iron exists in the 
ferric (Fe3+) state and must be reduced to the ferrous state (Fe2+) before it can be 
absorbed[164]. This is achieved by the enterocyte brush border ferric reductase protein 
duodenal cytochrome B (Dcytb)[164]. Ferrous iron is imported via the divalent metal 
transporter (DMT1)[165]. Iron is then stored within the enterocyte bound to ferritin 
(where subsequent shedding of the cell into the GI lumen will result in loss of the iron) 
or exported through and out of the cell via the basolateral transporter ferroportin, a 
process facilitated by the ferroxidase activity of the ceruloplasmin homologue 
hephaestin[159]. This ferric iron is then free to bind to serum transferrin (Tf) and be 
transported throughout the body in a stable state[160]. Transferrin is secreted by 
hepatocytes and has two iron binding sites, each able to bind one iron atom. Cells 
requiring iron express the transferrin receptor (TfR1 or CD71) which selectively binds 
diferric Tf[160]. The TfR1 is a type 2 180kDa transmembrane glycoprotein consisting of 
two identical monomers joined via disulphide bonds[160]. Each monomer possesses a 
large extracellular C terminal domain with a binding site for Tf, a single pass 
transmembrane domain and a short intracellular N terminal domain[166]. Cell 
membrane expressing the receptor-ligand complexes invaginate to from clathrin 
coated endosomes[166]. Clathrin is removed and the endosome imports protons 
resulting in endosomal acidification; this leads to conformational changes in the Tf and 
TfR1 with iron release[160]. Ferric iron is reduced to the ferrous state via actions of 
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steap3[167], a ferrireductase, and transported out of the endosome via DMT1[165]. 
Iron can be utilised by the cell or stored in an inert form bound to ferritin.  
 
1.12.1 Duodenal cytochrome b (Dcytb) is localised alongside DMT1 on the apical 
membrane of enterocytes and is upregulated in iron deficiency[168]. It acts as a 
ferrireductase reducing Fe3+ to Fe2+ prior to uptake into the enterocyte by 
DMT1[164;165]. This physiological role is debatable. In murine studies of Dcytb silencing 
animals do not become anaemic when fed a normal diet[169]. It is possible that dietary 
factors such as ascorbate are responsible for the reduction of Fe3+ rendering Dcytb non-
essential[169]. 
 
1.12.2 Divalent metal transporter 1 (DMT1) mediates the transport of numerous divalent 
metals (Fe2+, Zn2+, Mn2+, Co2+, Cd2+, Cu2+, Ni2+, Pb2+) though its prime role appears to be 
iron transport[165]. This function was identified in the mk mouse and Belgrade rat which 
have the same DMT1 mutation and both suffer iron deficiency anaemia[159;170]. 
Transcription of the DMT1 gene has four splice variants. The 5′ -end mRNA  variant is 
spliced at two distinct transcription start sites at exon 1A or exon 1B[171;172]. Splice 
variant DMT1A is found within the gastrointestinal epithelium whilst DMT1B is expressed 
within the TfR1 endosome and responsible for the reduction of iron released from 
transferrin[173]. The two splice variants at the 3′ -end affect the UTR; one has an iron 
responsive element (IRE) (DMT1 IRE+ve) the other does not (DMT1 IRE-ve)[174]. The 
relevance is the ability of the transcribed mRNA to be sensitive to intracellular iron 
concentrations (DMT1 IRE+ve) and therefore under control of the IRE/IRP system (see 
below)[172]. 
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1.12.3 Ferritins are highly conserved proteins with close similarity in structure and 
function between bacteria, plants and humans[160]. In humans ferritin is a 
heteropolymer of 24 subunits of H (‘heavy’ or ‘heart’, Mr=21,000) and L (‘light’ or ‘liver’, 
Mr=19,500) chains with a total mass approaching 450,000[160]. Although the ratio of H to 
L chains varies with cell type both are required in all ferritin polymers with knockout of 
the H chain being lethal in utero[175]. In the liver and spleen L chains predominate within 
the polymer whilst in myocardium and skeletal muscle the H type 
predominates[176;177]. Small quantities of ferritin is found within the serum; this is 
increased during times of stress such as inflammation or iron overload[178-180]. 
Ferritin acts as a store for cellular iron and serves to capture and compartmentalise free 
cellular iron[181]. This protects the cell from iron induced stress and subsequent cellular 
damage[182]. Two ferrous iron atoms are taken into the ferritin shell by H chain 
ferroxidase and undergo oxidation[183]. Ferric iron is freed and relocated to the inner 
surface of the ferritin shell probably by the action of the L chains[184]. An individual 
ferritin protein can store up to 4500 iron atoms though in most tissues approximately half 
this is most frequently observed[160]. 
Translational control of ferritin is mediated by the presence of its 5′ –IRE 
structure[185;186]. In the state of low cellular labile iron IRP binds to the 5′ -IRE inhibiting 
mRNA translation[184]. Cellular control of iron through the IRE/IRP system is described in 
section 1.13.   
 
1.12.4 Ferroportin is the major cellular iron export protein and is localised at the 
basolateral membrane of enterocytes[187]. It is also found within the liver, spleen, 
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macrophages, heart and placenta[188]. Ferroportin is a highly conserved protein and is 
essential for survival. Ferroportin knockout is a lethal condition in utero blocking 
placental iron transport[189].  
Ferroportin function is influenced by the systemic iron regulator hepcidin and this is key 
to normal iron homeostasis[190] (below). In high iron states elevated hepcidin binds to 
ferroportin resulting in phosphorylation, internalisation and lysosomal degradation[190]. 
In this way iron export from the gut is inhibited[163;191]. Ferroportin mutations 
demonstrate the role of ferroportin in iron homeostasis. One mutation results in hepcidin 
insensitivity to ferroportin (the autosomal dominant ‘ferroportin disease’, see below for a 
description of the interaction between hepcidin and ferroportin) and mimics classic 
haemochromatosis[192]. Ferroportin remains at the cell surface exporting iron into the 
circulation regardless of the high systemic iron content and hepcidin levels[188]. This 
leads to hepatic and macrophage iron deposition with high serum transferrin 
saturation[188]. A second mutation results in ferroportin being unable to reach the 
basolateral cell surface and thus reduced iron uptake from the gut. This results in a low 
serum transferrin concentration[188]. Ferroportin also contains a 5′ -IRE and is thus 
influenced at the local level by the intracellular labile iron pool and hypoxia[187]. 
Interaction between iron regulatory proteins in a low iron state serves to reduce protein 
synthesis[187]. This observation requires further investigation as interaction between the 
IRP and IRE system is thought to regulate mRNA translation not transcription[187].  
 
1.12.5 Hephaestin is co-localised on the basolateral cell border of enterocytes with 
ferroportin[193;194]. It is a member of the copper oxidase family similar to ceruloplasmin 
and has an iron binding site[195]. The cell location and ability to take part in redox 
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reactions indicate a likely function of oxidising ferrous to ferric iron for transport by 
transferrin. Sex linked anaemia in mice is associated with reduced intestinal iron 
absorption and a mutation of hephaestin[196]. Normal iron uptake into the enterocyte is 
observed but export is inhibited[196].  
 
1.12.6 Transferrin receptor (TfR1). There are two transferrin receptors, TfR1 and TfR2. 
TfR1 is far more abundant and the most studied[160]. It is a type 2 transmembrane 
glycoprotein and a homodimer of two 90,000 kDa subunits joined by disulphide 
bonds[160]. The first 61 amino acids form a cytoplasmic domain followed by a 
hydrophobic sequence which traverse the cell membrane and then the extracellular 
transferrin binding site. The extracellular subunits contain a protease like domain, a β 
sheet and a helical domain[197]. Transferrin binds to the receptor with 2:2 
stoichiometry[198]. TfR2 is found predominantly in the liver. TfR2 mediated uptake of Tf 
is 25 fold less than that by TfR1[199].  
Diferric transferrin binds to TfR1 and is internalised via clathrin-coated pits into 
endosomes by receptor mediated endocytosis[199]. Protons are imported into the 
endosome and as the pH decreases Tf releases iron through conformational 
changes[200;201]. The TfR1 apo-transferrin complex is then recycled and relocated on 
the cell surface[199]. Ferric iron is reduced to ferrous iron by the actions of STEAP3[202] 
and exported out of the endosome via the divalent metal transporter (DMT1B)[170]. 
TfR1 expression is regulated at the post transcriptional level in response to intracellular 
iron levels[199;203]. At the 3′ -UTR TfR1 possesses 5 IRE’s. During levels of low cellular 
iron IRP levels increase; the binding of IRP’s with the 3′ -IRE stabilises the mRNA 
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protecting against degradation[203]. Consequently increased translation of TfR1 mRNA 
results in increased expression of membranous TfR1. 
 
 
1.13 Cellular regulation of iron transport and storage proteins 
Cellular iron is regulated via interaction between iron regulatory proteins 1 and 2 (IRP1, 
IRP2) and iron responsive elements (IRE). IRE’s are RNA elements within mRNAs which 
regulate the expression of pertinent iron transport proteins[204]. They are stem loop 
structures at the 3′ or 5′ untranslated regions (UTR) of multiple genes[204]. The location at 
the 3′ or 5′ end is key to the function of the IRE/IRP system and cellular control[203;205].  
In low iron conditions IRP’s bind to IRE’s[203;205]. This either inhibits translation or 
stabilises the mRNA dependent upon the binding site of the IRP with the IRE. Binding at 
the 3′ UTR stabilises the mRNA increasing protein translation whilst binding at the 5′ UTR 
marks the mRNA for degradation[204] (fig 9).  Genes with 3′ IRE’s include DMT1, TfR1[206] 
and the cell cycle protein CDC14A[207]. Those with a 5′ IRE include ferritin and 
ferroportin[187;208]. The relevant functions of IRP1 and 2 are dependent upon oxygen 
tension with IRP1 functioning in states of oxidative stress[209]. Under normal 
physiological oxygen tensions IPR2 is the dominant protein to bind with IRE’s[210;211]. 
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Figure 9. Cellular control of iron via interaction between IRP’s with IRE’s (reproduced 
from Roualt[204]).  
In low iron states iron regulatory elements (IRE’s) bind with iron regulatory proteins 
(IRP’s). Binding at the 3′ untranslated region (UTR) stabilises TfR1 and DMT1 mRNA 
whilst binding at the 5′ UTR of ferritin and ferroportin mRNA inhibits translation. The 
effect is enhanced iron import with repressed storage and export. Ferritin and TfR1 
mRNA are used as examples. 
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1.14 Systemic regulation of iron 
The elegant control of iron at the cellular level by the IRE/IRP system has only recently 
been understood. This is also the case with the systemic control of iron homeostasis. 
Control of total body iron is essential with deficiency resulting in anaemia and excess in 
iron overload and the risks associated with this[160]. It is only with the identification of 
hepcidin, a 25-amino acid peptide, in 2000[212] that this system has been 
understood[213]. Hepcidin was discovered by chance in a murine knockout 
experiment. Knockout of a nearby gene, USF2, also knocked out hepcidin with mice 
developing severe haemochromatosis[214]. When USF2 was knocked out with sparing 
of the hepcidin gene the mice exhibited a normal phenotype[214]. Humans, 
homozygous for mutations of the hepcidin gene, were then noted to suffer severe 
juvenile haemochromatosis[215]. The role of hepcidin in iron homeostasis became 
more clear when mice overexpressing hepcidin were iron deficient with iron export 
inhibited at the small bowel[216].  
Hepcidin is produced by the liver, circulated in plasma and excreted in urine[212;213]. 
It is secreted as prohepcidin. Following cleavage the mature 25 amino acid β-sheet 
hairpin is stabilised by four disulfide bonds[190]. The mechanism by which total body 
iron influences hepcidin expression is unknown[217]. Hepcidin production is inhibited 
by hypoxia within hepatocytes but stimulated by inflammatory mediators with anaemia 
of chronic disease mediated by chronic hepcidin overexpression[218]. Levels of urinary 
hepcidin are elevated amongst patients with anaemia of chronic disease and correlates 
with the degree of inflammatory burden[219]. Animals undergoing trauma have 
increased levels of hepcidin mRNA within hepatocytes[220]. Infection increases 
hepcidin expression; fish infected with Streptococcus iniae have increased hepcidin 
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mRNA expression, up to 4500 fold greater than normal levels[221]. The effects of 
infection or inflammation upon hepcidin are indirect[218]. Exposure of hepatocytes to 
lipopolysaccharide mildly elevates hepcidin expression but in the presence of 
monocytes this effect is much greater[219]. It has been identified that interleukin 6 is 
the cytokine responsible[219] whilst other inflammatory mediators including 
interleukin 1 and tumour necrosis factor α have no effect. Injection of interleukin 6 into 
human volunteers resulted in an increase of urinary hepcidin (average 7.5 times greater 
than control) within several hours. This was associated with a 30% decrease in serum 
iron and transferrin saturation[219]. 
Hepcidin elegantly controls body iron stores. Hepcidin binds to ferroportin, the sole 
known cellular iron export protein, triggering tyrosine phosphorylation, internalisation 
and lysosomal degradation[222;223]. In this manner hepcidin acts upon the intestine 
sequestering iron within enterocytes and inhibiting absorption of iron from the 
gastrointestinal tract. The enterocytes are then shed into the GI tract and excreted with 
the sequestered iron[190]. Conversely, in states of anaemia and hypoxia, iron import is 
facilitated by suppressing hepcidin. Effects are also seen in the macrophage where the 
release of iron recovered from erythrocyte degradation is inhibited[209;220]. This 
function is likely to relate to inflammatory mediators stimulating iron sequestration 
within macrophages as part of the innate immune system[209;220]. By sequestering 
iron within the reticuloendothelial system during episodes of infection less iron is 
available to pathogens. Hepcidin was originally defined by its antimicrobial properties 
(hepatic bactericidal protein)[218].  
Disorders of hepcidin homeostasis result in hereditary haemochromatosis (HH). There 
are essentially three causes of HH that result in the final common clinical condition of 
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iron overload[163]: [1] A mutation of the hepcidin gene, HAMP, prevents production of 
functional hepcidin[215] [2] mutations of genes which up regulate hepcidin expression 
(haemochromatosis gene[224] [HFE] – most common cause of HH, transferrin receptor 
2[225] [TfR2] and hemojevulin[226] [HJV]) [3] mutations of the ferroportin gene result 
in membranous ferroportin being insensitive to hepcidin thus control over iron import 
is lost[227]. There is great variance in the disease spectrum which is dependent upon 
the underlying cause, hetero and homozygosity and gene penetrance[163].   
 
 
1.15 Absorption, transport and metabolism of haem  
The acquisition, metabolism and recycling of haem has yet to be understood to the 
same degree as inorganic iron. Haem iron is the most bio-available form of iron from 
the gastrointestinal tract and is absorbed with approximately 10 times greater affinity 
than inorganic iron[191]. There is an increasing appreciation of systemic transport and 
uptake of haem from the circulation[228]. Recycling haem iron is essential due to the 
short life span of red blood cells (100-120 days) and the amount of iron within this 
pool. Daily recycling of approximately 20mg of iron from haemoglobin of senescent red 
blood cells is mediated by the action of macrophages[217]. However cellular 
transporters of haem iron have only very recently been characterised.  
Haem iron provides the majority of iron from the GI tract in carnivores and is absorbed 
mainly from the duodenum[229]. The acidic environment of the stomach and upper 
duodenum prevents haem from forming insoluble aggregates[229]. Haem is taken into 
the enterocyte in an energy-dependent manner by the haem carrier protein 1 (HCP-
1)[230]. Transport seems to be dependent upon the presence of the protoporphyrin 
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ring as zinc protoporphyrin (ZnPP), a haem analogue with a central zinc atom, is also 
taken up via HCP-1[230]. Anti-HCP-1 antibodies inhibit radiolabelled haem uptake 
strongly suggesting that HCP-1 has a direct role in intestinal haem absorbtion[230]. 
Within the enterocyte haem is likely to be degraded to release free iron, biliverdin and 
carbon monoxide by the actions of haem oxygenase 1 (HO-1)[231]. The iron atom 
enters the inorganic iron pathways described above being stored within ferritin or 
exported out of the enterocyte via ferroportin. Thus absorption of iron from the GI 
tract sourced from dietary haem remains under the control of hepcidin and ferroportin. 
Expression of HCP-1 mRNA is not affected by iron loading or iron deficiency but is 
positively influenced by hypoxia[230]. Cellular location of HCP-1 is however affected by 
exposure of the enterocyte to iron. Iron deficient mice strongly express HCP-1 at the 
brush border whilst iron replete mice demonstrate mixed membranous and 
cytoplasmic staining for HCP-1[230]. Following administration of oral iron to iron 
deficient rats the location of HCP-1 changes from being strongly membranous to 
cytoplasmic within hours[230]. Haem iron metabolism is linked to the IRE/IRP system. 
IRP2 binds haem with high affinity and when this occurs oxidation of cysteine results in 
conversion to alanine and subsequent marking of the IRP2-heam complex for 
degradation[232]. Thus cellular control of inorganic iron or haem iron are both 
mediated via a single mechanism, the IRE/IRP system[232]. 
 
There remains a final and huge potential source of haem iron: the circulating 
erythrocytes. One fate of senescent erythrocytes is to undergo degradation within the 
liver, spleen and marrow. Via the actions of HO-1 free iron is liberated[230]. Another 
fate of red cells, approximately 10-20%, is to undergo intravascular haemolysis[233]. 
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Circulating haemoglobin can be filtered and excreted via the kidneys[234] but this is 
prevented by binding with the acute phase protein haptoglobin[235]. Haptoglobin 
bound haemoglobin is recovered by hepatocytes[236] and macrophages[237;238]. Free 
haem, as opposed to haemoglobin, is a highly reactive species facilitating oxidative 
damage and has been linked to neurodegenerative disorders[239]. In the circulation 
another acute phase protein, haemopexin, can bind haem. Haemopexin is a 60kDa 
protein with the highest affinity for haem of any protein[240]. There is a functional 
overlap of both haptoglobin and haemopexin indicating the importance of haem 
scavenging[241].  
Fates of extracellular haem and haemoglobin are demonstrated in fig 10. Haem-
haemopexin complexes are taken up via receptor mediated endocytosis. The receptor 
responsible was recently identified by ligand affinity as the CD91 or LDL receptor-
related protein[242] (LRP-1). LRP-1 is a large (600kDa) transmembrane protein 
expressed by a wide variety of cell types including macrophages, hepatocytes and 
neurones[242]. Akin to other members of the LDL receptor group there are five 
structural units to the protein[243]. Over 30 ligands are recognised for the LRP-1 (table 
2) which represent diverse families of proteins including lipoproteins, proteinases, 
proteinase-inhibitor complexes, extracellular matrix proteins, bacterial toxins, viruses 
and various intracellular proteins[243]. 
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Figure 10. Receptor pathways for endocytosis of extracellular haem (Reproduced 
from Hvidberg[242]) 
CD163: macrophage haptoglobin receptor; LRP-1 LDL related protein 
 
Scavenging of haemoglobin and haem in plasma exist to protect against oxidative 
damage. Haptoglobin-haemoglobin complexes are recycled via the hepatic CD163 
receptor whist haemopexin-haem complexes are recycled via the CD91 or LRP-1 
receptor. 
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Ligand 
 
Ligand function 
ApoE 
Lipoprotein lipase 
Hepatic lipase 
Lipoprotein metabolism and transport 
tPA Fibrinolysis, signalling function in brain 
uPA Cell migration, wound healing 
Factors IXa, VIIIa, VIIa/TFP1 Coagulation 
MMP-13 and MMP-9 Angiogenesis and metastasis 
Spingolipid activator protein (SAP)  
Pregnancy zone protein 
α2M 
Pan-proteinase inhibitors, infection 
Complement C3 Infection  
PAI-1 Regulates tPA/uPA activity 
C1 inhibitor Regulates C1r/C1s activity 
Antithrombin III 
TFPI 
Heparin cofactor II 
Regulates clotting 
α1-antitrypsin Regulates neutrophil elastase 
APP Role unclear 
Thrombospondin 1 TGF-β activation, matrix cell 
interactions 
Thrombospondin 2 
Pseudomonas exotoxin A 
Collagen assembly, matrix cell 
interactions 
Lactoferrin Antibacterial 
Rhinovirus  
RAP Chaperone 
HSP-96 Chaperone 
HIV-Tat protein Transcriptional activation 
 
 
Table 2. Diverse ligands for the LDL related protein (LRP-1) 
LRP-1 is a large transmembrane protein expressed by a wide variety of cell types 
including macrophages, hepatocytes and neurones and has numerous diverse ligands. 
Haem bound haemopexin could be added to this list (Reproduced from Herz et al. LRP-
1: a multifunctional scavenger and signalling receptor[243]).  
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1.16 Cellular haem export 
Haem export from maturing erythroid cells occurs via the feline leukaemic virus 
receptor (FLVCR)[244] and presumably functions to protect the cell from the toxic 
effects of excess haem with repression seen during globin production and 
haemoglobinisation[244]. A second haem exporter has been identified as the ATP-
binding cassette G2 protein[245] (ABCG2). It was first identified by its ability to export 
chemotherapeutic agents and hence its alternative name breast cancer resistance 
protein[246] (BCRP). ABCG2 is upregulated during oxidative stress and functions to 
export haem and protoporphyrin presumably protecting the cell from oxidative 
damage[247].  
Expression of both FLVCR and ABCG2 has been identified within the GI tract[248] and 
Caco-2 cells have been shown to efflux haem[249]. This presents a possible mechanism 
of organic iron absorption from the gut and presumably bypasses the action of haem 
oxygenase 1. 
 
 
1.17 The role of iron in cancer 
Cancer cells have a high requirement for iron as it is essential for metabolism including 
energy production, DNA synthesis, cell proliferation and is required for numerous 
enzymes. Iron plays an essential role in cell cycle control and is required by a number of 
proteins that regulate cell cycle progression such as p53, WAF1/p21 and GADD45. In 
the absence of iron cells cannot proceed from G1 to S phase[250]. 
An early observation highlighting the high iron requirements of neoplastic cells was 
that of the elevated levels of TfR1 expression in breast cancer tissue[250]. This has 
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since been observed in many malignant cell types: colorectal[251], glioma[252], non-
Hodgkins lymphoma[253], chronic lymphoid leukaemia[254], adenocarcinoma of the 
lung[255], gynaecological tumours[256], transitional cell carcinomas[257], cervical 
carcinoma[258], melanoma[259], hepatocellular carcinoma[260] and 
hepatoblastoma[261]. Monoclonal antibodies to the TfR1 can block Tf uptake and 
inhibit cancer cell proliferation[262].  
 
Intriguing epidemiological and animal studies strongly suggest iron acts as an initiator 
or promoter of carcinogenesis. Iron dextran intramuscular injections have been 
associated with sarcoma development in rats[263] and years later in humans[264]. A 
review of studies reviewing colorectal cancer risk and dietary iron intake, presented by 
Nelson, demonstrated a positive association in the majority of the 33 studies[265]. 
Variables assessed within the study included dietary intake, iron vitamin 
supplementation and gene studies for HH[265]. A prospective study of 14,407 
Americans over 15 years identified iron intake and a higher Tf saturation to be 
associated with colorectal cancer development[266;267]. The incidence of pre-
malignant colorectal adenomas was greater in individuals with higher serum ferritin 
concentrations[268]. The iron overload condition hereditary haemochromatosis is 
associated with the development of colorectal carcinoma[269;270] (risk in Hfe 
mutation homozygotes: OR 7.7, 95% CI = 1.0-59.9[269]; risk in heterozygotes: RR 1.27, 
95% CI = 1.07-1.53[270]) as well as breast (OR 7.3, 95% CI = 0.8-65.7[269]) and 
hepatocellular tumours (RR 21, 95% CI 16-22[271]) . Accumulating iron levels within 
hepatocytes of HH patients leads to fibrosis, cirrhosis and eventually hepatocellular 
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carcinoma[272]. The risk of developing carcinoma once a patient has cirrhosis is 200 
times greater than controls[273;274].  
Free radical formation in the GI tract is observed following iron supplementation in 
healthy humans[275] and in animal models is associated with biochemical evidence of 
oxidative damage[276] and the development of aberrant crypt foci[277;278]. Patients 
with ulcerative colitis are at increased risk of developing colorectal cancer and 
frequently require dietary iron supplementation to treat chronic anaemia[279]. These 
two observations may not be causal as chronic inflammation is known to predispose to 
cancer risk. However, in mice given dextran sodium sulphate to induce a state similar 
to ulcerative colitis additional dietary supplementation with iron induced significantly 
more cancers than animals fed a normal diet[280;281]. 
Haem intake appears to be associated with an increased incidence of malignant 
diseases. A study of 494,036 elderly Americans identified higher rates of oesophageal 
(HR 1.51, 95% CI 1.09-2.08), colorectal (HR 1.24, 95% CI 1.12-1.36), hepatic (HR 1.61, 
95% CI 1.12-2.31) and pulmonary cancers (HR 1.2, 95% CI 1.1-1.31) in subjects with the 
highest intake of meat versus those with the lowest[282]. In a recent study to explore 
the role of haem in colorectal carcinogenesis Sesink et al fed rats control diet or diet 
supplemented with haem, protoporphyrin IX, ferric citrate or bilirubin[283]. 
Proliferation of colonic epithelium was induced only in the haem group and faecal 
water from these animals was highly toxic to erythrocytes. Interestingly when haem 
was added to the faecal water of the control rats cytotoxicity was not observed 
indicating that dietary haem is modified and becomes toxic in the GI lumen. Haem 
intake is also associated with breast cancer with increased incidence amongst those 
with high intakes of fried[284] and red meat[285]. 
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1.18 Iron chelation as a therapy against cancer 
Understanding the dependence of cancer cells for iron and the differential expression 
of TfR1 between malignant and benign tissues leads to potential therapeutic 
strategies[286-293]. Antisense cDNA to the TfR1 results in decreased TfR1 mRNA 
expression and inhibition of growth in malignant breast cells[294]. Significantly reduced 
effects were also observed in benign cells[294]. Iron chelation has been used in 
numerous cell, animal and some human studies. Desferrioxamine (DFO) is a 
siderophore licensed for use in patients with iron overload secondary to hereditary 
haemochromatosis or multiple blood transfusions, typically, patients with β-
thalassaemia.  DFO forms a complex with Fe3+ in a 1:1 molar ratio. Breast cancer cells 
exposed to DFO exhibit decreased proliferation and increased apoptosis[295;296]. In 
nude mice DFO reduced growth of implanted hepatocellular carcinoma tumours by 
60%[297]. There are several trials of iron chelation in humans: seven of nine children 
with neuroblastoma showed reduced bone marrow infiltration and one reduced 
tumour mass following a five day course of DFO[298]. In a further study of patients 
with unresectable neuroblastoma a complete response to chemotherapy, which 
included DFO, was observed in 3 patients, a partial response in 6 and a minor response 
in 1 patient[299]. Another study of multiple therapeutic agents including DFO, this time 
in patients with inoperable hepatocellular carcinoma, resulted in increased survival 
with decreased tumour burden when compared to five non randomised controls[300]. 
DFO has limitations, it is hydrophilic, must be given parenterally and has poor cell 
membrane permeability. More recent advances included the development of lipophilic 
iron chelators[301]. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) is 
an iron chelator and a potent inhibitor of ribonucleotide reductase, an enzyme 
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required for DNA synthesis[302]. Several phase I and II studies have demonstrated no 
clinical benefit of Triapine in small cohorts of patients with advanced pancreatic 
adenocarcinoma[303], acute myeloid leukaemia[304], non-small-cell lung 
carcinoma[305] and renal cell carcinoma[306]. Methaemoglobinaemia stopped 
treatment of some patients in all studies. It had been suggested that Triapine could 
become the first widely used iron chelator in anticancer therapy[307]. The agent di-2-
pyridylketone-4-4,-dimethyl-3-thisemicarbazone (Dp44mT) has shown promise in-vitro 
and in animal models. It inhibits iron uptake by transferrin and has a higher efficacy 
than DFO[308]. The Dp44mT-Fe complex induces ROS and subsequent apoptosis[308]. 
This effect is independent of p53 status which contrasts with some conventional 
therapeutic agents[293] as defective p53 inhibits cytotoxic mediated apoptosis.  
When compared with 11 other chelators (DFO, Triapine, DOX, PKIH, PKTH, PKBH, 
PKBBH, Dp4aT, Dp4eT, Dp4mT, Dp4pT) Dp44mT was the most active against 28 tumour 
cell lines and significantly more toxic than established cytotoxic agents such as 
doxorubicin[293]. DFO was the least effective with an IC50 that ranged from 3 to >25 
µmol compared to Dp44mT with the lowest IC50 range (0.005 to 0.4 µmol). The average 
IC50 for Dp44mT was 0.03 ± 0.01 µmol and significantly lower than triapine at 1.41 ± 
0.37 µmol. Dp44mT demonstrates selective antitumour activity when compared with 
fibroblasts with an average IC50 of 0.03 ± 0.01 µmol vs. >25 µmol[308]. In a murine lung 
cancer model twice daily Dp44mT reduced tumour size to 47% of control after 5 
days[308] and in a murine melanoma xenograft model daily use for seven weeks 
reduced tumour burden to 7% of control[293]. As mentioned above Dp44mT 
demonstrates activity against cells that have drug resistance to conventional 
chemotherapeutic agents. Resistance with traditional therapy is a marked clinical 
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problem[309]. As well as being effective against tumour cells, regardless of p53 status, 
Dp44mT was equally efficacious against cell line clones resistant and not resistant to 
etoposide and vinblastine[293]. However, concerns exist over the safety of these 
agents. Severe transient myelosuppression was observed in a trial of desferoxamine in 
children with unresectable neuroblastoma[299]. Triapine has also been associated with 
haematological suppression – anaemia, thrombocytopenia, leucopoenia – and met-
haemoglobinaemia[310]. The development of met-haemoglobinaemia and haemolysis 
is severe in patients with glucose-6-dehydrogenase deficiency due to Triapines redox 
activity and the inability of these patients to reduce methaemoglobin to its ferrous 
state[311]. In murine models dose dependent cardiotoxicity was observed. Toxicity was 
manifested as ischaemic fibrosis and likely related to increased deposition of iron 
within myocardial cells[293]. Dp44mT remains to be trialled in humans. 
 
 
1.19 Natural iron chelators 
In 1969 Burtkitt associated intake of dietary fibre with a protective effect against the 
development of colorectal carcinoma[312] which has subsequently been observed by 
other authors[313-317]. Various explanations for this association have been made. The 
most simple is intuitive: increasing colonic fibre and stool bulk reduces transit time and 
therefore limits the duration to which a potential carcinogen would be exposed to 
colorectal mucosa[318]. Fibres have also been demonstrated to bind numerous toxic 
agents within the gastrointestinal tract (dioxins[319], heterocyclic amines[320], 
pentachlorobenzenes[321], binding of bile acids and in particular secondary bile 
acids[266;322-326]).  
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Despite enteric iron being strongly associated with colorectal 
carcinogenesis[266;267;275;277;278] there are few studies that directly look at 
modifying the levels of iron in the GI tract.  
 
1.19.1 Phytic acid. Phytic acid is a major component of cereals and pulses[327] and it 
has been proposed that the ability of seeds to survive hundreds of years is due to the 
ability of phytate to maintain iron in the Fe3+ state obstructing the creation of ROS and 
oxidative damage[328;329]. In a rat model of colorectal adenocarcinoma addition of 
phytic acid to the diet decreased colonic cell proliferation[330]. In those given a 
carcinogen (azoxymethane) tumour burden was significantly decreased with the 
addition of phytic acid[331-333]. Nelson looked specifically at iron induced colorectal 
carcinogenesis in a rat model using 1,2 dimethylhydrazine to induce carcinogenesis. 
Tumour burden was significantly augmented by the addition of oral iron an effect 
which was inhibited by the simultaneous administration of phytic acid[334].  
 
1.19.2 Seaweed and alginate. Another group of organic compounds known to bind 
various metals including heavy metals such as Cadmium2+, Copper2+, Mercury2+ and 
Lead2+ are alginates[335]. Alginates are salts of alginic acid, a component of the cell 
wall of algae of the Phaeophyta division or otherwise known as brown algae[335]. The 
cell wall consists of a fibrillar skeleton and amorphous matrix of alginic acid and 
smaller amount of polysaccharide, fig 11.  
 
1.19.2.1 Seaweed. Epidemiological studies associate seaweed intake with decreased 
incidence of various tumours. High intake of seaweed amongst the Japanese was 
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associated with protective effects against the development of colorectal cancer and a 
relative risk of 0.2 (95%CI 0.0-0.9; p<0.01)[336]. Seaweed intake was associated with 
decreased incidence of oesophageal squamous carcinoma with an odds ratio of 0.42 
(95%CI 0.29-0.6) in a second Japanese study[337]. In a third study intake of seaweed 
was associated with a protective effect against breast cancer[338;339]. In-vitro 
experiments demonstrated a seaweed extract, mekabu, to induce apoptosis in three 
breast cancer cell lines with higher efficacy than conventional therapeutic agents[338]. 
The ability of seaweeds to induce apoptosis has been observed by other authors: 
sensitivity of human malignant lymphoid cells to etopside was augmented two-fold by 
exposure to brown seaweed cell wall whilst  seaweed on its own demonstrated no 
toxic effects[340]. In the gastric carcinoma cell line AGS seaweed extracts induced 
apoptosis and decreased expression of the Bcl-2 proteins and increased the caspase 
cascade[341].  
As the artificial chelators DFO[342] and Dp44mT[308] augment apoptosis in the 
presence of conventional cytotoxic therapy it seems plausible to associate the iron 
binding properties of seaweeds with their anti-tumour effects. 
 
1.19.2.2 Alginates. Brown algae are harvested for a wide range of commercial uses 
which include water holding for frozen food and syrups; gelling agents for instant 
puddings; dessert gels; explosives; emulsifying properties of polishes; stabilising 
properties in ceramics, welding rods and cleaners[335]. Alginate is one of the 
functional ingredients of the over the counter medicine GavisconTM. Alginates are a 
group of linear polysaccharides containing various quantities of 1,4-linked β-D-
mannuronic (M) and α-L-gluronic (G) acid residues arranged in an irregular pattern 
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along the chain[343] (fig 12). The salts with divalent or polyvalent metal ions are 
insoluble[344]. The affinity for divalent metals increases as the G content of the 
alginate increases, this is explained by the ‘zigzag’ structure which accommodates the 
divalent metals. Through dimerisation the chains interconnect promoting gel network 
formation[344]. The greater the linkage and interconnection the greater the viscosity 
of the gel[335]. Sargassum fluitans binds 0.99 mmolFe2+/g alginate[345]. Alginate can 
also bind ferric iron sequestering 66 atoms of Fe3+ per chain[346].  
In the gastrointestinal tract alginate binds iron rendering it unavailable for absorption. 
In a study of ileostomy patients receiving supplemental oral alginate the excreted 
content of iron via the ileostomy was greater than the oral intake at +12µM Fe 
compared to control (no alginate) at -8µM Fe[347].  
The potential role of alginates in the treatment of various human cancers is yet to be 
anywhere near fully explored. Their attraction is increased enormously by the fact that 
they are non toxic, cheap, natural compounds and readily available. 
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Figure 11. The cell wall of brown algae (reproduced from Davis et al 2003[335])  
The alginate contained within the cell wall is responsible for the binding of divalent and 
toxic metals to seaweeds 
 
 
 
 
M = 1,4-linked β-D-mannuronic acid residue; G = α-L-guluronic (G) acid residue 
Figure 12. Alginate polymer (reproduced from Davis et al 2003[335]) 
Alginates bind divalent metals to become insoluble salts. In the gastrointestinal tract 
they sequester iron. Increasing the proportion of α-L-gluronic (G) acid residues 
increases the iron binding potential. 
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1.20 Hypothesis 
 
Increasing evidence associates iron excess with the development of oesophageal 
adenocarcinoma. The expression of iron import and export proteins or haem import 
proteins in normal oesophagus, Barrett’s oesophagus and oesophageal 
adenocarcinoma is unknown. This study hypothesises that expression of iron and haem 
transport proteins becomes modulated in the progression to oesophageal 
adenocarcinoma. Furthermore it is postulated that exposing oesophageal 
adenocarcinoma cells to iron or haem affect proliferation and a malignant phenotype. 
Finally chelating iron with alginates may provide a simple and non toxic way of 
inhibiting iron mediated effects. 
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1.21 Aims 
 
The aims of this study are to: 
 
1. Characterise the expression of iron and haem transport proteins in oesophageal 
adenocarcinoma compared to Barrett’s and normal oesophageal epithelia 
 
 
2. Identify the effects of exposing oesophageal adenocarcinoma cell lines to iron and 
haem-iron 
 
 
3. Identify if the addition of alginate can rescue any iron or haem mediated effects 
 
 
4. Identify the contribution of the main haem import protein LRP-1, the haemopexin 
receptor, to haem import by silencing its expression in oesophageal adenocarcinoma 
cells 
 
  
  
51 
 
CHAPTER 2: MATERIALS AND METHODS 
 
2.1 MATERIALS 
2.1.1 General, Cell Culture and Molecular Biology Reagents 
General, cell culture and molecular biology reagents were obtained from the following 
sources: 
Abcam, Cambridge UK  
Anti CDC-14A (mouse IgG, clone DCS-291) 
Amersham Pharmacia, Amersham, Buckinghamshire  
ECLTM reagent; Hybond PVDF, Hyperfilm x-ray film, RPN800 rainbow ladder  
Applied biosystems, Cheshire  
96 well optical plate, optical adhesive covers, TaqMan ribosomal RNA control reagent 
Appleton Woods, Selly Oak, Birmingham  
10ml and 25ml pipettes  
Boehringer Mannheim, Lewes, East Sussex  
Ampicillin; Mycoplasma detection Kit 
Cambrex Bio Science Wokingham, Ltd  
ViaLight HS kit (ATP assay)  
Chance Propper, Smethwick, West Midlands  
Glass coverslips 
Difco, West Moseley, Surrey  
Bactoagar; Bacto Tryptone; Yeast Extract 
Fisher Scientific, Loughborough, Leicestershire   
BCA protein assay 
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FMC BioPolymer, Drammen, Norway  
LFR 5/60 alginate, batch number 599345 
Frontier Scientific, Logan, UT, USA  
Zinc protoporphyrin 
Geneflow, Southampton  
Acrylamide 
Genus pharmaceuticals, Newbury, Berkshire  
Ciprofloxacin 
Invitrogen, Paisley, Renfrewshire (incorporating Gibco BRL)  
Dulbecco's Modified Eagles Medium (DMEM) with Glutamax-1, pyridoxine and 
4500mg/L glucose; Foetal Calf Serum; Lipofectamine 2000 and Lipofectamine PLUS 
reagents; Normal goat serum; Optimem medium; Penicillin and Streptomysin solution; 
RPMI medium with 25mM Hepes buffer and L-glutamine; Trizol reagent; Trypsin EDTA 
Iwaki, Stone, Staffordshire (Subsidiary of Barloworld scientific) 25, 75 and 150cm2 
tissue culture flasks 
Mayne Pharma  
Desferrioxamine mesilate 500mg 
Pall Corporation, Newquay, Cornwall  
0.2µm filters 
Peptides international, Louisville, Kentucky, USA  
Hepcidin peptide -1 0.1mg/ml 
Promega, Chilworth Research Centre, Southampton 
Dual-Luciferase Reporter Assay System; Nuclease free water; Reverse Transcription 
System 
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Radiolabelled haem55Fe, kind gift Prof. A McKie, London 
Roche Applied Science, Lewes, East Sussex 
BrdU proliferation assay 
Sigma Chemical Company Limited, Poole, Dorset 
Ammonium acetate; ammonium persulphate; aprotinin; -mercaptoethanol; calcium 
chloride; citric acid (tri-sodium citrate); DAB (3,3’-diaminobenzidene 
tetrahydrochloride) tablets; DAPI (4’,6-diaminido-2-phenylindole); deoxynucleotide 
(dNTP) mix; dimethyl formamide; DNAse I; formalin; GenElute mammalian genomic 
DNA kit; glycerol; glycine; N-[2-Hydroxethyl]piperazine-n’-[2-ethanesulfonic acid] 
(HEPES); hydrochloric acid; hydrogen peroxide 30% w/v; hydroquinone (1,4-
Benzenediol); immunofluorescence mounting media; isopropanol; lauryl sulphate; 
lithium chloride; Mayer’s haematoxylin 0.1% solution; methanol; paraformaldehyde; 
polyoxyethylenesorbitan monolaurate (Tween 20); phosphate buffered saline; 
potassium acetate; potassium chloride; proteinase inhibitor cocktail; sodium acetate; 
sodium bicarbonate; sodium bisulfite; sodium carbonate; sodium chloride; sodium 
fluoride; TEMED; trichostatin A; tris hydrochloride; trizma base; Urea; xylene cyanol 
TPP, Switzerland 
6 well plates for tissue culture 
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2.1.2  Antibodies 
2.1.2.1 Primary Antibodies. Primary antibodies, their source, class, positive controls 
and optimum working concentrations are described in table 2.1. 
Target 
Antigen 
Molecular 
weight 
Source and 
clone 
Antibody 
class 
Positive 
control 
Optimum Dilution 
APC C 
terminus 
312Kda Santacruz 137 
Rabbit IgG anti-
human 
RKO CELLS WB: 4µg/ml (1/50)  
Beta- catenin 95kDa 
BD biosciences 
13 
Mouse IgG anti-
human 
 
IF: 10µ/ml 
WB: 1µl/ml (1/1000) 
CDC-14A 67kDa Abcam ab10536 
Mouse IgG anti-
human 
A431 cell 
lysate 
WB: 0.9µg /ml 
(1/2000) 
Cytokeratin 19 45kDa Calbiochem 9656 
Mouse IgG anti-
human 
 
WB: 0.5µg/ml 
(1/2000) 
Dmt1 95kDa Sigma 
Rabbit IgG anti-
human 
Duodenum  
IH: 10µl/ml 
WB: 1µg/ml (1/2000) 
DcytB 30kDa Sigma 834 
Rabbit IgG anti-
human 
Duodenum  
IH: 1/100 
WB: 1µg/ml (1/1000) 
E-cadherin 120kDa 
BD biosciences 
34 
Mouse IgG anti-
human 
 
IH and IF: 1.5 µg/ml  
WB: 0.1 µg/ml 
(1/2000) 
Ferroportin 65kDa Sigma 3566 
Rabbit IgG anti-
human 
Duodenum  
IH: 1/100 
WB: 1µg/ml (1/1000) 
Ferritin 
40kDa dimer, 
20kDa subunit 
Sigma 
Rabbit IgG anti-
human 
Liver 
IH: 1/1000 
WB: 0.5µg/ml 
(1/2000) 
HCP 50kDa 
Kind gift Prof. A 
McKie 
Rabbit IgG anti-
human 
Duodenum  
IH: 1/50 
WB: (1/500) 
Hepcidin-25 32kDa Abcam ab31877 
Rabbit IgG anti-
human 
Liver 
WB: 0.5µg/ml 
(1/1000) 
IH: 1/100 
Hephaestin  161kDa 
Alpha diagnostics 
11-A 
Rabbit IgG anti-
human 
Duodenum  
IH:20µl/ml 
WB: 5µg/ml (1/200) 
LRP1 84kDa Abcam ab694095 
Mouse IgG anti-
human 
Liver 
IH: 1/100; IF: 1/50 
WB: (1/1000) 
TfR-1 
190kDa dimer, 
95kDa subunit 
Zymed 236-
15375 
Mouse IgG anti-
human 
Breast 
cancer 
IH: 1/40 
WB : 0.5 µg/ml 
 
Table 2. 1. Primary antibodies 
(IH= Immunohistochemistry; IF= Immunofluorescence; WB= Western Blotting). 
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2.1.2.2 Secondary Antibodies 
Secondary antibodies were obtained from the following sources, and used at the given 
concentrations for appropriate applications (IF: Immunofluorescence; IH: 
Immunohistochemistry; WB: Western Blotting): 
 
Amersham Pharmacia, Amersham, Buckinghamshire  
Peroxidase conjugated anti-mouse IgG (WB: 1:10,000); Peroxidase conjugated anti-
rabbit IgG (WB: 1:10,000) 
 
Dako, Denmark House, Ely, Cambridgeshire 
Dako REAL™ EnVision™ Detection System, Mouse/Rabbit kit (IH: all components used 
at 1:1000) 
 
  
56 
 
2.1.3 Oligonucleotides 
The following oligonucleotides were used in qRT-PCR reactions (F=Forward, 
R=Reverse).  
 Probe (5’FAM 
3’TAMRA) 
Forward Primer, 5’-3’ Reverse Primer, 5’-3’ 
DMT-1  CTGCATTCTGCCTTAGT
CAAGTCTAGACAGCTAA
ACC 
AGCTGTCATGCCACACA
AC 
GCTTCTCGAACTTCCTGCTT
ATTG 
Ferroportin AGGATTGACCAGTTAAC
CAACATCTTAGCCCC 
AGCAAATATGAATGCC
ACAATACG- 
CAAATGTCATAATCTGGCC
AACAG 
Ferritin H  CCAACGAGGTGGCCGA
ATCTTCCTT 
GGAACATGCTGAGAAA
CTGATGAA 
CATCACAGTCTGGTTTCTTG
ATATCC 
Hephaestin ACA GTG ACA TAG TGG 
CTT CCA GCT TCT TAA 
AGT CTG 
GGAAGAAATGTCATCA
CGAACCA 
TCC CCC TAT CCG GTT CTT 
G 
TFR1 AAA GAC AGC GCT CAA 
AAC TCG GTG ATC ATA 
G 
CGT GAT CAA CAT TTT 
GTT AAG ATT CA 
CCA CAT AAC CCC CAG 
GAT TCT 
Dcytb CCAGGGCATCGCCATCA
TCGT 
CATGGTCACCGGCTTCG
T 
CAGGTCCACGGCAGTCTGT
A 
Hemopexin 
receptor 
CD 91 
TGC CAT TTA CTC AGC 
CCG TTA CGA CG 
TGG ATT GAC GCC GGT 
CAG 
CCC GAA GCA CCT CCA 
TGT 
HCP ATG GGT TGC TTT TCC 
TGT CAT TAG TCA TCA 
CA 
CTA TCA CGC CTC TCA 
TGT TCA CA 
GGA GAG TTT AGC CCG 
GAT GAC 
HO-1 TGA CCC GAG ACG GCT 
TCA AGC TG 
CTG AGT TCA TGA GGA 
ACT TTC AGA AG 
TGG TAC AGG GAG GCC 
ATC AC 
Hepcidin AGCTGCAACCCCAGGA CCCACAACAGACGGGA
CAA 
TCTGGAACATGGGCATCC 
IRP-1 ACTCCTATGGCTCCCGC
CGAGG 
CCTGCCTAACTCCACGA
GAATT 
TGCCATGACGGCGTCAT 
IRP-2 TTTGACAAACAGAGGC
CTTACCCC 
AGGAATAGTGCTGCCG
CTAAGT 
TCGAGCTCCGTAAGAGTTG
AATT 
MYC CAGCACAACTACGCAG
CGCCTCC 
TCAAGAGGTGCCACGT
CTCC 
TCTTGGCAGCAGGATAGTC
CTT 
E-cadherin AAA TTC ACT CTG CCC 
AGG ACG CGG 
GGC GCC ACC TCG AGA 
GA 
TGT CGA CCG GTG CAA 
TCT T 
 
Table 2. 2. Probes and primers used in qRT-PCR reactions 
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2.1.4 Tissue Samples 
Selection of control tissue 
For oesophageal adenocarcinoma the most suitable control tissue was considered to be 
matched Barrett’s epithelium from the same patient. For benign Barrett’s samples 
matched gastric and oesophageal epithelium were used as control tissues. 
 
2.1.4.1 Fresh Material 
Oesophageal cancer resection specimens. Samples (n=24) of oesophageal 
adenocarcinoma matched with normal gastric and oesophageal mucosa from the same 
subject were collected during surgery and stored at -80°C.  
11 of these adenocarcinoma samples had Barrett’s tissue surrounding part or all of the 
adenocarcinoma and sections of the Barrett’s were also stored.  
Normal duodenum, liver and breast carcinoma were used as positive controls where 
appropriate (see Table 2.1 above). 
Biopsy samples. In order to obtain Barrett’s tissue in patients without adenocarcinoma 
biopsies were obtained at endoscopy from patients undergoing endoscopic surveillance 
of Barrett’s epithelium. Samples of Barrett’s mucosa (n = 13) were confirmed on 
histological assessment in all cases.  
 
2.1.4.2 Archived paraffin embedded material  
Paraffin sections of oesophageal adenocarcinoma with associated Barrett’s and normal 
mucosa present in the same section (n=16), Barrett’s with low grade dysplasia (LGD) 
(n=10), Barrett’s with high grade dysplasia (HGD) (n=20), and biopsy specimens of 
Barrett’s with no evidence of dysplasia with normal mucosa in the same section (n=26) 
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were selected for immunohistochemistry. These sections were identified within the 
archived tissue bank, Dept of Pathology, Queen Elizabeth’s Hospital Birmingham and 
processed for our use. Archive material was screened by Dr Phillipe Taniere, consultant 
histopathologist Queen Elizabeth’s Hospital Birmingham, to confirm the samples 
contained the relevant tissue types.  
 
2.1.4.3 Tissue microarray 
76 oesophageal adenocarcinoma samples (from a separate cohort of patients to those 
above; kindly provided by Jonathan Bury, Sheffield) were presented on three slides for 
use in immunohistochemical experiments. These samples were used to evaluate the 
association between iron transporter expression and prognostic factors. The following 
variables were assessed: tumour differentiation (well, moderate, poor as assessed by 
the original reporting consultant pathologist), T stage of the tumour (T1: tumor invades 
lamina propria or submucosa; T2: tumor invades muscularis propria; T3: tumor invades 
adventitia; T4: tumor invades adjacent structures), serosal involvement, number of 
lymph nodes assessed (N0 – no lymph node metastases; N1 – 1 or more resected 
lymph nodes possess metastatic oesophageal adenocarcinoma), the presence of 
Barrett’s metaplasia and vascular invasion. 
To facilitate the screening of multiple tissue blocks from each patient, tissue 
microarrays were prepared containing 3 representative samples of tumour per patient. 
Sections were cut from each array block onto charged slides (Surgipath, UK) and heated 
for 1 hour at 600C followed by processing for immunohistochemistry and scored as 
described below.  
  
  
59 
 
2.1.5 Cell Lines 
The following cell lines were used during the experiments: 
OE21[348]: A human oesophageal squamous carcinoma cell line, also known as 
JROECL21, was established in 1993 from a squamous carcinoma of mid oesophagus of a 
74 year-old male patient. The tumour was identified as pathological stage IIA(UICC) and 
showed moderate differentiation.  
OE33[348]: A human oesophageal adenocarcinoma cell line, also known as JROECL33, 
was established from the adenocarcinoma of the lower oesophagus (Barrett's 
metaplasia) of a 73 year old female patient. The tumour was identified as pathological 
stage IIA (UICC) and showed poor differentiation  
SEG1[349]: A human ‘moderately differentiated oesophageal adenocarcinoma’ (see 
below) cell line 
OE19[348]:  The cell line OE19, also known as JROECL19, was established in 1993 from 
an adenocarcinoma of gastric cardia/oesophageal gastric junction of a 72 year old male 
patient. The tumour was identified as pathological stage III (UICC) and showed 
moderate differentiation. The cell line OE19 expresses HLA-A, -B and -C antigens (MHC 
class I) constitutively. Treatment with interferon-gamma induced the expression of 
ICAM-1 (CD54). Expression of HLA-DR (MHC class II) on interferon-gamma addition was 
only measured in a sub-population of OE19. The cells express epithelial cytokeratins 
and are tumourigenic in nude mice. 
MCF7: A human moderate-well differentiated breast carcinoma cell line. 
THP1: Derived from a paediatric patient with acute monocytic leukaemia. Cells grow in 
suspension and were maintained at 2-9x105 cells/ml. 
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Hep G2: Derived from a 15year old male with well differentiated hepatocellular 
carcinoma.  
 
OE19 and OE33 cell lines were used for experiments as a model of oesophageal 
adenocarcinoma. SEG1 cells were used for the initial 30 months of the project. Towards 
the end of the project it has been identified the line is a lung cancer derived cell 
line[349] despite being widely used in oesophageal adenocarcinoma research. It were 
felt that any data derived using this cell line would be inaccurate and misleading and 
was thus disregarded and removed from data interpretation, analysis and reporting. At 
this point the OE19 cell line was obtained and all previous experiments with SEG1 cells 
repeated. OE21 cells were used in some experiments for interest into the behaviour 
and expression profile of iron transport proteins in a squamous tumour but the data is 
not presented in this body of work. 
MCF7 cells were used as positive controls for TfR1 expression. THP1 cells were used as 
positive controls for in-vitro experiments using hepcidin. HepG2 cells were used as 
positive controls for in-vitro experiments assessing haem transporter expression.  
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2.2 METHODS 
 
2.2.1 Immunostaining of paraffin sections  
2.2.1.1 Immunohistochemistry 
Slide mounted sections were dewaxed by immersion in xylene twice followed by 100% 
ethanol twice, each for five minutes. The slides were placed in a hydrogen 
peroxide/methanol (1:10) mixture for 5 minutes in order to remove endogenous 
peroxidase activity. This was followed by 15 minutes microwave antigen retrieval using 
0.01M Citric acid pH 6.0 (3x5 minutes with topping up of citric acid as required). Cooled 
sections were blocked with normal goat serum (20% v/v with antibody diluent) for 30 
min and then incubated for 1 hr with appropriate primary antibody (above). Following 
extensive washing sections were then incubated with the appropriate peroxidase 
linked secondary antibody and immunoreactivity visualised using diaminobenzidine 
reagent followed by counterstaining with haematoxylin. Sections were then washed in 
tap water, taken through ethanol for 10 minutes and xylene for 10 minutes, then 
mounted in Depex. Controls included: duodenal mucosa as positive control for DMT1, 
DcytB, ferroportin, Hephaestin TfR and HCP, liver for ferritin, LRP1 and hepcidin, and 
omission of primary antibody as a negative control. Where the peptide was available a 
further control existed of antibody-peptide solution, pre mixed and left at room 
temperature for 30 minutes.  
Images were visualised using a Nikon Eclipse E600 microscope and digital image taken 
using a Nikon DXM1200F camera (Surrey, UK). Nikon ACT-1 version 2.62 software was 
used for image acquisition (Surrey, UK). 
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2.2.1.2 DAB-enhanced Perls’ Prussian blue staining of iron 
Paraffin sections were dewaxed, washed in dH20 and incubated in a 1:1 solution of 4% 
(v/v) HCl and 4% (w/v) ferrous cyanate for 30 minutes. Following incubation in PBS for 
5 minutes, sections were incubated in DAB (Diaminobenzidine) Chromogen Solution 
50X (Dako ChemMate)(1:200) for 15 minutes followed by a further incubation for 15 
minutes in DAB (1:50) in substrate buffer (Dako ChemMate). Sections were either 
counterstained with haematoxylin for 30 seconds or processed for 
immunocytochemistry.  
 
2.2.1.3 Immunofluorescence  
 Paraffin sections were dewaxed and dehydrated as in 2.2.1.1 then blocked in PBS with 
5% normal goat serum and 1% bovine serum albumin (BSA) for 20 minutes. Primary 
antibodies were added to sections for 1 hour at room temperature. Sections were 
washed with PBS for 3 x 5 minutes and incubated for 1 hour with FITC or Texas Red 
conjugated secondary antibodies. Sections were washed with PBS (3 x 5 min) and 
nuclei were stained with DAPI (4,6-diaminido-2-phenylindole) at a concentration of 
0.1mg/ml for 1 minute. Sections were washed in PBS (3 x 5 min), allowed to air dry, and 
mounted in immunofluorescence mounting medium (Sigma).  
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2.2.1.4 Evaluation of immunostained sections 
Immunostained material was blindly scored by three independent observers – Keith 
Roberts, Chris Tselepis, Sharon Hughes. Phillipe Taniere, consultant histopathologist at 
Queen Elizabeth Hospital, also evaluated slides to ensure staining was specific and 
occurred at the known cellular location of protein of interest. Staining intensity was 
scored on two factors: [1] a scale of 0 to 3 (0 = absent, 3 = strong) and [2] percentage of 
cells within the microscopic field of view positively stained (0 = no cells, 1 = 1-25%, 2 = 
26-50%, 3 = 51-75%, 4 = 76-100% of cells). These two scores were multiplied to give a 
total score of 0-12 (after Martino et al[350]). 
 
2.2.2 Electrophoresis and western blotting 
2.2.2.1 Sample preparation 
Samples were derived from two sources: frozen tissue samples, and cultured cells. 
Tissue specimens and cell pellets were lysed into radioimmunoprecipitation assay 
(RIPA) buffer (1%NP40, 0.5% sodium deoxycholate, 0.1% SDS) containing a cocktail of 
protease inhibitors (AEBSF [4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride], 
2µg/ml aprotinin, 1µg/ml pepstatin and 10 µg/ml leupeptin). 1% (v/v) β-
mercaptoethanol and 0.001% (v/v) bromophenol blue were added to the samples 
which were then heated to 100oC for 5 minutes.   
 Cell lysates were prepared from cell culture dishes containing a confluent cell 
monlayer by initially washing with phosphate buffered saline then adding 0.5ml ice-
cold RIPA buffer (0.1% (w/v) SDS, 0.5% (w/v) Deoxycholic Acid, 1% NP40, 10µg/ml 
aprotinin; 5 mM EDTA, 150 mM NaCl, 50 mM Tris HCl pH 7.5, 0.2mM PMSF).  Cells were 
scraped into the RIPA buffer and the resultant suspension was aspirated into a 1.5 ml 
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Eppendorf tube. This was rotated on a wheel for 30 minutes at 4 C and then 
centrifuged at 11,000g for 10 minutes. The supernatant was decanted, protein content 
determined by BCA protein assay and again adjusted to 1.5 mg/ml of protein in 
Laemelli sample buffer and boiled for 5 minutes. 
 
2.2.2.2 Protein normalisation   
Protein content was determined by performing a western blot analysis using 10µl of 
each sample. Cytokeratin 19 antibody was used and protein content of each sample 
estimated. Further western blots were produced varying the amount of sample to 
achieve uniform band densitometry. The volume of each sample required to produce 
these bands was recorded and used in subsequent experiments.  
 
2.2.2.3 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
BioRad Protean–II mini-gel apparatus was used and the appropriate percentage 
resolving gel was poured (see Table 2.3 for recipe). The stacking gel was added, combs 
inserted and the wells equilibrated with electrophoresis running buffer (0.192 M 
glycine, 0.01% (w/v) SDS, 25 mM Tris HCl pH 8.3) prior to use. Appropriate volume of 
sample (see above) was loaded into each well, in addition to wide range kaleidoscopic 
pre-stained standards (5µl) to determine protein molecular weights. Electrophoresis 
was carried out at 200V until the dye front had reached the bottom of the gel. 
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Constituent Stacking gel Separating gels 
4% 5% 8% 10% 12.5% 
Water 3.7ml 6.75ml 4.8ml 3.5ml 1.9ml 
Acrylamide 1.3ml 3.25ml 5.2ml 6.5ml 8.1ml 
Buffer 5ml 0.2% SDS; 0.25M 
Tris HCl, pH6.8 
10ml 0.2% SDS; 0.75M Tris HCl, pH 8.8 
Ammonium 
Persulphate 
30mg 30mg 
TEMED 60µl 60µl 
Table 2. 3. SDS-Polyacrylamide Resolving Gel Composition 
 
2.2.2.4 Western Blotting: Transfer of SDS-PAGE gels and protein detection 
Proteins separated by SDS-PAGE were wet transferred directly onto Hybond PVDF 
membranes pre-soaked in methanol for 1 minute. SDS-PAGE gels were initially soaked 
in electrophoresis transfer buffer (48mM Tris HCl; 39mM glycine, 20% (v/v) methanol, 
0.0375% (w/v) SDS) for 5 minutes.  Transfer was performed at 100V for 1 hour, with 
constant cooling from an ice pack within the transfer apparatus.  
 Following transfer, the membrane was blocked for 30 minutes in 10% (w/v) dried 
skimmed milk in Tris-buffered Saline Tween (TBST, 10mM Tris-Cl pH 8.0, 150mM NaCl, 
0.05% Tween-20). This was followed by incubation with the primary antibody for 1-2 
hours (dependent upon antibody optimisation) at room temperature. Membranes 
were then washed in TBST (6 x 5 min), incubated with secondary peroxidase 
conjugated antibody for 30 min at room temperature, then washed again in TBST (6 x 
5min). The membrane was then exposed to ECLTM reagent for 1-240 minutes 
(dependent upon optimisation) prior to visualisation on Kodak X-OMAT AR film, which 
was subsequently developed using an X-OGRAPH X2 automatic developer. 
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2.2.3 Cell Culture 
2.2.3.1 Routine cell culture 
All cell culture procedures were performed in a laminar flow tissue culture cabinet 
using aseptic technique and cells were placed in an incubator at 37 C in a 5% CO2 
atmosphere. Cell lines were grown in Dulbecco's Modified Eagles Medium (DMEM) 
with Glutamax-1, pyridoxine and 4500mg/L glucose supplemented with 10% (v/v) 
Foetal Calf Serum (FCS), 50U/ml penicillin and 50µg/ml streptomycin (OE33, SEG1, 
OE19) or RPMI medium supplemented with FCS, penicillin and streptomycin at the 
same concentrations as in DMEM (OE21, MCF7, THP1). Adherent lines were passaged 
at ~90% confluence by aspirating the culture medium, washing in medium without FCS 
and incubating with 3 ml of 0.05% (w/v) trypsin EDTA until cells had detached. 5 ml of 
culture media was added and cells were disaggregated by trituration and then 
centrifuged at 250g. The cell pellet was either re-suspended in culture media and 
reseeded to typically a 30% confluence or was re-suspended in 1 ml of 10% (v/v) 
dimethyl sulphoxide (DMSO) in FCS and placed in a cryovial for cryopreservation. Vials 
were kept at –70oC for 3 days before transfer to liquid nitrogen storage. Frozen cells 
were recultured by rapid warming of the cryovial in a 37oC waterbath and the cells 
were then washed and suspended in pre-warmed culture media.  Cells were then 
seeded into tissue culture flasks and grown in the standard manner. 
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2.2.3.2 Iron and haem loading of cell lines 
Cells were plated out at 1x105 cells per ml to achieve an initial 50-60% confluence into 
6-well (3ml of medium per well) or 96-well plates (100µl per well) depending upon the 
experiment protocol. Cells were allowed to adhere to the plastic overnight and the next 
day the medium was replaced with fresh medium as follows: 
 
Inorganic Iron: 0.14g iron sulphate was dissolved in 50ml dH2O to give a stock solution 
concentration of 0.01M.  A 100µM solution was used in experiments and thus 1µl of 
stock solution was added to each ml of medium in addition to ascorbate (0.1µl/ml). The 
ascorbate maintains iron in the reduced ferrous Fe2+ form.  
 
Organic Iron stock haem solution (1.5mM) was prepared from 0.02g haem dissolved in 
just enough 0.1M NaOH (typically 0.5ml) and made up to 20ml with dH2O. To achieve a 
50µM solution 3.33 ml of stock haem was added to each 100ml of culture medium.  
 
2.2.3.3 Iron chelation 
Desferroxamine was used at 250µM in normal culture medium.  
 
2.2.3.4 Supplementation with alginate or Gaviscon 
LFR 5/60 alginate was used at a concentration of 1mg/ml. Gaviscon was used at 0.1% 
(v/v). 
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2.2.3.5 Zinc protoporphyrin uptake studies 
Zinc protoporphyrin (ZnPP) is taken into cells via the haem carrier protein 1[351] and is 
used to demonstrate cellular uptake of haem. Under a fluorescent light ZnPP appears 
red. 
A stock 0.3mM solution of ZnPP was produced with 1% ethanolamine (v/v) and 
10 mg/ml of bovine serum albumin. This solution was buffered to pH 7.4 with 1.0M HCl 
and kept in the dark at 4°C. 
Working solutions (20, 5 and 1µM) were made by diluting the stock with uptake 
solution (50mM HEPES, pH 7.4, 130mM NaCl, 10mM KCl, 1mM CaCl2, and 
1mM MgSO4).  
Tissue culture medium was aspirated off cultured cells which were then gently washed 
with uptake solution. All subsequent steps were performed in the dark or in a tissue 
culture hood that was as close to total darkness as practical. The working solution was 
placed on the cells and incubated for varying lengths of time (0.5, 2, 4, 24 hours) at 1, 5 
and 20 µM. Control consisted of uptake solution only. To terminate the uptake process, 
the incubation solution was removed, and the cells were washed three times with ice-
cold 5% bovine serum albumin (w/v) in uptake buffer followed by two more washes 
with uptake buffer. The bovine serum albumin incubation was done to remove surface 
bound ZnPP not internalised by the cells.  
Cells were viewed under green light and images taken via a Zeiss AxioCam 5 attached 
to the microscope and stored using AxioVision V4.5 software. All fluorescence studies 
were performed with identical camera settings and a rhodamine-Texas red filter. All 
cells received the same fluorescence exposure, with each region of the cells being 
exposed to minimal fluorescence excitation only once, to ensure that the images 
  
69 
 
obtained from a given experiment were directly comparable. Control images were 
taken of the same field under normal light. Overlaying the two images demonstrated 
the cellular location of the ZnPP. 
 
2.2.3.6 Radiolabelled haem55Fe uptake 
Haem55Fe was a kind gift from Prof. AT McKie. Stock solution of 1.79mg haem55Fe was 
dissolved in 100µl of methanol:cholorform:acetic acid (89:10:1); (specific activity of 
0.28mCi/mg or 0.5mCi/100µl). 
To maintain haem in a monomeric form and to avoid precipitation a working solution 
was made by a 1/100 dilution into stock haem solution described above. This was 
prepared fresh prior to each experiment. By dilution with culture medium a final 
solution of 50µM haem was used. 
Cells were cultured in the presence of haem55Fe for two hours following which the 
medium was aspirated and 0.5ml added to 4.5ml of scintillant. The adherent cells were 
gently washed with sterile PBS twice with subsequent removal by the addition of 
trypsin. 10% of this solution was kept for a protein assay whilst the remaining 90% was 
centrifuged at 3500g for 5 minutes. The cell pellet was then resuspended in 0.5ml 0.1% 
Triton X which was added to 4.5ml of scintillant.  
 
2.2.3.7 Growth of cells with hepcidin 
Cells were grown in medium with hepcidin at a final concentration of 1µM for 24 hours. 
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2.2.3.8 MTT cell viability assay  
The MTT assay was used to quantify viable cells following a period of tissue culture. 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is based on 
the ability of a mitochondrial dehydrogenase enzyme within viable cells to cleave the 
tetrazolium rings of the pale yellow MTT and form dark blue formazan crystals which 
are largely impermeable to cell membranes. Solubilisation of the cells by the addition 
of a detergent results in the liberation of the crystals which are solubilised. The number 
of surviving cells is directly proportional to the level of the formazan product created. 
The colour is quantified using a colorimetric assay and read on a multiwell scanning 
spectrophotometer (ELISA reader).  
MTT was dissolved in PBS at 5mg/ml and filtered to sterilize and remove any insoluble 
residue present. 20µl of MTT was added to each 100µl well following a defined length 
of tissue culture (i.e. 24 or 48 hours). The plates were then incubated for 4 hours at 37 
oC. Tissue culture media was removed and 80µl of DMSO were added. The plates were 
left for 20 minutes and read on a Molecular Devices VersaMax microplate reader at 
490nm wavelength. 
 
2.2.3.9 BrdU proliferation assay 
During cell proliferation the pyrimidine analogue BrdU (5-bromo-2'-deoxyuridine) is 
incorporated into the cellular DNA in place of thymidine. Following a defined period of 
time allowing cell proliferation (2-24 hours) the cell DNA is denatured to improve the 
accessibility of the BrdU to antibody. Anti-BrdU binds to newly synthesized DNA and 
with the addition of substrate a colour change is observed – the intensity is 
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proportional to the number of cells proliferating. 10 µl of BrdU were added to cells 
cultured in 100 µl of media in a clear 96 well plate. Cells required 2 hours of exposure 
to BrdU. The media/BrdU were removed and 200µl of DNA denaturing solution added 
(100% ethanol) to each well with the plate incubated at room temperature for 30 
minutes. The ethanol was removed, 100µl per well of anti-BrdU solution added and 
incubated for 90 minutes at room temperature. This solution was removed and 3 cycles 
of washing individual wells performed with the washing solution provided. The washing 
solution was replaced with 100µl/well of substrate and the plate incubated at room 
temperature for 5-30 minutes until a colour change was observed. The plates were 
read in a Berthold technologies Centro LB 960 luminometer at a wavelength of 490nm. 
 
2.2.3.10 Ferrozine iron (Fe2+) assay 
Ferrozine assay was used to quantify inorganic iron within cells following tissue culture. 
Adherent cells were mobilised using trypsin and centrifuged at 225g for 5 minutes. 
Trypsin was aspirated off the cell pellet following which 100µl of Hepes buffered saline 
was used to resuspend the cells, 10μl of this solution was removed for protein 
quantification. 200μl of 20% (w/v) trichloroacetic acid in 4% (w/v) sodium 
pyrophosphate was added and the solution kept at 100°C for 10 minutes following 
which each ependorf was centrifuged at 13,000g for 5 minutes. The supernatant was 
removed and kept. The tissue pellet was again resuspended in 100μl of trichloroacetic 
acid sodium pyrophosphate and then kept at 100°C for 10 minutes followed by 
centrifuge at 10,000rpm for 5 minutes. The supernatant was removed and added to the 
previous supernatant. This process was repeated 2 more times. 200μl of the 
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supernatant was removed and added to 100μl of 0.23M sodium ascorbate, 80μl of 
10mM ferrozine and 420μl of 2M sodium acetate. 200µl of this solution was added to a 
clear 96 well plate (each in triplicate). A blank set of 3 x 200µl wells and standard set of 
3 x 200µl wells were used for control purposes. Blank = 200μl of trichloroacetic acid 
sodium pyrophosphate, 100μl of ascorbate, 80μl of ferrozine and 420μl of sodium 
acetate. Standard = 1μl of FeCl3 with 200μl of trichloroacetic acid sodium 
pyrophosphate, 100μl of ascorbate, 80μl of ferrozine and 420μl of sodium acetate. 
Plates were read using Molecular Devices VersaMax microplate reader. 
Protein assay. 10μl of cell suspension was obtained during the preparation of the 
ferrozine assay for protein assessment (see above). This was used to quantify and 
express the results derived from the ferrozine assay as nmol iron/mg protein.  
Standard concentrations of protein (albumin) were prepared according to 
manufacturers instructions using the BCATM protein assay kit (Pierce). These 
concentrations were 0.25, 0.5, 0.75, 1 1.5 and 2 mg/ml along with a blank control. The 
10μl of protein available from cell samples was diluted 1 in 10 to achieve 100μl.  
25μl of each standard and unknown sample were transferred into a microplate well in 
triplicate. 200μl of the working reagent was added to each well and the plate mixed 
thoroughly on a plate shaker for 30 seconds followed by incubation at 37°C for 30 
minutes. After this period the plate was allowed to cool to room temperature following 
which absorbance was read at or near 562 nm on a Molecular Devices VersaMax 
microplate reader. 
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2.2.3.11 Soft agar colony forming assay 
This assesses the anchorage independent ability of single cells to grow. Normal dividing 
cells require contact with neighbouring cells or basement membrane, without this they 
are programmed to undergo apoptosis. Anchorage independent growth correlates 
strongly with tumourigenicity and invasiveness. After preparing a base gel layer cells 
were prepared in a single cell gel suspension following trypsinisation and plated out at 
a concentration of 1x104/ml. To ensure cells are single cells they were passed through a 
50μm cell sieve. The base gel comprised 3.3% agar containing 5ml 2xDMEM, 10ml 
1xDMEM and 2ml foetal calf serum and the superficial gel from 1.8% agar containing 
6.7ml 2xDMEM, 3.6ml 1xDMEM and 1.7ml foetal calf serum. Each regime was 
conducted in 6 well plates.  
The base gel was warmed to 45°C in a water bath. 2ml was plated into each well of a 6 
well plate in a tissue culture hood (carefully to avoid bubbles in the solution). It was 
allowed to set and cool for 30 minutes. The superficial gel was kept warm at 37°C and 
the cells were added. 0.5ml of the superficial gel was placed on top of the base gel.  
The six well plates were kept in a humidified incubator at 37°C for 14 days after which 
colonies are counted. Images were visualised using a Zeiss Axiovert 40 CFL microscope 
and camera with Axiovision Rel. 4.6 imaging software (N=6 for each well, 36 images 
total). Number of colonies and surface area of colonies were recorded using the above 
software. 
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2.2.3.12 Wound healing assay 
When wounded or scratched, cell monolayers respond to the disruption of cell-cell 
contacts with an increased concentration of growth factors at the wound margin by 
healing the wound through a combination of proliferation and migration; these 
processes reflect the behaviour of individual cells as well as the properties of the cell 
sheet as a surrogate tissue. The wound heals in a stereotyped fashion – cells polarize 
toward the wound, initiate protrusion, migrate, and close the wound.  
Cells were cultured on a 6 well plate until 100% confluent. A mark was made along the 
underside of each well (for orientating when measuring the wound size) and a ‘wound’ 
created in each well that crossed the mark. The wound was made using a 100μl pipette 
tip at 45° to the base. The cells were then washed with PBS and control or treatment 
media added. The wound was imaged using Zeiss Axiovert 40 CFL microscope at a 20x 
magnification and digital images recorded (N=12, two images per wound, 6 wells) with 
Axiovision Rel. 4.6 imaging software. The total wound surface was measured (N=12) at 
each time point. Mean wound surface area and SD were thus calculated for each 
experimental regime at each time point. The 6 well plates were replaced in the 
incubator and every subsequent 12 hours the wounds were photographed using the 
marks on each well to ensure the same part of the wound was being imaged. 
Measurement continued until the wound had healed. 
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2.2.4.1 Cell Transfection 
Transient (48-72 hours) cell transfection was undertaken. This was carried out using 
lipofectamine PLUS reagents, a liposomal delivery system. Optimum number of cells 
seeded and plasmid DNA:lipofectamine:PLUS ratios for highest transfection efficiencies 
had previously been ascertained by workers in the lab for the cell lines used (J Boult, 
personal communication). 5 x 105 cells were trypsinised and plated into a 6-well dish 
and incubated overnight, such that they reached confluence of ~90%. Optimised 
quantities of plasmid DNA (2µg OE33, 4µg OE19) were diluted in 100µl of Optimem 
medium with PLUS reagent (8µl OE33, 16µl OE19). Lipofectamine (12µl OE33, 16µl 
OE19) was then diluted in 100µl Optimem and incubated at room temperature for 15 
minutes. Both aliquots of Optimem were then combined, incubated at room 
temperature for 15 minutes and then added dropwise to wells containing cells (media 
removed, cells washed with PBS and 800µl Optimem added), with constant agitation.  
 
2.2.4.2 Plasmid Preparation 
 Plasmids for transfection were grown in transformed E. Coli in Luria-Bertani (LB) 
medium (1% (w/v) Tryptone Peptone, 0.5% (w/v) Yeast Extract, 1% (w/v) NaCl) 
supplemented with ampicillin (50µg/ml)). Plasmids were stored in sterile glycerol (1:1 
ratio) at –70oC. Two culture sizes were grown for the purposes of the experiments 
outlined: (a) Cultures for ‘mini’ preps consisting of 10µl of glycerol plasmid stock in 5ml 
LB medium. (b) Cultures for ‘maxi’ preps consisting of 100µl of glycerol plasmid stock in 
50ml LB medium. Both culture types were grown by shaking at 18g in a 37oC incubator 
overnight. Purification of DNA from both ‘mini’ and ‘maxi preps was achieved using an 
alkaline lysis method. 
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2.2.4.2.1 ‘Maxi’ plasmid preparations 
 This purification method was used to produce large volumes of high purity plasmid for 
transfection purposes. After overnight culture bacteria were pelleted by centrifugation 
at 1,500g for 10 min at 4 C then resuspended in 4 ml GET buffer (50 mM glucose, 10 
mM EDTA, 25 mM Tris HCl, pH 8) and incubated on ice for 5min. Cells were lysed by 
vigorous mixing with 8 ml 0.2M NaOH, 1% SDS then left on ice for 5 min, followed by 
the addition of 30% (w/v) potassium acetate in 11.5% (v/v) acetic acid, vortexing and 
leaving on ice for 10min. Bacterial cell debris was removed by centrifugation at 1,500g 
for 15 min at 4 C with the supernatant being filtered through a 0.45 µm filter. DNA was 
precipitated by the addition of 17ml isopropanol and chilling at –70oC for 15 minutes. 
DNA was then pelleted by centrifugation at 1,500g for 15 minutes. The supernatant 
was discarded and excess fluid removed by desiccation. The pellet was resuspended in 
2 ml TE (0.1 mM EDTA, 10 mM Tris HCl, pH 7.5) buffer following which 2.5ml of 4.4M 
LiCl was added to precipitate DNA. This was incubated at 4 C for 1 hour and then 
centrifuged at 1,500g for 10 minutes. The supernatant was incubated with 20ml of 
ethanol at 4 C for 10 minutes and again centrifuged 1,500g for 10 minutes. The pellet 
was washed in 70% ethanol and allowed to air dry before resuspending in 1.5ml TE. 
100µg of RNAse A, preheated to 37 C, was added. After incubation at 37 C for 15 
minutes, 20µl of 10% SDS was added and the solution heated to 70 C for 10 minutes. 
An equal volume of phenol was added, vortexed and centrifuged at 2,000g for 1 
minute. The upper aqueous layer containing DNA was aspirated and an equal volume 
of chloroform were added, vortexed and centrifuged at 2,000g for 1 minute. The upper 
aqueous layer was aspirated and two further phenol-chloroform extractions were 
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performed. Sodium acetate (10% of the volume of DNA) and ethanol (2.5x total volume 
of DNA plus sodium acetate) were added to precipitate DNA, which was pelleted by 
centrifugation at 8,500g. The DNA pellet was washed with 70% ethanol, allowed to air 
dry and then resuspended in nuclease free water.   
 
2.2.4.2.2 ‘Mini’ plasmid preparations 
 This purification method was used to produce small volumes of low purity plasmid for 
the purpose of restriction digest analysis of colonies derived from DNA sub-cloning, and 
is an abbreviated version of the protocol for ‘maxi’ preps (all solutions used are of the 
same composition as those used in 2.2.4.2.1).  1.5ml of an overnight culture was 
centrifuged at 1,500g for 1 minute, then resuspended in 100µl GET buffer and 
incubated on ice for 5 minutes. Bacteria were lysed by shaking in 200µl NaOH/SDS for 5 
minutes then vortexed in 150µl potassium acetate and placed on ice for 5 minutes. 
Bacterial debris were pelleted by centrifugation at 1300rpm for 5minutes at 4oC, then 
to the supernatant a phenol and chloroform extraction was performed as described in 
2.2.4.2.1. 2 volumes of ethanol were added to precipitate DNA and the solution left to 
stand at room temp for 5 minutes. DNA was precipitated by centrifugation at 8,500g 
for 5 minutes, washed with 70% ethanol, allowed to air dry and then resuspended in 
50µl nuclease free water containing RNAse A (20µg/ml). 10µl of resuspended DNA was 
used in each restriction, see 2.2.4.2.1. 
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2.2.4.3 Reporter plasmid transfections 
OE19 and OE33 cells were optimised for transfection with lipofectamine PLUS as 
described above. The day following the transfection solution was removed by 
aspiration, and cells were either processed for reporter assay, or further stimulated 
with the appropriate media. Those cells which were further stimulated were cultured 
for a further 24 hours at 37°C with 1ml of stimulant media before extraction for the 
reporter assay.  
 
 
Plasmid construct Plasmid origin 
Reporter plasmids  
pGL3/TOP Dr Shiva Akbarzadeh, University of Birmingham, UK 
pGL3/FOP Dr Shiva Akbarzadeh, University of Birmingham, UK 
Other plasmids  
pCDNA3/β-catenin-S37A Dr Chris Tselepis 
pCDNA3 Dr Jessica Boult, University of Birmingham, UK 
 
Table 2. 4. Plasmids used during transfection and their origin 
 
2.2.4.4 Measurement of promoter activity  
 The vector pGL3basic has a firefly Luciferase cDNA located downstream of a multiple 
cloning site. Promoter activity from the vectors (pGL3/TOP, pGL3/FOP or empty 
vectors) can be inferred by measuring firefly luciferase activity. Co-transfecting the 
vector pRLTK, in which a renilla luciferase cDNA is located downstream of a 
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constitutively active herpes simplex virus-thymidine kinase promoter, and measuring 
renilla luciferase activity in the same wells of cells that firefly luciferase is measured, 
allows normalisation of firefly luciferase activity for transfection efficiency. The dual-
luciferase reporter activity system, in which firefly and renilla luciferase activities were 
sequentially measured, was used to analyse promoter activity of pGL3/TOP. Cells 
grown in 24-well plates were transfected as described above. Growth medium was 
removed, and cells were washed with 500μl of sterile PBS. The PBS was then aspirated 
and 100µl of passive lysis buffer (PLB) were added to the cells, then the cells were 
gentle shaken for 30 minutes. The suspension was aspirated and pipetted several times 
to obtain a homogenous solution. 20μl of these lysed cells were then added in triplicate 
into an opaque white 96-well plate. 100μl of luciferase assay reagent II were added to 
each well, and then mixed for 10 seconds by shaking. The luminescence was then 
measured for 10 seconds on a Wallac Victor 2 1420 multilabel counter, the final value 
representing relative luciferase activity (RLU) of the firefly luciferase. 100µl of Stop and 
Glo® reagent were added to each well and mixed for 10 seconds by shaking before the 
luminescence of renilla luciferase was measured for 10 seconds, the final value 
representing the RLU of the renilla luciferase. The RLU of firefly luciferase was then 
normalised to the RLU of the renilla luciferase to give a relative reporter activity value 
for each well. These could then be compared to control and a normalised RLU 
expressed as a percentage of this. 
 
2.2.5 RNA interference 
RNA interference (RNAi) is a technique of inhibiting gene function by inhibiting the 
translation of target mRNA. Short hairpin RNAs (shRNAs) are a method of RNAi where 
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the antisense nucleotide to the mRNA of interest is transcribed and, due to the 
construct design, a hairpin is created. The cell recognises this double strand RNA 
(dsRNA) as potential viral dsRNA. The shRNA is cleaved by the action of RNA-induced 
silencing complex (RISC) and the endonuclease DICER into short (20-25 base pair) 
dsRNA sequences. The anti guide strand is degraded leaving an antisense RNA 
sequence bound to the RISC complex which is free to bind to its complementary mRNA. 
This combination results in destruction of the complex or directly blocks the 
transcription of the related protein.  
 
2.2.5.1 Lentiviral cell transfection 
This technique uses a viral vector to overcome transfection resistance associated with 
conventional reagents. The transfection efficiency of OE33 cells never exceeded 1% of 
the cell population despite using several reagents (lipofectamine 2000, lipofectamine- 
plus, fugene, turbofect). As a consequence a GIPZ lentiviral vector was used to insert 
shRNA into the OE33 cell genome. There are several important aspects to using the 
viral vector: once incorporated into the genome of interest the viral genome cannot 
replicate; vectors other than for the shRNA of interest are included in the genome such 
as for green fluorescent protein, antibiotic resistance to help create a stable cell line 
and elements that enhance the stability and translation of transcripts. 
 
2.2.5.2 LRP-1 Knockdown 
LRP-1 knockdown was finally achieved by transfecting short hairpin RNA (shRNA) 
encoding bacterial plasmids into OE19 cells. shRNA consists of sense and anti-sense 
strands separated by a spacer region, and encodes a small portion of the mRNA of 
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interest, in this case LRP-1. These shRNA are cleaved cytoplasmically by the enzyme 
RNAase III Dicer to give double stranded short interfering RNA (siRNA), 21-23 
nucleotides in length. This siRNA is then incorporated into RNAi-induced silencing 
complex (RISC) which mediates cleavage of mRNA bearing the same 21 nucleotide 
sequence as the guide siRNA. Thus there is repression of the protein expression due to 
post-transcriptional mRNA destruction. This reduced protein expression occurs stably 
as the shRNA encoding plasmid is retained within the cell and so shRNA production is 
maintained. Plasmids encoding three different shRNAs were used (Open Biosystems, 
UK): one encoded a non-silencing shRNA to act as a control while the other two 
encoded shRNAs corresponded to different sections of the LRP-1 (table 2.5) and should 
thus promote LRP-1 knockdown.  
 
  Sequence 
Catalog 
No. Function Sense Anti-Sense Loop 
RHS4346 Non-
Silencing 
Not disclosed but verified to produce siRNA with no match 
in mammalian genome 
RHS4430-
98513013 
LRP-1 
Silencing 
ACC CGC GAG 
GAC TAC ATT 
GAA T 
ATT CAA TGT 
AGT CCT CGC 
GGG C 
TAG TGA AGC 
CAC AGA TGT A 
RHS4430-
98841553 
LRP-1 
Silencing 
AGG CCT GAC 
TGT GTT TGA 
GAA T 
ATT CTC AAA 
CAC AGT CAG 
GCC G 
TAG TGA AGC 
CAC AGA TGT A 
 
Table 2. 5.  Sense, anti-sense and loop sequences for shRNA used for LRP-1 
knockdown. 
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2.2.5.4 Preparation of shRNA encoding plasmids 
Plasmids were supplied in E.Coli bacteria which were amplified by initial culture on agar 
with 100µg/ml ampicillin as plasmids encoded ampicillin resistance. After overnight 
culture at 37°C one colony for each plasmid was transferred to 3ml LB broth for 8hr 
pre-culture at 37°C before transfer to 500ml LB broth (5g tryptone, 2.5g NaCl and 2.5g 
yeast extract in 500ml distilled water). Having thus amplified the cells, plasmids were 
extracted and purified using PureLink HiPure Plasmid Filter Purification Kit (Invitrogen, 
UK) as per instructions and using supplied solutions. Briefly, cultures in LB broth were 
spun at 4000g for 10 minute and supernatant discarded with pellet re-suspended in 
20ml supplied resuspension buffer and transferred to 50ml centrifuge tube. 20ml of 
lysis buffer was added and cells were mixed and incubated at room temperature for 5 
minutes. 20ml precipitation buffer was then added and mixed by inversion. The 
solution was passed through a maxi column with filtration cartridge and allowed to 
flow through by gravity until flow stopped. Columns were then rinsed with 10ml wash 
buffer and the filtration cartridge removed and discarded. The column was washed 
with 60ml wash buffer which flowed through by gravity. All flow through solutions 
were discarded and 15ml elution buffer were added to columns and allowed to flow by 
gravity collecting purified plasmids. To this 10.5ml Isopropanol was added and mixed 
by inversion. Tubes were centrifuged at 15000g for 30 minutes and supernatant 
discarded. The pellet was re-suspended in 70% ethanol before being re-spun at 15000g 
for 5 minutes with the supernatant discarded and the pellet air dried at room 
temperature for 20 minutes.  The DNA pellet was then re-suspended in 500µl TE Buffer 
(0.1mM EDTA in 10mM Tris-HCl, pH 8). 
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2.2.5.5 Verification of purified plasmids 
To ensure that purified DNA was that from the plasmids encoding the target shRNA, a 
restriction enzyme digest was carried out. DNA was diluted to 1µg/µl and 1µl was 
added to 1µl Sal-1 restriction enzyme, 2µl enzyme buffer and 16µl nuclease free water. 
This was incubated at 37°C for 1 hr then labelled using bromophenol blue. 
Electrophoresis at 50V for 1.5 hours was performed using a 0.7% agarose gel (700mg 
agarose, 100ml TAE buffer (80mM Tris, 1M Acetic acid, 1mM EDTA)) with ethidium 
bromide in TAE buffer.  The gel was visualised using a GeneFlash UV Transilluminator 
(Syngene Bioimaging, UK). Using highranger and clonesizer DNA Ladders (Norgen 
Biotek, Canada) bands were seen at 5124bp, 4298bp and 2188bp for all three plasmids 
(figure 2.2) confirming these as being the shRNA encoding plasmids. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. 1. Electrophoresis of plasmid digestion.  
Lane A = Highranger ladder, Lane B = Control Plasmid, Lane D = C8 shRNA encoding 
plasmid, Lane F = H2 shRNA encoding plasmid. Bands labelled 1, 2 and 3 correspond to 
5124bp, 4298bp and 2188bp of ladder. (White arrow indicates direction of flow, lanes 
C, E and G were undigested plasmids.) 
A      B      C      D      E      F      G 
1 
2 
3 
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2.2.5.6 Transfection of shRNA encoding plasmids 
OE19 cells for transfection were plated in 500µl of antibiotic free DMEM with 10% FCS 
in 12 well plates at a confluence of 20%. These were then incubated at 37°C overnight 
to achieve 40% confluence, a cell density shown by optimisation to give best 
transfection efficiency. The shRNA encoding plasmids were then transfected into the 
cells using Lipofectamine Plus transfection system (Invitrogen, UK) as described above. 
Transfection efficiency was measured by microscopy of cells under blue light with 
transfected cells fluorescing green due to GFP expression. 
 
2.2.5.7 Cell sorting of cells transfected with shRNA encoding plasmids 
OE19 cells transfected with a low efficiency. To increase the proportion of transfected 
cells they  were passed through a cell sorter [FACSVantage SE (Becton Dickinson, CA, 
USA) fitted with a 100 µm nozzle and using 488 nm laser light from an Enterprise II 
laser (Coherent, Santa Clara, CA, USA) for sample excitation]. FACSFlow (Becton 
Dickinson, CA, USA) was used as sheath fluid. Fluidic conditions were as follows; sheath 
pressure 8 PSI, sample differential pressure 0.8 PSI, giving a sample data rate of 500 
events/second. Forward scattered laser light (FS) was collected through a 488/10 nm 
bandpass filter and neutral density filter. Side scattered laser light was collected 
through a 488/10 nm bandpass filter. Green fluorescence light (FL1) (GFP) was 
collected through a 530/30 nm bandpass filter CellQuest v 3.3 (Becton Dickinson, CA, 
USA) and was used for data acquisition, data analysis and to control the populations 
which were sorted. The population to be sorted was described by a sequential gating 
strategy. First single cells were defined by a single polygonal gate on a 2 dimensional 
dot plot of FS height (linear) v SS height (log). A second gate on a 1 dimensional 
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histogram of FL1 height (log) (GFP) was set so that the most fluorescent 5% 
(approximately) of the single cell population was defined as "GFP high". This is the 
population which was sorted and kept. The process was carried out under sterile 
conditions and the cells were reseeded into 24 well plates with 1ml of culture media. 
Cells were then left for 24hours before experiments were initiated. 
 
2.2.6 Immunofluorescence on cultured cells 
2.2.6.1 Preparation of cells for immunofluorescence 
5 x 105 cells were seeded in their normal growth medium into tissue culture plates (24 
well) or onto glass coverslips placed in a 6-well tissue culture dish. Coverslips had been 
sterilised by immersion in ethanol and then allowed to air dry immediately before use. 
When cells had reached confluence cell culture medium in the well was aspirated and 
cells were washed with PBS x 2 at room temperature. Cells were fixed in 2ml ice-cold 
methanol:acetone (1:1) at 4oC for 20 minutes. Coverslips were then removed from 
wells and immunofluorescent analysis, as detailed below, was performed on cells.  
 
2.2.6.2 Immunofluorescence protocol 
Fixed coverslips were blocked in PBS containing 10% (v/v) goat serum and 1% (v/v) BSA 
for 30 minutes at room temperature. Coverslips were then incubated with primary 
antibody in PBS containing 1% BSA (PBS/BSA) for 1 hour at room temperature, then 
washed in PBS/BSA (3 x 5min) and incubated in FITC or Texas Red conjugated 
secondary antibody in PBS/BSA for 30 min at room temperature. Coverslips were then 
washed in PBS/BSA (3 x 5min), allowed to air dry, mounted in immunofluorescence 
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mounting medium and visualised on an Zeiss Axiovert 40 CFL microscope camera and 
images were captured with Axiovision Rel. 4.6 imaging software.  
2.2.7 DNA extraction  
2.2.7.1 Genomic DNA extraction from cells 
 Cells were cultured in 6-well dishes in normal or treatment growth medium. Following 
completion of the experiment culture medium was aspirated and the cells gently 
washed with PBS. This was removed and replaced with 1ml of lysis buffer (100mM 
NaCl, 10mM Tris-hydrochloride at pH 7.5, 5mM EDTA at pH 8, 0.5% sodium dodecyl 
sulphate (SDS) made up with distilled water. Just prior to lysis 1mg/ml of Proteinase K 
was added) for 60 minutes at 37 oC. 70µl of sodium acetate at pH 5.5 were added; the 
solution mixed, followed by the addition of 0.5ml phenol. This mixture was shaken and 
then centrifuged at 13,000g for 1minute. The upper aqueous layer was retained and 
0.5ml phenol added; the solution shaken and centrifuged again. The upper layer was 
removed and added to 0.5ml of chloroform; the solution shaken and centrifuged. The 
upper layer was again retained and added to two times its volume of absolute ethanol. 
This mixture was shaken to precipitate DNA. It was kept at -20oC for 30 minutes and 
shaken again before being centrifuged at 13,000g for 10 minutes. The liquid was 
removed leaving the pellet which was gently washed with 70% ethanol. The pellet was 
finally air dried before being dissolved in 10µl of nuclease free water. 
 
2.2.8 RNA extraction from frozen tissue and cells  
2.2.8.1 RNA extraction from frozen tissue 
 RNA was extracted from samples of (a) oesophageal adenocarcinoma with matched 
gastric and squamous oesophagus mucosa (n=24) and associated Barretts (n=11) and 
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(b) Barretts biopsy tissue (n=26) with matched gastric control (n=13). Tissue was 
thawed on ice and homogenised in 0.75ml Trizol using a PolyTurrax homogeniser on 
ice. Samples were incubated for 5 min at room temperature to allow complete 
dissociation of nucleoprotein complexes. 0.1ml of chloroform was added and the tube 
vortexed for 15 seconds, then incubated at room temperature for 15 min. Samples 
were then centrifuged at 12,000g for 15 min at 4oC, and the upper aqueous phase 
harvested. RNA was precipitated by addition of 0.25ml isopropanol and incubation for 
10 min at room temperature. RNA was pelleted by centrifugation at 12,000g at 4oC for 
10 min, washed with 75% ethanol (which was subsequently allowed to evaporate) and 
resuspended in 10µl nuclease free water. Optical Density of the resuspended RNA was 
measured at 260nm on a spectrophotometer and the concentration of RNA calculated 
using the equation 1 OD unit = 40µg/ml RNA. RNA was stored at -80 oC. 
 
2.2.8.2 RNA extraction from cells 
 Cells were cultured in 6 well plates as per experimental protocol. At the end of the 
experiment medium was aspirated and cells were washed twice with filter sterilised 
PBS. 0.5ml Trizol reagent were added to cells and left at room temperature for 10 
minutes following which the cells were non adherent and were aspirated; RNA 
extraction continued as in section 2.2.8.1.  
 
2.2.9 cDNA Generation 
cDNA was synthesised from RNA using a reverse transcription system utilising avian 
myelomatosis virus (AMV) reverse transcriptase. 0.5μg of total RNA were added to 
nuclease free water, made to a total volume of 4.5μl before the sample was denatured 
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at 70°C for 10 minutes, then held at 4°C for 5 minutes. 5.5μl of the reverse 
transcription mastermix containing, 2μl 25mM magnesium chloride, 1μl of reverse 
transcription buffer (10x), 1μl dNTP mix, 0.25μl RNAsin (1U/μl) 0.25μl AMV-reverse 
transcriptase (15U/μg), 0.5 μl random hexamer oligonucleotides (0.05μg/μl) and 0.5μl 
of nuclease free water per reaction, were then added to the denatured RNA. Each 
sample was subjected to the reverse transcription thermal cycle consisting of 10 
minutes at 19°C, 50 minutes at 42°C, 5 minutes at 99°C and then held at 4°C. The 
synthesized cDNAs were subsequently stored at -20°C until required for qRT-PCR. 
 
2.2.9.1 TaqMan quantitative real-time polymerase chain reaction (qRT-PCR) 
The technique of qRT-PCR involves monitoring the PCR as it occurs with data collected 
in realtime. Primers were designed to allow the amplicon to span an exon/exon 
boundary in the mRNA of the gene of interest in order to eliminate contamination from 
genomic DNA. Fluorogenic probes incorporating a 5´ reporter dye and a 3´ quencher 
dye were designed to a sequence which lay between the two primer annealing sites, 
the sequences of these and the primers are given in Table 2.2. Cleavage of the probe, 
through a Taq DNA polymerase, separates the two dyes and permits reporter dye 
fluorescence. Further probing leads to cleavage with every cycle resulting in an increase 
in the intensity of the fluorescence which is proportional to amount of amplicon 
produced.  
 
2.2.9.2 qRT- PCR technique 
Newly synthesised cDNA was diluted five-fold and 1μl was added in triplicate into an 
optical 96-well reaction plate. The RT-PCR mastermix comprised: 12.5μl 2x PCR 
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reaction buffer ‘SensiMixTM’ (containing dNTPS, DNA polymerase, magnesium chloride, 
uracil-N-glycosylase, stabilisers and ROX passive reference), 1.5μl to 3μl of 1.25pM 
gene specific flourogenic probe (optimised for volume and these are listed in Table 
2.6), and 2.5μl of 9pM forward and reverse primers specific for the gene of interest, 
along with 0.125μl of 18s forward and reverse primers and VIC labelled probe, and 
nuclease free water (3.125μl to 4.625μl) to adjust final volume to 24μl for each reaction 
well. Once 24μl of this mastermix has been placed into each well the plate is sealed 
with an optical adhesive cover and loaded into the Applied Biosystems 7500 Fast Real-
Time PCR detection system. The standard reaction protocol consists of 10 minutes at 
95°C, then 40 cycles of 10 seconds at 95°C, and finally 1 minute at 60°C.  
 
2.2.9.3 Probe optimisation 
Each newly designed and synthesised gene-specific flourogenic probe required 
optimisation in order to maximize the acquired fluorescent signal. Using 1μl of positive 
control cDNA reactions were set up as described above but with varying volumes of 
1.25pM probe from 0.5μl up to 4μl, the final volume adjusted to 25μl by varying the 
nuclease free water volume. Following the same thermal cycle real-time protocol the 
results were graphically analysed as cycle threshold against volume and the point at 
which the resultant curve levelled off was used as the optimum volume for subsequent 
reaction for each gene specific probe. All optimised specific probes are listed by volume 
for each reaction in Table 2.6. 
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2.2.9.4 Real-time PCR analysis 
Samples from the protocol described in 2.2.9.2 were analysed using SDS software and a 
Microsoft Excel spreadsheet. Each reaction was associated with a fluorescence 
threshold at which the baseline was adjusted to. The cycle number at which 
fluorescence reaches this is termed the cycle threshold (CT). This value is used for 
analysis, and a δCT value calculated by subtracting the 18s (internal standard) CT 
number from that of the target gene for each sample. Each δCT value is now subtracted 
from the average control δCT to give the δδCT. The fold change can thus be calculated 
from this by using the equation 2-δδCT   Each sample was run in triplicate with an average 
of these giving the normalised fold change value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. 6. Volumes of optimised fluorogenic probe used for TaqMan q-RT-PCR 
reactions   
Gene Optimised Reaction Volume (μl) 
CYBRD1 (Dcytb) 2.5 
SLC11A2 (DMT1) 1.5 
IREB2 (IRP2) 1.5 
TFRC (TfR1) 2 
FTH (H-ferritin) 2.5 
SLC11A3 (ferroportin) 2.5 
HEPH (hephaestin) 3 
HCP1 (Haem carrier protein1) 2.5 
HMOX1 (Haem Oxygenase1) 2 
LRP1 (Haemopexin receptor) 2 
HAMP (hepcidin) 3 
CDH1 (E-cadherin) 2.5 
MYC (c-myc) 3 
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2.2.10 Statistical Analysis 
Analyses were performed using SPSS version 10.0 (SPSS Inc, USA).  Two-tailed 
assessments were performed with significance taken at the 5% level. Normal 
distribution of data was not assumed and therefore non-parametric tests were 
employed. 
 Mann Whitney test was employed to determine if statistical significance existed 
between the medians of two data sets. Comparison between categorical variables was 
made using a χ2 analysis. Significance was accepted at p≤0.05 and all data are 
presented as means ± 2 standard error of the mean (SEM) which represents an 
estimation of the 95% confidence limits of a data set. 
 
2.2.11 Ethical approval 
This work has been carried out in accordance with the declaration of Helsinki (2000) of 
the World Medical Association. Ethical approval for this study was approved by the 
Solihull Local Research Ethics Committee (LREC 06/Q2706/65). All patients providing 
tissue samples gave informed written consent. 
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CHAPTER 3: CHARACTERISATION OF INORGANIC IRON TRANSPORT 
PROTEINS IN THE MALIGNANT PROGRESSION OF OESOPHAGEAL 
ADENOCARCINOMA 
 
3.1 Introduction 
Iron is implicated in the development and progression of various malignant diseases. It 
is required for DNA synthesis and progression through the cell cycle[250] and as such is 
essential for cancer cell proliferation and growth. Iron chelation blocks these effects 
demonstrating the essential requirement of iron for cancer cells [297;298;342]. Iron 
may also exacerbate or induce malignant change. Excess cellular iron facilitates 
production of reactive oxygen species in the presence of oxidative stress, which can 
subsequently induce damage to lipids, protein and DNA[150]. Iron deposition at sites of 
injury in the oesophagus has been demonstrated[148]. In an animal model of gastro-
oesophageal reflux, supplemental iron increases the incidence of BM and OAC[149]. 
Animals without reflux but receiving supplemental iron did not develop either BM or 
OAC, demonstrating the synergistic effect of iron and chronic inflammation[149]. High 
iron requirements and TfR1 overexpression have been demonstrated in various 
tumours including breast[166], non-Hodgkin’s lymphoma[253], glioma[252] and lung 
adenocarcinoma[255]. More recent work demonstrates that cancer cells also express 
the other iron import and export proteins involved in the absorption of iron from the GI 
tract[251]. In colorectal adenocarcinoma the expression of iron transport proteins is 
such that import exceeds export, with subsequent iron loading[251]. The expression of 
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these iron transport proteins is in the progression of Barrett’s metaplasia to 
oesophageal adenocarcinoma is unknown.  
 
Aims: 
1. Examine the patterns of iron deposition within normal oesophagus, BM and OAC by 
immunocytochemistry and quantify this by ferrozine assay 
2. Examine the expression of iron transport proteins (DMT1, Dcytb, TfR1, ferroportin, 
Hephaestin, Ferritin) in normal oesophagus, BM and OAC 
3. Examine the expression of iron transport proteins (DMT1, Dcytb, TfR1, ferroportin, 
Hephaestin, Ferritin) in patients with advanced malignant disease  
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3.2 Intracellular quantification of iron content in oesophageal adenocarcinoma  
 
3.2.1 Assessment of cellular iron by enhanced Perl’s Prussian semiquantitative 
immunohistochemistry 
Enhanced Perl’s Prussian staining was used to identify the cellular location of 
intracellular iron stores in paraffin sections of oesophageal tissue (fig 3.1).  
In normal squamous oesophagus there was no discernable staining other than in the 
occasional basal keratinocyte (fig 3.1 A, E). In sections of Barrett’s metaplasia there was 
evidence of both diffuse cytoplasmic staining and also prominent apical surface 
staining (fig 3.1 B, F). In the majority of oesophageal adenocarcinoma specimens there 
were discrete areas of iron staining which appeared to be both nuclear and cytoplasmic 
in localisation (fig 3.1 C, G). The liver of a haemochromatosis patient is included as a 
positive control and demonstrates widespread iron deposition throughout the cell (fig 
3.1 D, H). 
 
3.2.2 Assessment of cellular iron content by ferrozine assay 
This assay was used to quantify iron stores within tissue samples of oesophageal 
adenocarcinoma. Specimens of tissue were carefully prepared to remove connective 
tissue, muscle and deeper layers leaving mucosa only. These were homogenised and 
the assay performed. Significant increases in cellular iron content were seen in 
oesophageal adenocarcinoma when compared to matched samples of Barrett’s 
metaplasia and squamous oesophagus (n=5, p<0.02) (fig 3.2). 
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Figure 3. 1. DAB-enhanced Prussian staining in the oesophagus 
Elevated diaminobenzidine (DAB) enhanced Prussian staining in oesophageal 
adenocarcinoma. Sections of normal oesophagus (n = 20; S), Barrett’s metaplasia 
(n=20; BM) and oesophageal adenocarcinoma (n = 20; OAC) were subject to DAB 
enhanced Perl's Prussian staining. In normal squamous epithelium there was no 
detectable staining (A and E) while in Barrett’s metaplasia there was marked staining at 
the luminal border and weak cytoplasmic staining (B and F) and in oesophageal 
adenocarcinoma diffuse cytoplasmic and nuclear staining was seen (C and G). Sections 
of liver from a patient with hereditary heamochromatosis, used as a positive control, 
demonstrate diffuse and dense staining for iron thoughout the hepatocyctes (D and H). 
(A-D original magnification x20; E-F original magnification x50). 
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Figure 3. 2. Ferrozine assay upon homogenised oesophageal adenocarcinoma and 
matched Barrett’s metaplasia. 
Sections of oesophageal adenocarcinoma with matched Barrett’s metaplasia (n=5) 
were processed in a ferrozine assay. The total quantity of iron in each tumour sample 
exceeded that of the matched Barrett’s epithelium in every instance (this was 
statistically significant for the group, p<0.02). The average quantity of iron in 
oesophageal adenocarcinoma was 1.97 times greater than that in matched Barrett’s 
epithelium (0.72 ± 0.05 vs 0.36 ± 0.11 nmol Fe/mg tissue protein). 
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3.3 Immunocytochemistry of cellular iron transport proteins in the progression of 
Barrett’s metaplasia to oesophageal adenocarcinoma 
Semiquantitative immunohistochemistry was used to elucidate the cellular localisation 
and to approximate the level of expression of the cellular iron transport proteins 
(Dcytb, DMT1, TfR1, ferritin, ferroportin, and hephaestin) in archived paraffin tissue 
specimens of normal oesophagus (n=10), Barretts metaplasia and matched samples of 
oesophageal adenocarcinoma (n=20).  
 
3.3.1 Semiquantitative immunohistochemistry of Dcytb in the malignant progression 
of oesophageal adenocarcinoma 
Strong immunoreacitvity for Dcytb was observed in the cytoplasm and on the plasma 
membrane of cells at the basal dividing layer of squamous oesophagus (Figure 3.3 
Dcytb S). Weaker immunoreactivity was observed in cells within the stratified 
epithelium away from the basal layer. In Barretts metaplasia immunoreactivity was 
localised to the villous tips and decreased in cells lying deeper within crypts (Figure 3.3 
Dcytb BM). Vesicular staining for Dcytb was observed throughout the cytoplasm. This 
pattern was observed in low and high grade dysplasia and oesophageal 
adenocarcinoma (Figure 3.3 Dcytb ADC). Dcytb immunoreactivity was significantly 
stronger in oesophageal adenocarcinoma and high grade dysplasia when compared to 
non dysplastic Barrett’s metaplasia (p = 0.0001 and 0.045 respectively; Table 3.1).  
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3.3.2 Semiquantitative immunohistochemistry of DMT1 in the malignant progression 
of oesophageal adenocarcinoma 
No immunoreactivity for DMT1 was observed within normal oesophagus (Figure 3.3 
DMT1 S). In Barrett’s metaplasia DMT1 was localised at the apical surface, a pattern 
similar to that of small bowel, whilst in cells deeper within crypts weaker 
immunoreactivity was observed (Figure 3.3. DMT1 BM). Immunoreactivity increased 
from low to high grade dysplasia. In oesophageal adenocarcinoma immunoreactivity 
was the strongest with dense localisation throughout the cytoplasm but with sparing of 
the nucleus (Figure 3.3. DMT1 ADC). Semiquantitative analysis demonstrated 
significantly increased DMT1 immunoreactivity in oesophageal adenocarcinoma 
compared to non dysplastic Barrett’s metaplasia (p = 0.001; Table 3.1).  
 
3.3.3 Semiquantitative immunohistochemistry of TfR in the malignant progression of 
oesophageal adenocarcinoma 
No immunoreactivity for TfR was observed in squamous oesophagus (Figure 3.3. TfR S). 
In Barrett’s metaplasia TfR was localised to cells at the apical border where dense 
immunoreactivity was observed throughout the cytoplasm (Figure 3.3. TfR BM). The 
strongest immunoreactivity was observed in oesophageal adenocarcinoma where TfR 
was abundantly expressed within the cytoplasm and plasma membrane (Figure 3.3. TfR 
ADC).  
Semiquantitative analysis demonstrated significantly greater expression of TfR in 
oesophageal adenocarcinoma and high grade dysplasia when compared to non 
dysplastic Barrett’s epithelium (p = 0.0001 and 0.0001; Table 3.1). 
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Figure 3. 3. Immunolocalisation of iron import proteins Dcytb, DMT1 and TfR in the 
malignant progression of oesophageal adenocarcinoma 
Immunolocalisation of iron import proteins in paraffin embedded sections of normal 
squamous oesophagus (S; n=10), Barrett’s metaplasia (BM; n=20) and matched 
oesophageal adenocarcinoma (ADC; n=20). Duodenal cytochrome B (Dcytb) was 
expressed in squamous oesophagus whilst no appreciable expression of either divalent 
metal transporter 1 (DMT1) or transferrin receptor (TfR) was observed. At the apical 
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membrane of Barrett’s metaplasia staining for Dcytb, DMT1 and TfR was observed. In 
oesophageal adenocarcinoma Dcytb was expressed within vesicles whilst 
immunoreactivity for DMT1 and TfR was strongly expressed throughout the cytoplasm 
and at the cell membrane.  Negative controls were performed during the experiments 
by omission of primary antibody followed by processing with the appropriate 
secondary antibody. Arrows denote areas of positive expression (original magnification 
x40). The dashed line represents the basement membrane. 
 
3.3.4 Semiquantitative immunohistochemistry of the cellular iron storage protein 
ferritin in the malignant progression of oesophageal adenocarcinoma 
H-ferritin expression was observed in normal oesophagus where immunoreactivity was 
strongest in the basal dividing cells with distribution throughout the cytoplasm (Figure 
3.4 ferritin, S). Immunoreactivity was observed throughout the cells of the Barrett’s 
metaplasia sections (Figure 3.4 ferritin BM). Stronger immunoreactivity was present in 
sections of oesophageal adenocarcinoma where H-ferritin was distributed throughout 
the cells with abundant cytoplasmic immunoreactivity (Figure 3.4 ferritin, ADC).  
Semi-quantitative analysis revealed significantly increased immunoreactivity in 
oesophageal adenocarcinoma sections compared to non dysplastic Barrett’s metaplasia 
(p = 0.04; Table 3.1).  
 
 
3.3.5 Semiquantitative immunohistochemistry of the cellular iron export protein 
ferroportin in the malignant progression of oesophageal adenocarcinoma 
No expression of ferroportin was observed in sections of normal oesophagus (Figure 
3.4 FPN, S). Ferroportin immunoreactivity in Barrett’s metaplasia was strongest in 
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apical cells being mainly supranuclear becoming weaker deeper in the crypts (Figure 
3.4 FPN, BM). In adenocarcinoma immunoreactivity was stronger than in Barrett’s with 
abundant ferroportin expression in cytoplasmic vesicles (Figure 3.4 FPN, ADC). 
Semiquantitative analysis revealed significantly more expression of ferroportin in 
oesophageal adenocarcinoma compared with non dysplastic Barrett’s metaplasia (p = 
0.002; Table 3.1). 
 
3.3.6 Semiquantitative immunohistochemistry of the cellular iron export protein 
hephaestin in the malignant progression of oesophageal adenocarcinoma 
Weak immunoreactivity was observed in squamous oesophageal cytoplasm (Figure 3.4 
HEPH, S). In sections of Barrett’s metaplasia diffuse hephaestin immunoreactivity was 
observed in columnar cells being strongest at the basal pole (Figure 3.4 HEPH, BM). In 
oesophageal adenocarcinoma there was week immunoreactivity for hephaestin which 
was diffuse and not localised at the cell border (Figure 3.4 HEPH, ADC).  
There was no significant difference in the expression of hephaestin between tissue type 
when performing semi-quantitative analysis (p=ns; Table 3.1). 
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Figure 3. 4.  Immunolocalisation of the iron storage and export proteins in the 
malignant progression of oesophageal adenocarcinoma 
Immunolocalisation of iron export and storage proteins in paraffin embedded sections 
of normal squamous oesophagus (S; n=10), Barrett’s metaplasia (BM; n=20) and 
matched oesophageal adenocarcinoma (ADC; n=20). Dashed line represents basal layer 
of squamous oesophagus. 
Little immunoreactivity for ferroportin (FPN, D) or hephaestin (HEPH, G) in squamous 
epithelium whilst H-ferritin was localised mainly to the dividing layer of basal cells 
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(arrows, A). Cytoplasmic immunoreactivity for both ferroportin (arrows, E) and HEPH 
(H) was observed in apical cells in Barrett’s metaplasia whilst H-ferritin was expressed 
throughout the cells (B). Extensive immunoreactivity for ferritin was observed 
throughout the oesophageal adenocarcinoma cells (C) whilst ferroportin was also 
abundantly expressed, mainly in vesicles (arrows, F). A repression of HEPH expression 
was observed in oesophageal adenocarcinoma (I).  
Negative controls were performed during the experiments by omission of primary 
antibody followed by processing with the appropriate secondary antibody. Arrows 
denote areas of positive expression (original magnification x40). 
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  Mean difference in protein expression 
 
LGD vs 
BM+ve 
HGD vs 
BM+ve 
ADC vs BM+ve 
Dcytb 0.54 1.65* 7.72* 
DMT1 1.67 1.72 7.06* 
TfR 0.98 5.43* 5.07* 
H-ferritin 0.15 1.67 3.38* 
Ferroportin  1.17 1.08 2.80* 
Hephaestin 0.98 1.53 1.21 
 
Table 3. 1.  Semi-quantitative analysis of the immunoreactivity of iron transport 
proteins in the progression from Barrett’s metaplasia through low and high grade 
dysplasia to oesophageal adenocarcinoma 
Paraffin sections of Barrett’s with low grade dysplasia (LGD) (n=10) and Barrett’s with 
high grade dysplasia (HGD) (n=20) were compared to Barrett’s metaplasia from 
sections adjacent to oesophageal adenocarcinoma (BM+ve) (n=20). Oesophageal 
adenocarcarinoma (ADC) sections were compared to the adjacent matched Barrett’s 
metaplasia (BM+ve).  
Samples were subject to immunohistochemistry with antibodies to duodenal 
cytochrome b (Dcytb), transferrin receptor (TfR), divalent metal transporter 1 (DMT1), 
ferroportin, hephaestin, and H-ferritin. Scoring of the slides is described in materials 
and methods; briefly 0 = no staining, 12 = strong staining of all epithelial cells within the 
slide. The mean score is presented and numbers in bold denote statistical significance 
(*p<0.05; Mann-Whitney-U test). 
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3.4 Correlation of cellular iron transport protein expression with prognostic variables 
using an oesophageal adenocarcinoma tissue microarray  
Oesophageal adenocarcinoma samples (n=76, separate to those used elsewhere in this 
work) were prepared as a tissue microarray embedded in paraffin (kind gift from 
Jonathan Bury) and subjected to semiquantitative immunohistochemistry analysis. 
Expression of the iron transport proteins TfR, DMT1, Dcytb, ferritin, hephaestin and 
ferroportin was quantified and correlated with prognostic variables. These variables 
were T stage (T1-4), presence of nodal metastasis, vascular invasion, serosal 
involvement and differentiation (well, moderate or poor). There were 1 T1, 15 T2 and 
60 T3 tumours; 3 well, 52 moderate and 21 poorly differentiated tumours; serosal 
involvement in 23 tumours; nodal metastasis in 52 tumours; vascular invasion in 19 
tumours. The single T1 tumour and 3 tumours assessed as being well differentiated 
were excluded from comparison due to the low numbers. There were no T4 tumours 
(these are by definition not treated by surgical resection and therefore unavailable for 
assessment). Increased immunoreactivity for DMT1 was observed in tumours with 
nodal metastasis (p = 0.0068) compared to those without. There was no significant 
correlation between immunoreactivity for any other iron transport protein and 
prognostic variable (Table 3.2).  
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T stage Differentiation 
Vasular 
invasion Nodal metastasis 
Serosal 
involvement 
Protein 
T2 T3 
Moder-
ate Poor -ve +ve -ve +ve -ve +ve 
DMT1 2.5 3.02 3.02 2.38 2.77 3.24 1.93* 3.34* 2.58  3.59  
Dcytb 4.97 4.44 4.85 4.43 4.78 4.87 4.9 4.79 5.11 4.51 
TfR 5.96 9.36 9.04 7.4 7.84 9.00 4.56 9.88 8.16 9.56 
H-ferritin 1.65 2.49 2.75 1.66 2.43 2.17 1.52 2.69 2.25 2.39 
Ferroportin 2.99 2.6 2.66 2.33 2.7 2.38 2.33 2.71 2.77 2.36 
Hephaestin 0.14 0.28 0.3 0.11 0.24 0.16 0.35 0.15 0.11 0.39 
 
Table 3. 2. Semiquantitative analysis of immunoreactivity of iron transport proteins 
in an oesophageal adenocarcinoma tissue microarray (n=76) 
Paraffin embedded oesophageal adenocarcinoma tissue array was used to correlate 
immunoreactivity of iron transport proteins (Dcytb, DMT1, TfR, H-ferritin, ferroportin 
and hephaestin) with prognostic variables (T stage, vascular invasion, lymph node 
metastasis, serosal involvement and degree of cellular differentiation). Assessment of 
immunostaining is  described in section 2.2.1.3.  
Increased immunoreactivity for DMT1 was observed in cases with lymph node 
metastasis. No further association between iron transporter immunoreactivity and 
prognostic variable was identified. The mean scores are presented and numbers in bold 
denote statistical significance (Mann-Whitney-U test with Bonferroni adjustment for 
multiple comparison; statistical significance accepted at p ≤ 0.0083). 
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3.5 Quantitative analysis of iron transport mRNA expression in the malignant 
progression of oesophageal adenocarcinoma by qRT-PCR  
To explore if the expression of iron transport proteins in normal oesophagus, Barrett’s 
metaplasia and adenocarcinoma is regulated at a transcriptional level qRT-PCR was 
utilised. The mRNA expression of Dcytb, DMT1 IRE+ve isoform, TfR, H-ferritin, 
ferroportin and hephaestin was determined relative to 18s ribosomal mRNA internal 
standard. Non dysplastic Barrett’s metaplasia (BM-ve) (over 3cm in length and 
confirmed as columnar epithelium with intestinal type goblet cells) with no evidence of 
adenocarcinoma or dysplasia was compared to matched samples of squamous 
oesophagus and gastric epithelium (n=14). Oesophageal adenocarcinoma samples 
(n=29) were compared to matched samples of normal squamous oesophagus and 
gastric epithelium and when present associated Barrett’s metaplasia (BM+ve) (n=11).  
 
3.5.1 mRNA expression of duodenal cytochrome B in the malignant progression of 
oesophageal adenocarcinoma 
There was no significant difference in Dcytb mRNA expression between BM-ve and 
matched gastric epithelium with an average fold difference of 1.09±0.35 (mean±2SEM). 
There was significant upregulation when compared with matched squamous 
epithelium 2.91±0.74 (p<0.05). Expression of Dcytb mRNA was greater in all but one 
sample of oesophageal adenocarcinoma compared to BM+ve (4.05±0.78; p=0.001) (fig 
3.5 A). 
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3.5.2 mRNA expression of DMT1 in the malignant progression of oesophageal 
adenocarcinoma 
DMT1 IRE+ve mRNA expression was greater in BM-ve compared with matched gastric 
epithelium (1.79±0.56; p<0.05) and squamous epithelium (1.71±0.23; p=0.006). 
Expression in oesophageal adenocarcinoma was greater than BM+ve in every sample 
(6.51±1.8; p=0.0002) (fig 3.5 B). 
 
3.5.3 mRNA expression of TfR1 in the malignant progression of oesophageal 
adenocarcinoma 
Significantly greater expression of TfR was seen in BM-ve compared to matched 
squamous (1.75±0.37; p<0.05) but not gastric epithelium (1.87±0.96; p=0.3). All but one 
sample of oesophageal adenocarcinoma expressed more TfR than BM+ve (11.5±1.7; 
p=0.003) (fig 3.5 C). 
 
3.5.4 mRNA expression of H-ferritin in the malignant progression of oesophageal 
adenocarcinoma 
There was no significant difference in the expression of H-ferritin between BM-ve and 
matched gastric epithelium (2.37±0.6; p=0.38). 11/14 samples of BM-ve expressed 
more ferritin than matched squamous (3.97±0.93; p<0.05). Oesophageal 
adenocarcinoma expressed more ferritin than BM+ve (2.98±0.89; p=0.02) (fig 3.5 D). 
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3.5.5 mRNA expression of ferroportin in the malignant progression of oesophageal 
adenocarcinoma 
Significantly greater expression of ferroportin was seen in BM-ve compared to matched 
squamous (6.91±2.6; p<0.05) but not gastric epithelium (2.95±0.85; p=0.16). 
Ferroportin expression was greater in oesophageal adenocarcinoma than BM+ve 
(14.8±2.4; p=0.01) (fig 3.5 E). 
 
3.5.6 mRNA expression of hephaestin in the malignant progression of oesophageal 
adenocarcinoma 
Significantly greater expression of hephaestin was seen in BM-ve compared to matched 
squamous (14.95±0.26; p<0.05) but not gastric epithelium (1.96±0.28; p=0.17). There 
was no significant difference in expression between oesophageal adenocarcinoma and 
BM+ve (1.2±0.69; p=0.11) (fig 3.5 F). 
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Figure 3. 5. Mean expression of iron import (A – Dcytb; B – DMT1; C – TfR), storage (D 
– ferritin) and export (E – ferroportin; F – hephaestin) proteins.  
There was an increased expression of DMT1 mRNA in non dysplastic Barrett’s 
epithelium (BM-ve, n=14) compared with matched gastric epithelium (G). Increased 
expression of each iron transport protein was observed in non dysplastic Barrett’s 
epithelium compared with matched squamous epithelium (S). Significantly greater 
expression of each transport protein, with the exception of hephaestin, in oesophageal 
adenocarcinoma (OAC, n=11) compared with matched Barrett’s epithelium (BM+ve).  
Dcytb – duodenal cytochrome b; DMT1 divalent metal transporter 1; TfR – transferrin 
receptor; ferritin – H-ferritin.  2SEM shown; * p<0.05; ** p<0.01 
  
111 
 
3.6 Quantitative expression of iron transport proteins in the malignant progression of 
oesophageal adenocarcinoma 
The expression of iron transport proteins (transferrin receptor, H-ferritin and 
ferroportin) was determined by western blotting using optimised antibodies. Normal 
oesophagus was compared with matched non dysplastic Barrett’s epithelium (n=15) 
and oesophageal adenocarcinoma with matched dysplastic Barrett’s epithelium (n=10).  
 
3.6.1 Expression of TfR1 protein in the malignant progression of oesophageal 
adenocarcinoma 
Expression of TfR1 was greater in oesophageal adenocarcinoma than in matched 
Barrett’s (32.4±14.3 vs. 1±0.44; p<0.01) whilst there was no significant difference 
between squamous oesophagus and non dysplastic Barrett’s epithelium (1±0.1 vs 
1.2±0.3; p=ns) (fig 3.6A). 
 
3.6.2 Expression of ferritin protein in the malignant progression of oesophageal 
adenocarcinoma 
There was no significant difference in expression of H-ferritin between the tissue 
samples (sqaumous oesophagus 1±0.1; non dysplastic Barrett’s 1.3±0.4; dysplastic 
Barrett’s 1±0.5; oesophageal adenocarcinoma 0.7±0.3; all p=ns) (fig 3.6B). 
 
3.6.3 Expression of ferroportin protein in the malignant progression of oesophageal 
adenocarcinoma 
An overexpression of ferroportin protein was observed in oesophageal 
adenocarcinoma versus matched Barrett’s epithelium (11.3±4.0 vs 1±0.4; p<0.05). A 
  
112 
 
non significant increase in expression was observed between non dysplastic Barrett’s 
epithelium versus matched squamous oesophagus (3.1±2.5 vs 1±0.1; p=ns) (fig 3.6C). 
 
 
 
 
Figure 3. 6.  Analysis of iron storage and export proteins in normal oesophagus, 
Barrett’s metaplasia and oesophageal adenocarcinoma  
Western blotting was utilised to determine the protein expression of iron storage and 
export proteins in squamous compared with matched BM-ve (n=15). OAC was 
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compared with matched BM+ve (n=10). A mouse monoclonal antibody to TfR (90kDa), 
rabbit polyclonal antibodies to H-ferritin (21kDa) and ferroportin (64kDa) were used.  
Densitometry was used to quantify immunoreactive bands and normalised to 
cytokeratin 19 (CK19; 40kDa) as a loading control. A significant increase in TfR and 
ferroportin protein expression but not ferritin was observed in OAC versus matched 
BM+ve whilst no significant change was seen against BM-ve with squamous.  
Squamous - normal oesophagus; BM-ve - non dysplastic Barrett’s metaplasia; BM+ve - 
dysplastic Barrett’s metaplasia; OAC - oesophageal adenocarcinoma; TfR – transferrin 
receptor; FPN  – ferroportin; ferritin – H-ferritin; mean values ± 2SEM shown; * p<0.05; 
** p<0.01 
 
3.7 Expression of iron regulatory protein 2 in the malignant progression of 
oesophageal adenocarcinoma  
The expression of TfR, ferritin, ferroportin and DMT1 (IRE+ve isoform) is influenced by 
interaction between their iron regulatory elements and iron regulatory protein 2. 
Expression of IRP2 mRNA was assessed by qRT-PCR in samples of oesophageal 
adenocarcinoma with matched Barrett’s metaplasia (n=11) and in samples of 
squamous and gastric epithelium with matched benign Barrett’s metaplasia (n=14) (fig 
3.7).  
 
There was a non significant decrease in IRP2  mRNA expression between BM-ve 
and matched squamous epithelium with an average fold difference of 0.61±0.38 
(p=0.07) (mean±2SEM) there was however a significant reduction when compared with 
matched gastric epithelium with an average fold difference of 0.56±0.34 (p=0.03). 
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There was a non significant upregulation of IRP2 when oesophageal adenocarcinoma 
was compared to BM+ve (4.6±3.1; p=0.07) (fig 3.7).  
 
 
 
 
Figure 3. 7.  Mean expression of IRP2 mRNA in the malignant progression of 
oesophageal adenocarcinoma 
Fig 3.7 demonstrates decreased IRP2 mRNA expression in non dysplastic Barrett’s 
epithelium (BM-ve, n=14) compared with matched gastric epithelium (G) (p=0.03). Non 
significant decrease when compared to matched squamous epithelium (p=0.07) and 
non significant increase in IRP2 expression in OAC versus matched Barrett’s epithelium 
(BM+ve) (p=0.07).  
IRP – iron regulatory protein. Mean values ± 2SEM shown; * p<0.05 
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3.8 Expression of the iron regulatory protein hepcidin in oesophageal 
adenocarcinoma samples 
Hepcidin expression in oesophageal adenocarcinoma tissue was assessed by qRT-PCR in 
samples of adenocarcinoma with matched Barrett’s metaplasia (figs 3.8 A) and a larger 
group of adenocarcinoma samples without matched Barrett’s (n=11) (fig 3.8 B). 
Immunohistochemistry was used to assess the cellular location of hepcidin expression 
(fig 3.9). 
 
3.8.1 Hepcidin mRNA expression in the malignant progression of oesophageal 
adenocarcinoma 
Hepcidin mRNA expression was observed in the majority of tumours (6 of 8) with 
matched Barrett’s metaplasia (mean 1/dCt expression of hepcidin mRNA in these 
tumour samples was 0.035 ± 0.002). Only one sample of Barrett’s metaplasia expressed 
hepcidin mRNA (fig 3.8 A) (Fishers exact test p=0.02). 11 of 19 oesophageal 
adenocarcinoma samples without matched Barrett’s metaplasia expressed hepcidin 
mRNA (mean 1/dCt expression of hepcidin mRNA in these tumour samples was 0.027 ± 
0.001) (fig 3.8 B). 
 
3.8.2 Semiquantitative immunohistochemistry of hepcidin expression in the 
malignant progression of oesophageal adenocarcinoma 
Immunohistochemistry revealed weak immunoreactivity for hepcidin which was 
predominantly localised to the basal membrane samples of Barrett’s metaplasia (fig 3.9 
B). Dense cytoplasmic immunoreactivity for hepcidin with sparing of the nucleus was 
observed in oesophageal adenocarcinoma samples (fig 3.9 C,E,D,F). 
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Figure 3. 8. Hepcidin mRNA expression in samples of oesophageal adenocarcinoma 
Samples of oesophageal adenocarcinoma with matched Barrett’s metaplasia (fig 3.8 A; 
B-Barrett’s metaplasia, T – matched tumour, TN – sample number) and in a larger 
group of oesophageal adenocarcinoma samples without matched Barrett’s (fig 3.8 B). 
Results are presented as 1/dct between hepcidin and 18s internal control as the 
majority of Barrett’s and some of the adenocarcinoma samples expressed no hepcidin.  
Oesophageal adenocarcinoma samples were more likely than matched Barrett’s to 
express hepcidin mRNA (p=0.02) (fig 3.8A). The majority of adenocarcinoma samples 
expressed hepcidin mRNA (fig 3.8B); for each sample matched squamous oesophagus 
and gastric mucosa were screened for hepcidin expression but every sample was 
negative (results not shown).  
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Figure 3. 9.  Hepcidin immunohistochemistry in the malignant progression of 
oesophageal adenocarcinoma 
Weak immunoreactivity for hepcidin was observed in Barrett’s metaplasia at the basal 
cell border (figs A and B, 40x and 100x magnification respectively). Dense 
immunoreactivity for hepcidin was observed throughout the cytoplasm of all 
oesophageal adenocarcinoma cells (figs C, E and D, F, 40x and 100x magnification 
respectively). No hepcidin immunoreactivity was seen in neighbouring normal 
squamous epithelium adjacent to invasive adenocarcinoma (fig 3.9C). Fig G and H are 
sections of liver; G is a negative control with no anti-hepcidin but incubation with goat 
serum and secondary antibody; H is a positive control with addition of anti-hepcidin 
antibody. 
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3.9 Conclusions 
This is the first time that iron transport proteins have been investigated in oesophageal 
adenocarcinoma. Other tumours have been associated with overexpression of 
transferrin receptor[166;252;253;255] and perhaps it is not surprising to identify this in 
OAC. Cancer cells have requirements for iron over and above that of benign cells; iron 
is required by cell division proteins such as cyclin dependent kinases[250] and is 
essential for cell metabolism. This work is more complete and novel not only because it 
is the first to observe the expression of transferrin receptor in oesophageal 
adenocarcinoma but also evaluates other cellular import, storage and export proteins. 
Furthermore, we have observed the expression of the proteins in the progression of 
normal oesophagus to Barrett’s metaplasia and oesophageal adenocarcinoma.  
 
The expression of these iron transport proteins within the proximal upper 
gastrointestinal tract seems very unlikely to be related to the absorption of intestinal 
iron. The expression profile and cellular location indicate that iron acquisition occurs 
mainly via transferrin receptor endocytosis. The role of Dcytb is however unclear. In the 
duodenum it acts as a luminal ferrireductase aiding import via DMT1[164;165]. We 
have observed cytoplasic immunoreactivity within adenocarcinoma and weak staining 
within the basal layer of proliferating normal squamous oesophagus. Whether Dcytb 
has other roles or its expression is constitutive within these cells being lost as they 
develop is unclear.  
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The widespread deposition of iron seen throughout OAC tissue sections is presumably a 
phenotype resulting from increased iron import and dysregulation of storage/export. 
mRNA expression of the iron export protein ferroportin was greater in adenocarcinoma 
than in associated Barrett’s metaplasia. Its cytoplasmic location however, as revealed 
by immunocytochemistry, suggests a non functional role[190]. The cause of the re-
localisation of ferroportin is unclear. It seems logical that a prime candidate is the 
hepatic anti-microbial peptide hepcidin[217;218] which we have shown to be 
expressed by the majority of oesophageal adenocarcinoma samples. This would 
mediate a loss of membranous ferroportin expression (which we observed in samples 
of oesophageal adenocarcinoma tissue). It could be postulated that this results in iron 
sequestration within tumour cells. Possible effects would include cells becoming more 
aggressive since increasing cellular iron can drive cellular proliferation[250], modulate 
cell adhesion and through Fenton reactions mediate free radical production[160]. The 
last may be a method of creating further cell aberrations such as DNA 
adducts/mutation with evolution of the cancer[160]. Why tumour cells express 
hepcidin whilst native oesophageal and metaplastic Barrett’s tissue do not is unclear 
though. The major trigger for hepatic hepcidin production is inflammatory 
mediators[218], whereas hypoxia inhibits hepcidin production. The effects of infection 
or inflammation upon hepcidin are indirect[218], with interleukin 6 being identified as 
the cytokine responsible[219]. Overexpression of interleukin 6 has been observed in 
the malignant progression of Barrett’s by other authors, with levels increasing as 
Barrett’s becomes dysplastic[352] and highest levels being observed within 
oesophageal adenocarinoma[353], however the association with hepcidin expression 
has not previously been reported. Overexpression of interleukin 6 is a feature common 
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to gastrointestinal malignancies including gastric adenocarcinoma[354], pancreatic 
adenocarcinoma[355] and colonic adenocarcinoma[356]. The expression of hepcidin 
within these tumour types has  not yet been characterised, though we have 
demonstrated hepcidin expression in colorectal adenocarcinoma tissue samples[357]. 
The stimulus for tumour cells to express hepcidin is unclear. Potential autocrine effects 
could result in iron loading of cells that express ferroportin. 
 
The mechanism of cellular control in the expression of iron transport proteins in the 
malignant progression of oesophageal adenocarcinoma is unclear. On the basis of 
increased cellular iron in oesophageal adenocarcinoma (as demonstrated by 
immunohistochemistry and quantified by ferrozine assay) one could predict the 
expression profile of the pertinent cellular transport proteins if the IRE/IRP system was 
functioning. This should result in decreased transferrin receptor, DMT1 and increased 
ferritin and ferroportin expression[204]. This is not the case, with transferrin receptor, 
DMT1 and ferritin being overexpressed. Ferroportin overexpression is seen in 
adenocarcinoma but the cytoplasmic location away from basal cell border implies a 
non-function role[217;218]. Auto- or paracrine expression of hepcidin could explain the 
relocalisation of ferroportin but other mechanisms of cellular control must play a role, 
though they are as yet uncharacterised.  
 
In the presence of repeated reflux of acid/bile into the oesophagus and consequent 
inflammation it is likely that these OAC cells are at risk of oxidative stress and iron 
mediated free radical damage[148;149;155;307;358]. This may drive carcinogenesis 
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and possibly explain the rapid progression and poor prognosis of the majority of 
OAC’s[307]. The lack of correlation in iron transport expression and known prognostic 
markers identified by the tissue microarray (with the exception of increased expression 
of DMT1 with nodal metastasis) indicates that accumulation of iron and cellular 
damage are likely to occur early in the development of OAC. The change in iron 
transporter expression was most obvious between OAC and matched samples of BM. 
Immunocytochemistry and mRNA assessment associated increased expression of 
Dcytb, DMT1, TfR1, ferritin and ferroportin with the development of OAC. When high 
grade dysplasia was compared with Barrett’s from patients with OAC, an increase in 
TfR1 and a mild increase in Dcytb was observed. There was no difference between low 
grade dysplasia and BM.  
The second striking difference in the progression of BM and OAC from squamous 
oesophagus was between the normal squamous epithelium and BM. The expression of 
every iron transport mRNA and protein was different. The cumulative effect appears to 
be associated with increased iron deposition as seen by Perls Prussian staining in BM 
sections compared with normal squamous epithelia. This may in part reflect the 
characteristics of the different epithelia, however, it is interesting to observe iron 
deposition in benign Barrett’s epithelium. Whether this reflects the normal state for 
this epithelium it is not clear. In the presence of repeated inflammation, mediated by 
repeated episodes of gastroesophageal reflux, oxidative damage and highly reactive 
oxygen species may be exacerbated in the presence of increased cellular iron. This may 
provide a mechanism by which Barrett’s epithelium becomes increasingly dysplastic 
and finally into invasive adenocarcinoma. 
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An interesting aspect of oesophageal adenocarcinoma is the relatively infrequent 
development of OAC within pre-existing BM (approximately 1% per year). It would be 
interesting to quantify iron transport protein, interleukin-6 and hepcidin expression in a 
cohort of patients with benign BM. If this cohort underwent endoscopic surveillance 
tissue samples could be used to observe changes in protein expression profile with 
time and more interestingly amongst the few subjects that progress to dysplasia and 
adenocarcinoma. Unfortunately such a study would require a large number of 
participants due to the low rate of progression. 
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CHAPTER 4: EFFECTS OF IRON, WITH OR WITHOUT ALGINATE, IN 
OESOPHAGEAL ADENOCARCINOMA 
 
4.1 Introduction 
Iron is implicated in the development of Barrett’s metaplasia and progression to 
oesophageal adenocarcinoma. Epidemiological studies of dietary patterns associate 
iron intake with Barrett’s metaplasia[132] and oesophageal 
adenocarcinoma[26;134;135;137-139]. Patients with the iron overload disease 
hereditary haemochromatosis have an increased risk of oesophageal 
adenocarcinoma[158]. In murine models of gastroesophageal reflux supplemental iron 
increases iron deposition at sites of inflammation, dysplasia and adenocarcinoma 
formation[148;149;155].  
The consequences of iron loading upon oesophageal adenocarcinoma cells are 
unknown. Indirect evidence suggests this has the potential to modify cell behaviour. 
Iron is essential for proteins that regulate cell cycle and proliferation. Iron is required 
for the activity of ribonucleotide reductase (the enzyme responsible for the synthesis of 
deoxyribonucleotides) and iron deprivation inhibits its function[359-362]. The cell 
division cycle 14A protein controls progression of cells through the cell cycle. It has 
recently been identified to possess an iron responsive element within its mRNA 3′ -
untranslated region, linking intracellular iron levels, the IRE/IRP system and control of 
cell cycle[207]. Iron is also required by other cell cycle proteins, cyclins and cyclin 
dependent kinases[363-365]. 
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In colorectal carcinoma iron induces Wnt signalling and increases β-catenin[366], an 
effect which is abrogated by restoration of APC function. Iron also suppresses 
expression of the cell-cell adhesion molecule E-cadherin[251;367]. Loss of APC function 
occurs in almost all cases of oesophageal adenocarcinoma. Futhermore suppression of 
E-cadherin is observed in the development of oesophageal adenocarcinoma and 
subsequent metastasis[92;100;365;368], suggesting a potential role for iron mediated 
effects in oesophageal adenocarcinoma through an APC deficient route.  
N-myc downstream regulated gene (Ndrg-1) is a tumour suppressor gene that acts to 
control cell proliferation[369;370] and protects cells from developing an invasive and 
metastatic phenotype[370;371]. Ndrg-1 expression is inhibited by iron[372;373] and 
provides another mechanism by which the migratory potential of malignant cells is 
promoted by iron. 
Researchers have utilised the high requirement of cancer cells for iron to develop 
potential therapeutic strategies. Iron chelation has been used as a therapy in the 
treatment of different cancer types. Desferroxamine decreased tumour mass in 
children with neuroblastoma[298;299] and increased length of survival and decreased 
tumour burden in patients with inoperable hepatocellular carcinoma[300]. In-vitro 
experiments demonstrate that novel iron chelators increase sensitivity of tumour cells 
to conventional chemotherapeutics, even amongst cells that express natural 
resistance[293], increasing apoptosis[295;296]. Toxic complications associated with 
these therapies detract from and limit their use[299;310;311]. However, natural iron 
chelators such as alginates are non toxic, cheap and readily available[328;347]. In 
epidemiological studies diets high in alginates are associated with a protective effect 
against various malignant processes[336-339] though the underlying protective 
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mechanisms are unclear. In a murine model of colorectal dysplasia natural chelation 
was associated with decreased cell proliferation and tumour burden[330]. The role of 
alginates as a therapy against the development of oesophageal adenocarcinoma has 
not been identified. 
 
The increases in cellular iron content and dysregulated expression of iron transport 
proteins in the progression of oesophageal adenocarcinoma described in chapter 3 
indicate a role for iron in the malignant progression of oesophageal adenocarcinoma. 
Furthermore the role of iron binding by alginates is unclear but may inhibit iron 
mediated effects. 
 
Thus the aims of this chapter are to: 
1. Determine the ability of oesophageal adenocarcinoma cells to import iron and the 
effects upon expression of iron transport proteins 
2. Determine the effects of iron exposure in an in-vitro model of oesophageal 
adenocarcinoma with respect to cellular proliferation, viability, migration and 
anchorage independent growth 
3. Determine whether effects observed in 2. above can be modulated, by the natural iron 
chelator, alginate  
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4.2 Quantification of cellular iron content in oesophageal adenocarcinoma cell lines: 
effects of iron, desferroxamine and alginate 
 
4.2.1 Iron loading of oesophageal adenocarcinoma cell lines 
A ferrozine assay was used to quantify the iron content of oesophageal 
adenocarcinoma cell lines OE33 and OE19 (fig 4.1A) following culture with iron. In OE33 
cells the cellular iron content increased with increasing duration of exposure to iron 
(100µM ferrous sulphate). Following 12 hours of culture little difference in iron content 
was observed but after 24 hours a significant increase was observed with a further 
increase observed in cells cultured for 48 hours (p<0.001). In OE19 cells following 12 
hours of cell culture a non significant increase in cellular iron content was observed 
which became strongly significant after 24 and 48 hours of culture (p<0.001).   
 
4.2.2 Cellular iron loading is inhibited by the addition of the iron chelator 
desferroxamine to the media 
To determine the ability of iron chelation to inhibit iron uptake by oesophageal 
adenocarcinoma cells desferroxamine was added to the culture media with and 
without the addition of supplemental iron. A ferrozine assay was used to measure 
intracellular iron content following 48 hours of culture (fig 4.1B).  
In OE33 cells cultured with supplemental iron there was 9.3 fold increase in iron 
content relative to control (7.4 ± 1.3 vs. 0.8 ± 0.7 nmols iron per mg cell protein; 
p<0.01). There was non-significant increase in cellular iron content when cells were 
cultured with iron and desferroxamine relative to control cells (1.9 ± .9 vs. 0.8 ± 0.7 
nmols iron per mg cell protein). There was no difference in iron content between 
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control cells and cells cultured in normal growth media with desferroxamine (0.8 ± 0.7 
vs. 0.9 ± 0.3 nmols iron per mg cell protein).  
 
In OE19 cells cultured with supplemental iron there was 7.6 fold increase in iron 
content compared to control (6.3 ± 1.4 vs. 0.8 ± 0.1 nmols iron per mg cell protein; 
p<0.01). There was a non-significant decrease in cellular iron content when cells were 
cultured with iron and desferroxamine relative to control cells (0.8 ± 0.7 vs. 0.6 ± 
0.1nmols iron per mg cell protein). There was also a non significant difference in iron 
content between control cells and cells cultured in normal growth media with 
desferroxamine (0.8 ± 0.7 vs. 0.6 ± 0.1nmols iron per mg cell protein). Following 
culture with desferroxamine for 5 days cell death occurred with both OE33 and OE19 
cells. 
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Figure 4. 1. Iron loading of oesophageal adenocarcinoma cell lines OE33 and OE19 
increases cellular iron content, an effect inhibited by iron chelation 
OE33 and OE19 cell lines were exposed to iron (100µM ferrous sulphate) for increasing 
lengths of time (fig 4.1 A). In both lines prolonging exposure increased cellular iron 
content. Non-significant increases were observed after 12 hours which became 
significantly greater after 24 and 48 hours of culture (p<0.01). Addition of the iron 
chelator desferroxamine (250µM) to the culture media inhibited cellular uptake of iron 
after 48 hours of culture (fig 4.1 B). There was no significant increase in iron content 
when cells were co-cultured with iron and desferroxamine. After increasing the 
duration of co-culture cell death occurred in both control and iron loaded cells in the 
presence of desferroxamine (data not shown).  
Ctl – Control; DFO – desferroxamine; *p<0.01 relative to control. 
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4.2.3 Cellular iron loading is inhibited by the addition of alginate to culture media 
Having demonstrated that oesophageal adenocarcinoma cells internalise iron 
following exposure to ferrous sulphate the ability of alginates to bind iron in solution 
was explored. A 1% w/v solution of LFR5/60 alginate or a 0.1% v/v solution containing 
the over the counter medicine Gaviscon was added to culture media with or without 
supplemental ferrous sulphate. A ferrozine assay was used to measure intracellular 
iron content following 48 hours of cell culture (fig 4.2A – OE33 and fig 4.2B – OE19). 
 
In OE33 cells cultured with supplemental iron there was 3.2 fold increase in iron 
content compared to control (5.2 ± 0.6 vs. 1.6±0.2 nmols iron per mg cell protein; 
p<0.0001). The addition of alginate to media resulted in a decrease in iron content 
relative to control (0.9±0.2 vs. 1.6±0.2 nmol/mg cell protein p<0.01) whilst Gaviscon 
also decreased cellular iron content (1.2±0.1 vs. 1.6±0.2 nmol/mg cell protein p<0.01). 
Addition of alginate to iron loaded media resulted in a decrease in iron content relative 
to cells cultured with iron loaded media (3.3±0.2 vs. 5.2±0.6  nmol/mg cell protein 
p<0.01) as did Gaviscon (1.7±0.1 vs. 5.2±0.6 nmol/mg cell protein; p<0.001).  
In OE19 cells cultured with supplemental iron there was 8.4 fold increase in iron 
content compared to control cells (22.5 ± 1.7 vs. 2.7 ± 0.3 nmols iron per mg cell 
protein; p<0.0001). The addition of alginate to control media resulted in a decrease in 
iron content relative to control cells (1.9±0.5 vs. 2.7±0.3 nmol/mg cell protein; p<0.01) 
whilst Gaviscon had no effect (2.6±1.7 vs. 2.7±0.3 nmol/mg cell protein; p=ns). 
Addition of alginate to iron loaded media resulted in a decrease in iron content relative 
to cells cultured with supplemental iron (8.5±0.6 vs. 22.5±1.7 nmol/mg cell protein; 
p<0.001) as did Gaviscon (14.9±0.5 vs. 22.5±1.7 nmol/mg cell protein; p<0.001).  
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Figure 4. 2.  Alginates suppress iron uptake by oesophageal adenocarcinoma cells 
Cells were cultured in the presence of alginate (1% w/v) or Gaviscon (0.1% v/v) ± iron 
(100µM ferrous sulphate) for 48 hours. Addition of alginate to control media resulted 
in a significant reduction of iron content in both cell lines. The addition of Gaviscon to 
control media resulted in a reduction of iron content in OE33 cells. Addition of alginate 
or Gaviscon to media loaded with iron resulted in a reduction of iron content in both 
cell lines compared to cells cultured in iron alone.  
+ p<0.01 relative to control cells; * p<0.00001 relative to control cells; ‡ p<0.01 relative 
to cells exposed to iron; ‡‡ p<0.001 relative to cells exposed to iron. CTL: control; ALG: 
alginate; GAV:  Gaviscon; IRON: ferrous sulphate 
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4.3 Iron loading of oesophageal adenocarcinoma cell lines increases the cell 
population  
To indirectly determine the effects of iron upon proliferation a MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to quantify the 
number of viable cells following culture with or without iron (n=12). In addition 
alginate or Gaviscon were added to control and iron loaded media to determine 
effects of alginates upon cell viability (fig 4.2) (n=12). Results are demonstrated 
relative to control cells normalised to a value of 1. 
 
In OE33 cells a significantly greater number of viable cells were present following 48 
hours of cell culture with iron (1.55 fold greater, 2SEM 0.02; p<0.001). The addition of 
alginate to control media resulted in a decrease in viability (0.56 ± 0.09 vs 1 ± 0.07; 
p<0.01) as it did to iron loaded media (iron alone 1.55 ± 0.02 vs. 0.9 ± 0.17; p<0.001). 
Gaviscon produced similar effects in addition to control media (0.68 ± 0.1 vs 1 ± 0.07; 
p<0.01) and iron loaded media (iron alone 1.55 ± 0.02 vs. 1.1 ± 0.11; p<0.001), fig 4.2A.  
In OE19 cells iron also increased the number of viable cells following 48 hours of cell 
culture (1.49 fold greater, 2SEM 0.05 vs. 1 ± 0.01; p<0.001). The addition of alginate to 
control media resulted in a decrease in viability (0.83 ± 0.09 vs. 1 ± 0.01; p<0.01) as it 
did to iron loaded media (iron alone 1.49 ± 0.05 vs. 0.9 ± 0.17; p<0.001). Gaviscon did 
not effect the cell viability when added to control media (0.99 ± 0.1 vs. 1 ± 0.01; p=ns) 
but when added to iron loaded media resulted in a significant decrease (iron alone 
1.49 ± 0.05 vs. 0.99 ± 0.05; p<0.001), fig 4.2B. 
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Figure 4. 3.  Alginates inhibit iron mediated increase in cell population 
Cells were cultured in the presence of alginate (1% w/v) or Gaviscon (0.1% v/v) ± iron 
(100µM ferrous sulphate) for 48 hours (for each regime n=12). Iron significantly 
increased the viable cells in both cell lines. Addition of alginate to control media or iron 
loaded media resulted in a significant reduction in cell viabiltiy in both cell lines relative 
to control or iron loaded media respectively.  Gaviscon reduced cell population when 
added to control media of OE33 cells but not OE19 cells. When added to iron loaded 
media Gaviscon reduced the cell population of both cell lines.  
+ p<0.01 relative to control cells; * p<0.0001 relative to control cells; ‡ p<0.001 relative 
to cells exposed to iron. CTL: control; ALG: alginate; GAV:  Gaviscon; IRON: ferrous 
sulphate 
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4.4 Iron loading oesophageal adenocarcinoma cell lines increases cell proliferation  
A bromodeoxyuradine (BrdU) assay was used as an indirect measure of cellular 
proliferation following culture with or without iron (fig 4.4). To further identify effects 
of iron upon proliferation and the cell cycle analysis of the expression of the cell cycle 
control protein CDC14A was performed by western blotting (fig 4.5). To determine the 
effects of alginate or Gaviscon upon proliferation of oesophageal adenocarcinoma cells 
control and iron loaded cells were exposed to either alginate or Gaviscon. 
 
In OE33 cells the addition of alginate had no effect upon cellular proliferation 
compared to control (0.96 ± 0.04 vs. 1 ± 0.04; p=ns) whilst Gaviscon was associated 
with a decrease in BrdU uptake (0.88 ± 0.08 vs. 1 ± 0.04; p<0.05). Iron induced 
proliferation relative to control (1.76 ± 0.07 vs. 1 ± 0.04; p<0.0001), an effect partially 
inhibited by the addition of alginate (1.36 ± 0.19 vs. 1.76 ± 0.07; p<0.05) or Gaviscon 
(1.41±0.04 vs. 1.76±0.07; p<0.001), fig 4.3A.  
CDC14A is a cell cycle control protein involved in the exit of cell mitosis and initiation 
of DNA replication. Assessment by western blot analysis demonstrated a 3.3 fold 
increase in protein expression of CDC14A following iron exposure, fig 4.5.  
In OE19 cells the addition of alginate decreased cellular proliferation compared to 
control (0.59 ± 0.12 vs. 1 ± 0.07; p<0.001) whilst Gaviscon was associated with no 
significant difference in BrdU uptake (1.05 ± 0.06 vs. 1 ± 0.07; p=ns). Iron induced 
proliferation relative to control (1.36 ± 0.06 vs. 1 ± 0.07; p<0.0001), an effect 
completely inhibited by the addition of alginate (0.88 ± 0.07 vs. 1.36 ± 0.06; p<0.001) 
and partially inhibited by the addition of Gaviscon (1.14 ± 0.03 vs. 1.36 ± 0.06; p<0.05), 
fig 4.4B.  
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Figure 4. 4.  Iron loading oesophageal adenocarcinoma cell lines increases cell 
proliferation whilst addition of alginate or Gaviscon inhibits proliferation following 
48 hours of cell culture 
Cells were cultured in the presence of alginate (1% w/v) or Gaviscon (0.1% v/v) ± iron 
(100µM ferrous sulphate) for 48 hours (for each regime n=12). Iron significantly 
increased cell proliferation in both cell lines. Addition of alginate to control media 
resulted in a repression of proliferation in OE19 but not OE33. Gaviscon repressed 
proliferation in OE33 but not OE19 cells. The addition of alginate or Gaviscon 
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decreased cell proliferation when added to iron loaded media in both lines relative to 
cells cultured with iron loaded media.   
+ p<0.05 relative to control cells; ++ p<0.001 relative to control cells * p<0.0001 
relative to control cells; ‡ p<0.05 relative to cells exposed to iron; ‡‡ p<0.001 relative 
to cells exposed to iron 
CTL: control; ALG: alginate; GAV:  Gaviscon; IRON: ferrous sulphate 
 
 
 
 
 
Figure 4. 5.  Iron loading OE33 cells increases expression of the cell cycle control 
protein CDC14A 
A 3.3 fold increase in expression of the cell cycle control protein CDC14A was observed 
in OE33 cells following 24 hours of culture with 100µM ferrous sulphate. 
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4.5 The effect of iron and alginate upon cell migration 
Since it has been previously demonstrated that iron can influence E-cadherin 
expression, a transmembrane cell adhesion molecule involved in cellular migration and 
invasion, the effect of iron on oesophageal adenocarcinoma cell migration was 
assessed by wound migration assay (fig 4.6). The effects of supplemental alginate or 
Gaviscon upon cells cultured with control media or iron loaded media were also 
explored (figs 4.7 and 4.8 respectively). 
 
4.5.1 The effect of elevated intracellular iron upon cell migration 
In OE33 cell monolayers cells rapidly closed a large wound (fig 4.6A). This process was 
augmented when cells were cultured in the presence of 100µM ferrous sulphate. 
There was no difference in the initial wound size between the groups (p=0.3). After 12 
hours of culture 56.9 ± 8.9% of the control wounds remained vs. 43.8 ± 2.4% of 
wounds exposed to iron (p<0.05). After 24 hours of culture 26.0 ± 3.4% of control 
wound remained vs. 10.8 ± 2.2% of wounds cultured in iron (p<0.05).  
In OE19 cells wounds were slower to heal than for OE33 cells but again the addition of 
100µM ferrous sulphate increased the rate of wound closure (fig 4.6B). There was no 
difference in the initial wound size between the different groups (p=0.9). After 24 
hours of culture 68.0 ± 5.0% of control wound remained vs. 48.4 ± 0.7% of wounds 
exposed to iron (p<0.001). After 48 hours 52.1 ± 5.5% of control wounds remained vs. 
31.6 ± 2.4% of wounds cultured in iron (p=0.01). After 96 hours 23.1 ± 8.5% of control 
wounds remained vs. 7.2 ± 1.6% of wounds cultured in iron (p<0.01; all control wounds 
remained open while 4/6 wounds exposed to iron had closed). All wounds had closed 
after 120 hours. 
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Figure 4. 6. Exposing oesophageal adenocarcinoma cells to iron increases cell 
migration 
Confluent monlayers of OE33 (fig A) and OE19 (fig B) were wounded and cultured in 
control media (control) or media supplemented with 100µM ferrous sulphate (iron). 
Cell migration and the rate of wound closure in both cell lines was greater when 
exposed to iron (* p<0.05; N = 6 for each regime)  
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4.5.2 The addition of alginate or Gaviscon to media does not affect cell migration 
Alginate or Gaviscon inhibits iron mediated affects upon cell phenotype including cell 
migration. To identify effects of alginate or Gaviscon upon cell migration amongst cells 
cultured in normal culture media a wound healing assay was performed with or 
without these agents (fig 4.7). 
 
In OE33 cells there appeared to be inhibition of cell migration in cells cultured in the 
presence of Gaviscon but not alginate (fig 4.7A). There was a significant repression at a 
single time point: at 24 hours of culture 26.0 ± 3.4% of control wound remained vs. 
45.1 ± 13% of wounds cultured with Gaviscon (p<0.05). There was no significant 
difference when alginate was added at any time point.  
In OE19 cells there was no difference in cell migration between cells cultured with or 
without alginate/Gaviscon at any time point (fig 4.7B).   
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 Figure 4. 7. The addition of alginate or Gaviscon to normal culture media has 
minimal effects upon cell migration in a wound healing assay  
Confluent monlayers of OE33 (fig A) and OE19 (fig B) were wounded and cultured in 
control media (control) or media supplemented with 1% alginate or 0.1% Gaviscon. 
Cell migration and the rate of wound closure were similar in both lines when Gaviscon 
or alginate were added to control cells with the exception of Gaviscon at 24 hours in 
OE33 cell (* p<0.05; n = 6 for each regime).  
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4.5.3 The effect of elevated intracellular iron upon cell migration is inhibited by 
addition of alginate or Gaviscon 
Elevated intracellular iron induces a greater rate of cell migration in oesophageal 
adenocarcinoma cell lines. To assess whether alginate or Gaviscon can affect this 
observation the wound healing assay was performed with cells grown in media 
stimulated with 100µM ferrous sulphate ± alginate (1% w/v LFR5/60 alginate) or 
Gaviscon (0.1% v/v) (fig 4.8).   
 
In OE33 cells the addition of either alginate or Gaviscon to culture media with iron 
resulted in a reduced rate of wound closure (fig 4.8A). After 12 hours of culture 43.8 ± 
2.4% of wounds exposed to iron remained vs. 58.8 ± 7.1% iron + alginate (p<0.001) and 
vs. 55.9 ± 13.0% iron + Gaviscon (p<0.05). After 24 hours of culture 10.8 ± 2.2% of 
wounds cultured in iron remained vs. 39.5 ± 7.9% iron + alginate (p<0.05) and vs. 36.7 
± 9.5 iron + Gaviscon (p<0.05). After 36 hours all wounds cultured in the presence of 
iron alone had closed. At this point 18.4 ± 9.9% of iron + alginate wounds remained as 
did 12.5 ± 13.6% of iron + Gaviscon (both p<0.0001); fig 4.8A 
 
In OE19 cells again the addition of either alginate or Gaviscon to culture media with 
iron resulted in a reduced rate of wound closure (fig 4.8B). There was no difference in 
the initial wound size (iron vs iron +alginate p=0.27, vs. iron + Gaviscon p=0.24). After 
24 hours of culture 48.5 ± 0.7% of wounds exposed to iron remained vs. 72.0 ± 6.8% 
iron + alginate (p<0.05) and vs. 87.7 ± 3.7% iron + Gaviscon (p<0.0001). After 48 hours 
of culture 31.6 ± 2.4% of wounds cultured in iron remained vs. 58.3 ± 6.6% iron + 
alginate (p=0.02) and vs. 64.8 ± 7.6 iron + Gaviscon (p<0.01). After 72 hours of culture 
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18.3 ± 1.3% of wounds exposed to iron remained vs. 48.5 ± 9.1% iron + alginate 
(p=0.02) and vs. 43.8 ± 8.1% iron + Gaviscon (p=0.02). After 96 hours of culture 
7.2±1.6% of wounds cultured in iron remained vs 27.2±6.3% iron + alginate (p=0.02) 
and vs. 30.4±4.5 iron + Gaviscon (p<0.01). After 120 hours of culture all wounds 
cultured in iron had closed whilst 12.9±5.8% iron + alginate remained (p=0.07) and vs. 
4.5±4.5% iron + Gaviscon (p=0.36); fig 4.8B and fig 4.9. 
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Figure 4. 8. Addition of alginate or Gaviscon to iron loaded media decreases wound 
migration by oesophageal adenocarcinoma cells  
Confluent monlayers of OE33 (fig 4.7A) and OE19 (fig 4.7B) were wounded and 
cultured in media supplemented with 100µM ferrous sulphate (iron) or with additional 
alginate (1% W/V) or Gaviscon (0.1% V/V). Cell migration and the rate of wound 
closure in both cell lines was greater when exposed to iron (* p<0.05 iron vs both iron 
+ alginate and iron + gaviscon, ‡ <0.05 iron vs. Iron + alginate; N = 6 for each regime) 
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Figure 4. 9. Photo-montage of OE19 wound healing assay 
Cells were cultured in media supplemented with 100µM ferrous sulphate (iron) or with 
additional alginate (1% w/v) or Gaviscon (0.1% v/v).  
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4.6 The effect of iron and alginate upon anchorage independent growth of 
oesophageal adenocarcinoma cells 
Anchorage independent growth is an important process in carcinogenesis. Benign cells 
require cell – cell contact and exogenous growth factors for cell division whilst 
malignant cells have a much greater potential to divide independently.  To further 
explore effects of iron upon cell phenotype colony forming assay was performed (figs 
4.10 and 4.11). The effects of alginate to inhibit colony formation were also explored. 
Single cell agar suspension was seeded in 6 well plates (N=6 each regime) and cultured 
for 14 days. 3 photographs at random were taken of each well and colonies measured 
within each photograph. 
 
In OE33 cells iron increased the average size of colonies compared to control (7491 ± 
1097 vs. 5564 ± 1038 µM2, p=0.05). The addition of alginate or Gaviscon decreased the 
size of colonies relative to control (2514 ± 1014 and 2250 ± 840 respectively vs. 5564 ± 
1038 µM2, both p<0.0001). The addition of alginate or Gaviscon to iron loaded media 
resulted in a decrease in colony size relative to both iron loaded and control media 
(1731 ± 414 and 1565 ± 373 µM2 for iron + alginate and iron and Gaviscon vs. iron 
[7491 ± 1097 µM2] both p<0.0001 and vs. control [5564 ± 1038 µM2] both p<0.0001. 
There was no significant difference between cells cultured with aliginate ± iron 
(p=0.15) or with Gaviscon ± iron (p=0.16). Fig 4.10 A and B. 
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In OE19 cells iron increased the average size of colonies compared to control (14179 ± 
2878 vs. 5556 ± 1413 µM2, p=0.00002). The addition of alginate or Gaviscon had no 
significant effect upon the size of colonies relative to control (5281 ± 2180 and 6241 ± 
2457 respectively vs. 5556 ± 1413 µM2, both p=ns). The addition of alginate or 
Gaviscon to iron loaded media resulted in a decrease in colony size relative to iron 
loaded media (5504 ± 2160 and 4670 ± 1578 µM2 for iron + alginate and iron and 
Gaviscon vs. 14179 ± 2878 µM2 both p<0.0001). This was comparable to colonies 
grown in control media ± alginate or Gaviscon (both p=NS). Fig 4.11 A and B. 
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Figure 4. 10.  Colony forming assay OE33 adenocarcinoma cell line 
Cells were cultured in control media or media supplemented with 100µM ferrous 
sulphate (iron) ± additional alginate (1% w/v) or Gaviscon (0.1% v/v). Colonies were 
measured (fig A) and photographed (fig B, typical colonies are indicated with arrows) 
14 days after seeding a single cell suspension. * p<0.05; ** p<0.0001 vs control; ‡ 
p<0.0001 vs iron. 
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Figure 4. 11.  Colony forming assay OE19 cell line 
Cells were cultured in control media or media supplemented with 100µM ferrous 
sulphate (iron) ± additional alginate (1% w/v) or Gaviscon (0.1% v/v). Colonies were 
measured (fig A) and photographed (fig B, typical colonies are indicated with arrows) 
14 days after seeding a single cell suspension. * p<0.05;   ‡ p<0.0001 vs iron. 
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4.7 The effect of iron on the expression of the cellular iron transport proteins in 
oesophageal adenocarcinoma  
To identify how the exposure of oesophageal adenocarcinoma cells to iron affects the 
expression profile of the iron transporters TfR, DMT1, ferritin, and ferroportin, cells 
were cultured with or without supplemental iron. OE33 and OE19 cells were exposed 
to iron and the optimum time period for observing changes in mRNA expression was 
identified at 12 hours (other periods observed were 3, 6, 9, 24 and 48 hours, data not 
shown).  
 
Significant induction of TfR and DMT1 mRNA was observed when cultured with iron in 
both OE33 and OE19 cell lines. There was no significant effect upon the expression of 
ferritin or ferroportin mRNA in either cell line (table 4.1). 
 
 OE33  OE19  
 CONTROL 
IRON 
LOAD 
P CONTROL 
IRON 
LOAD 
P 
TfR 1±0.19 2.02±0.26 <0.01 1±0.03 3.36±1.01 0.02 
DMT1 1±0.23 1.9±0.2 0.02 1±0.36 2.71±0.16 <0.01 
Ferritin 1±0.28 1.35±.032 ns 1±0.19 0.59±0.32 ns 
Ferroportin 1±0.05 0.97±0.13 ns 1±0.2 0.9±0.37 ns 
 
Table 4. 1. Change in mRNA expression of TfR, DMT1, Ferritin and ferroportin 
following culture with or without supplemental iron.  
Data are the mean fold change in expression ± 2SEM standardised to control 
expression. Students T test. 
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4.8 Elevated expression of TfR and DMT1 mRNA is potentially due to aberrant Wnt 
signalling 
On the basis that increased deposition of iron was observed in samples of oesophageal 
adenocarcinoma following an iron challenge one could predict a reduction in TfR1 and 
DMT1 mRNA expression mediated via the IRP/IRE mechanism. This is not occurring as 
demonstrated by increased TfR1 and DMT1 mRNA expression following culture with 
iron in 4.7 above suggesting an aberration in IRP/IRE sensing or an alternative 
mechanism of control. In colorectal adenocarcinoma iron mediates upregulated 
expression of TfR and DMT1 through positive feedback in cells with an APC gene 
mutation[251;366]. The mechanism is due to aberrant Wnt signalling with 
accumulation of beta catenin and downstream upregulation of the oncogene c-myc. 
This in turn increases IRP2 and thus the increased expression of TfR and DMT1. To 
explore if similar biochemical events occur in oesophageal adenocarcinoma mRNA 
from oesophageal adenocarcinoma cell lines was analysed for c-myc and IRP2. Anti 
beta-catenin was used upon cell lysate to identify expression of beta catenin. Finally an 
assessment of APC status was performed upon the cell lines used in these experiments 
by gene sequencing and Western blotting.  
 
4.8.1 Expression of IRP2, c-myc and beta-catenin following iron loading oesophageal 
adenocarcinoma cells 
In OE33 cells cultured with iron an increased expression of IRP2 (2.71 ± 0.16, P<0.01) 
and c-myc (4.12 ± 0.45, P<0.05) mRNA was observed relative to control (1 ± 0.66, IRP2 
and 1 ± 0.32, c-myc) (fig 4.12). This was associated with an increased expression of 
beta-catenin protein expression (1.8 ± 0.1 vs 1 ± 0.13, P<0.001) (fig 4.13). 
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In OE19 cells cultured with supplemental iron similar changes were observed with 
increased expression of IRP2 (2.43 ± 0.67, p<0.05) and c-myc (2.58 ± 0.33, P<0.05) 
mRNA relative to control (1 ± 0.45, IRP2 and 1 ± 0.32, c-myc) (fig 4.11). This was 
associated with an increased expression of beta-catenin protein expression (1.6 ± 0.1 
vs 1 ± 0.24, P<0.001) (fig 4.13). 
 
 
 
Figure 4. 12.  mRNA expression of IRP-2 and c-myc following exposure to iron in OE33 
and OE19 cell lines 
After 12 hours of culture in normal media (control) or media with supplemental iron 
there was significant upregulation of both IPR-2 and c-myc mRNA expression in both 
cell lines.   
* p<0.05; ** p<0.01 
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Mean 
expression 2SEM 
P 
value 
CTL 1.00 0.13  
OE33 1.80 0.09 <0.001 
CTL 
OE19 
1.00 
1.56 
0.08 
0.15 
 
<0.001 
 
Figure 4. 13. β-catenin protein expression in OE33 and OE19 cell lines following 
exposure to iron  
Increased β-catenin expression was observed in both cells lines following culture with 
iron (n=3 each regime; p<0.001 both cell lines vs control; Student’s T test). 
 
4.8.2 APC status of OE33 and OE19 cell lines  
APC function is lost in most if not all cases of oesophageal adenocarcinoma[79;124]. 
Wnt signalling via APC together with axin and GSK-3β acts to phosphorylate beta-
catenin. A loss of APC function increases beta-catenin with downstream effects 
including the transcription of the oncogene c-myc. In colorectal carcinoma this is 
associated with an increase in iron regulatory protein 2 with subsequent increased iron 
import via TfR1 and DMT1[366]. The common mechanism of loss of APC function in 
oesophageal adenocarcinoma is APC gene methylation[124], though APC mutation can 
occur[79]. To investigate the APC status of the OE19 and OE33 cells used in this body of 
work gene analysis and assessment of protein function were performed.  
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4.8.2.1 APC gene sequencing of OE33 and OE19 cell lines 
Both cell lines were prepared according to protocol (see methods). PCR demonstrated 
successful isolation of the APC fragments G, H and I in both cell lines. There was no 
major gene mutation of the gene multiple cluster region fragments G, H or I in either 
cell line. A shift mutation occurred at locus 1493 in both cell lines. OE33 cells are 
homozygous for the A allele (fig 4.14A) whilst OE19 are homozygous for the G allele (fig 
4.14B). There is no functional significance as threonine remains threonine in both lines.  
 
 
Figure 4. 14.  APC gene analysis of OE33 and OE19 cell lines 
A polymorphism was present in both OE33 and OE19 cell lines in the APC fragment 15I 
at locus 1493. OE33 cells are homozygous for A allele (fig A) whilst OE19 are 
homozygous for the G allele (fig B). 
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4.8.2.2 APC protein function of OE33 and OE19 cell lines 
Western blot analysis to the C terminus of the APC gene was performed using RKO cells 
(wild type for APC) as a positive control. In neither OE19 or OE33 cell lines was 
functional APC observed (fig 4.15). This is in keeping with findings from other 
authors[66].  
 
 
 
Figure 4. 15.  APC analysis of OE19 and OE33 
In neither OAC cell line was APC protein expression observed. RKO cells wild type for 
APC provide a positive control  
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4.9 Conclusions 
Having observed the aberrant expression of iron transport proteins in the progression 
of oesophageal adenocarcinoma, the in-vitro results demonstrated in this chapter 
further implicate iron metabolism as a key component of this disease process.  
Iron is essential for the control of cell cycling through proteins such as p53, p21 and 
GADD45[250]. In addition iron is essential for cell metabolism, enzymatic reactions, 
energy production and DNA synthesis[160], with cells, such as tumour cells that are 
metabolically highly active and rapidly dividing, clearly requiring an elevated level of 
iron over less active cells[250]. At first glance the overexpression of iron import and 
repression of export proteins observed in chapter 3 appears likely to reflect the natural 
metabolism of oesophageal adenocarcinoma cells i.e. the profile of a metabolically 
active and rapidly dividing cell type. However, following exposure to iron, in-vitro, there 
appears to be positive feedback, with cells demonstrating increasing proliferation and 
thus the intriguing assumption that iron may actually drive carcinogenesis. Iron 
exposure of oesophageal adenocarcinoma cells is associated with an increase in 
expression of transferrin receptor, divalent metal transporter and relocalisation of the 
iron export protein ferroportin to the cytoplasm where it is non functional. Presumably 
this profile of iron transport proteins increases the quantity of iron within the cell 
generating positive feedback. Direct effects of this broadly induce a phenotype one 
would expect of a malignant cell i.e. increased proliferation, cell migration and 
anchorage independent growth. Direct evidence that iron induces proliferation is 
demonstrated with increased expression of the cell cycle control protein CDC14A. The 
observation in this chapter that exposure of both OAC cell lines OE33 and OE19 to iron 
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increases expression of the oncogene c-myc, which is accompanied by increased β-
catenin, implicates iron with aberrant Wnt signalling in oesophageal adenocarcinoma. 
This observation has been demonstrated within colorectal adenocarcinoma, where APC 
mutant cells have increased TOPFLASH reporter activity following culture with iron 
loaded media[366]. The consequence of this enhanced TCF signalling is activation of 
Wnt target genes, including the oncogene c-myc[366]. C-myc can induce expression of 
TfR1 and IRP2 whilst repressing expression of ferritin[374-376]. In APC deficient cells 
positive feedback is clearly demonstrated in that iron exposure results in elevated 
expression of TfR1. The physiological effects of this elevated cellular iron load is 
augmented by increased expression of IRP2. It would be expected that elevated IRP2 
would induce the cell to behave in an iron deficient manner, despite the actual 
elevated iron load, with further induction of TfR1 and DMT1[366]. Whilst the 
mechanism of APC inactivation is different in oesophageal adenocarcinoma compared 
to colorectal adenocarcinoma, gene methylation as opposed to mutation, the 
consequences of iron exposure appear the same with elevated expression of c-myc and 
TfR1, DMT1 and repression of ferritin. TOPFLASH assays were performed with both 
OE33 and OE19 cell lines to directly observe the effects of iron exposure upon Wnt 
signalling in oesophageal adenocarcinoma. Despite numerous attempts and with 
various transfection mechanisms/strategies it was not possible to reliably and 
efficiently transfect either cell line with the TOPFLASH reporter. Despite this other 
authors have demonstrated that OE33[377] and OE19[66] cells have aberrant Wnt 
signalling pathways and thus it would appear that iron mediated effects within 
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oesophageal adenocarcinoma replicate those seen in other APC deficient tumours[366] 
and are likely to reflect pathological Wnt signalling.   
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CHAPTER 5: CHARACTERISATION OF HAEM IMPORT PROTEINS AND 
EFFECTS OF HAEM, WITH OR WITHOUT ALGINATE, IN THE MALIGNANT 
PROGRESSION OF OEOSPHAGEAL ADENOCARCINOMA 
 
5.1 Introduction 
Epidemiological evidence associates diets high in iron content with Barrett’s 
metaplasia[132] and oesophageal adenocarcinoma[132-134]. In a rat model of 
oesophageal reflux iron deposition occurs at sites of oesophagitis which mirrors the 
cellular location of iron deposition seen in human tissue samples[155-157]. In the 
animal model metaplasia and adenocarcinoma only occurred in animals receiving 
supplemental iron[147-149]. Cancer cells have a high requirement for iron which is 
likely to give them a selective advantage through effects upon cell cycle control[250], 
tumour suppressor[162;163] and oncogene function[366]. 
 
It is unclear whether these effects are mediated by inorganic iron, haem or both. The 
potential for haem as a causal agent has, to date, been largely neglected. This is 
presumably due to a lack of understanding of mechanisms of haem absorption from 
the gut with cellular transport proteins only recently being characterised. The evidence 
that haem plays an important role in oesophageal adenocarcinoma is summarised as 
follows: 
 (1) The association of diets high in red meat with oesophageal adenocarcinoma the 
majority of epidemiological evidence associates haem, not inorganic iron, with this 
disease[132-135]. 
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(2) For omnivors haem is both more abundant in the diet and absorbed with greater 
affinity[230] than elemental iron, thus providing the majority of dietary iron[191]. 
(3) Body stores of haem and elemental iron should be considered together, as iron can 
pass from one pool to the other, depending upon body and cell requirements.  
(4) Haem absorbed by enterocytes can undergo metabolism to release iron which is 
exported via ferroportin and transported bound to transferrin. However increasing 
evidence demonstrates that haem can be exported intact (candidates include the feline 
leukaemic virus receptor [FLVCR[244]] and the ATP-binding cassette G2 protein 
[ABCG2[245]] which have both been identified within enterocytes and are known haem 
exporters within the reticuloendithelial system).  
(5) Elaborate control of cellular iron content is affected by the IRE/IRP system. It is 
interesting to note that haem binds IRP2 with high affinity[232] with subsequent 
degradation. Depleting IRP2 levels decreases cellular inorganic iron import and 
facilitates storage via ferritin[232]. Thus haem and inorganic iron within cells are linked 
via a common control mechanism.  
(6) Erythrocytes are a significant store of body iron, in the form of haem, and given the 
rate of red blood cell turnover recycling of this iron is essential. The fate of the majority 
of red cells is degradation within liver, spleen and bone marrow with release of free 
iron. However approximately 20% of cells undergo intravascular haemolysis with 
release of free haem[378] – a potent oxidant. Scavenging and recycling of this haem 
occurs via binding with haemopexin.  
(7) Haem is a potent oxidant[239] and thus oxidative damage in the malignant 
progression of Barrett’s metaplasia may be mediated via haem if native oesophagus, 
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metaplastic or adenocarcinoma cells possess haem transporters. This appears plausible 
as inflammation from gastro-oesophageal reflux, the trigger for Barrett’s metaplasia, is 
associated with increased expression of haemoxygenase-1, an enzyme which catalyses 
the degradation of haem in response to oxidative stress[155;379]. 
 
It is likely that as well as inorganic iron, haem may play a role in the malignant 
progression of oesophageal adenocarincoma. Therefore it is possible that chelation of 
haem may also provide a platform for therapeutic intervention. Whether alginates, 
which others have shown to be natural dietary iron chelators[345;346], are able to 
comparably bind haem is currently not known. 
 
Thus the aims of this chapter are to: 
1. Examine the expression of haem import proteins (HCP-1 and LRP-1) in normal 
oesophagus, BM and OAC 
2. Determine the ability of in-vitro cultured oesophageal adenocarcinoma cells to import 
haem and the effects upon expression of haem and iron transport proteins 
3. Determine the effects of haem exposure in an in-vitro model of oesophageal 
adenocarcinoma with respect to cellular proliferation, viability, migration and 
anchorage independent growth 
4. Determine whether effects observed in 3 above can be modulated, by the natural 
chelator, alginate  
5. Perform knockdown of LRP-1 expression by oesophageal adenocarcinoma cells and 
determine effects upon haem transport and cell phenotype 
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5.2 Semiquantitative immunohistochemistry of haem transport proteins in the 
malignant progression of oesophageal adenocarcinoma 
 
Semiquantitative immunohistochemistry was used to elucidate the cellular localisation 
and to approximate the expression of haem transport proteins haemopexin receptor 
(LRP-1) and haem carrier protein (HCP-1) in archived paraffin tissue specimens of 
normal oesophagus, benign Barrett’s metaplasia, Barrett’s metaplasia from sections 
adjacent to matched oesophageal adenocarcinoma and oesophageal adenocarcinoma.  
 
5.2.1 Immunolocalisation of LRP-1 in oesophageal tissue 
Weak immunoreactivity was observed in squamous oesophageal cells as they progress 
towards the luminal border. Immunoreactivity was present in the cytoplasm with no 
localisation at the cell border. No immunoreactivity was seen in cells in the basal layer 
(Figure 5.1 S – image A and B). In benign Barrett’s metaplasia there was weak 
immunoreactivity again seen in the cytoplasm of cells at the luminal border but not 
within the deeper crypts (figure 5.1 BM – images D and E). Dense immunoreactivity 
was observed in the nucleus and at the apical border of Barrett’s samples adjacent to 
oesophageal adenocarcinoma (Figure 5.1 BM with OAC – images F and G). Dense 
immunoreactivity was observed in oesophageal adenocarcinoma where LRP-1 was 
localised to vesicles near the apical border and along the apical membrane (Figure 5.1 
OAC images H and I).  
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5.2.2 Immunolocalisation of HCP-1 in oesophageal tissue 
No expression of HCP-1 was observed in squamous oesophagus (Figure 5.2 S – image 
A). In benign Barrett’s metaplasia there was very little immunoreactivity observed 
(figure 5.2 BM – images C and D). In samples of Barrett’s epithelium adjacent to 
oesophageal adenocarinoma expression was seen throughout the cytoplasm though 
staining was weak (figure 5.2 BM WITH OAC – images E and F). Strong 
immunoreactivity was observed in oesophageal adenocarcinoma where HCP-1 was 
found diffusely throughout the cytoplasm of invasive adenocarcinoma (Figure 5.2 OAC 
images G and H). 
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Figure 5. 1. Immunolocalisation of the LRP1 receptor in oesophageal adenocarcinoma 
LRP-1 immunolocalisation in sections of normal squamous oesophagus (S: A,B n=10), 
Barrett’s metaplasia (BM: D,E n=20), Barrett’s metaplasia with matched oesophageal 
adenocarcinoma (BM with OAC: F,G n=20) and oesophageal adenocarcinoma (OAC: H,I 
n=20). Weak staining for LRP-1 was observed in squamous oesophagus (S) and benign 
Barrett’s epithelium (BM). Staining was stronger in both Barrett’s associated with 
adenocarcinoma (BM with OAC) and adenocarcinoma (OAC). Negative controls (OAC: 
C) were performed during the experiments by omission of primary antibody followed 
by processing with the appropriate secondary antibody. Arrows denote areas of 
positive expression (original magnification A, D, F, H x20; B, C, E, G, I X40). 
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Figure 5. 2.  Immunolocalisation of the HCP1 protein in oesophageal adenocarcinoma  
Immunolocalisation of HCP-1 in sections of normal squamous oesophagus (S – A; n=10), 
Barrett’s metaplasia (BM – C and D; n=20), Barrett’s metaplasia from subjects with 
oesophageal adenocarcinoma (BM WITH OAC – E and F, n=20) and oesophageal 
adenocarcinoma (OAC – G and H; n=20). No HCP-1 expression was observed in 
squamous oesophagus. In Barrett’s epithelium HCP-1 expression was minimal but in 
Barrett’s adjacent to OAC expression was seen weakly through the cytoplasm. Staining 
was strong and diffusely spread throughout invasive adenocarcinoma. Negative 
controls were performed by omission of primary antibody followed by processing with 
the appropriate secondary antibody, positive control was human duodenum (B) 
(original magnification A, B, C, E, G x20; D, F, H X40). 
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5.3 Quantitative analysis of haem transport protein mRNA by real time qRT-PCR  
To explore if the expression of haem transport proteins in normal oesophagus, 
Barrett’s metaplasia and adenocarcinoma is regulated at a transcriptional level qRT-
PCR was utilised. The expression of LRP-1 and HCP-1 mRNAs was determined relative to 
18s ribosomal mRNA internal standard. Non dysplastic Barrett’s metaplasia (BM-ve) 
(over 3cm in length and confirmed as columnar epithelium with intestinal type goblet 
cells) with no evidence of adenocarcinoma or dysplasia was compared to matched 
samples of squamous oesophagus and gastric epithelium (n=10). Oesophageal 
adenocarcinoma samples were compared to matched samples of associated Barrett’s 
metaplasia (BM+ve) (n=12).  
 
5.3.1 Assessment of HCP-1 expression in oesophageal tissue by qRT-PCR 
There was no significant difference in HCP-1 mRNA expression between BM-ve and 
matched gastric epithelium (0.84 ± 0.40, mean ± 2SEM) or with matched squamous 
epithelium (1.61 ± 0.4). Expression of HCP-1 mRNA was greater in 11/12 samples of 
oesophageal adenocarcinoma compared to BM+ve (7.90 ± 3.97; p=0.035); fig 5.3A. 
 
5.3.2 Assessment of LRP-1 expression in oesophageal tissue by qRT-PCR 
There was no significant difference in LRP-1 mRNA expression between BM-ve and 
matched gastric epithelium with an average fold difference of 1.66 ± 0.67 (mean ± 
2SEM) or when compared with matched squamous epithelium 1.81 ± 1. Expression of 
LRP-1 mRNA was greater in every sample of oesophageal adenocarcinoma compared to 
BM+ve (6.20 ± 0.60; p=0.02); fig 5.3B. 
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Figure 5. 3.  Mean mRNA expression of haem transport proteins in the progression of 
oesophageal adenocarcinoma 
No significant difference in expression of HCP-1 (fig A) or LRP-1 (fig B) when comparing 
BM-ve with gastric or squamous oesophagus. Significant upregulation of HCP-1 and 
LRP-1 mRNA expression in oesophageal adenocarcinoma versus associated Barrett’s 
epithelium (n=12; p<0.05).  
HCP-1 – haem carrier protein; BM-ve - -benign Barrett’s epithelium; G - gastric 
epithelium; S - squamous oesophagus; OAC - oesophageal adenocarcinoma; BM+ve - 
Barrett’s epithelium associated with oesophageal adenocarcinoma ; * p<0.05 
 
5.4 Determination of haem import by oesophageal adenocarcinoma cell lines 
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To determine whether oesophageal adenocarcinoma cells are able to import haem the 
following assays were performed using oesophageal adenocarcinoma cell lines: 
(1) Cell culture in the presence of the fluorescent haem analogue, zinc protoporphyrin 
(ZnPP) 
(2) Cultured in the presence of haem followed by a ferrozine assay to assess cellular 
iron content  
(3) Cultured in the presence of radiolabelled haem55Fe 
 
5.4.1 Determination of fluorescence following culture with ZnPP 
After culture in the presence of ZnPP adherent cells were thoroughly washed with 5% 
albumin (w/v) solution to remove surface ZnPP. Cells were excited by light at 415 nm 
and observed at 630 nm. Both OE33 and OE19 cells showed evidence of fluorescence 
as demonstrated in figs 5.4 A and B. Most cells demonstrated moderate diffuse 
fluorescence whilst a few cells demonstrated marked fluorescence.  
 
5.4.2 Determination of cellular iron content by ferrozine assay following culture with 
haem  
After 24 hours of cell culture in the presence of 50µM haem a ferrozine assay was 
performed on both OE19 and OE33 cell lines (fig 5.5 A and B). Exposure to haem 
increased the iron content from 2.7 ± 0.3 to 14.6 ± 0.5 nmol Fe/mg cell protein 
(p<0.0001) in OE19 cells and from 4.0 ± 0.4 to 16.9 ± 0.9 nmol Fe/mg cell protein 
(p<0.0001) in OE33 cells.  
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5.4.3 Quantification of radiolabelled haem55Fe uptake in oesophageal 
adenocarcinoma cell lines 
OE19 cells were cultured in the presence of a 50µM haem solution containing 1% 
haem55Fe for two hours. The same volume of haem55Fe media was added to empty 
wells for the same duration. A further set of control wells contained OE19 cells cultured 
in media containing a 50µM haem solution without supplemental haem55Fe. Culture 
media were aspirated and added to scintillant. Adherent cells were washed following 
which they were trypsinised and resuspended in scintillant fluid. 91.0±2.4% of cell 
counts remained in the culture fluid from wells containing OE19 cells (fig 5.6 A). In the 
cell pellets little background radioactivity was evident in cells cultured in normal media, 
57 ± 25 DPM-1, but in those cultured with haem55Fe there were 20600 ± 163 DPM-1 (fig 
5.6 B, p<0.00001). 
 
  
  
168 
 
 
  
Figure 5. 4. Uptake of zinc protoporphyrin by OE33 (fig 5.4A x40) and OE19 (fig 5.4B 
x40) cells 
Both cell lines internalised ZnPP following 4 hours of culture. 
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Figure 5. 5.  Ferrozine assay upon oesophageal adenocarcinoma cells following 
culture with  haem  
OE19 (fig A) and OE33 (fig B) cells were cultured in a 50µM solution of haem or control 
media for 24 hours. Following this cells were washed, trypsinised with the subsequent 
cell pellet washed three times. Ferrozine assay demonstrated increased intracellular 
iron content of both OE19 and OE33 cells (both p<0.0001 *) 
 
 
Figure 5. 6.  Uptake of radiolabelled haem55Fe by OE19 cells  
haem55Fe loaded media (3ml with 50µM haem [99% haem, 1% haem55Fe] was added to 
wells containing OE19 cells or empty wells (fig A); a further control consisted of OE19 
cells cultured with haem with no radioisotope (fig B). After two hours the media was 
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aspirated and the disintegrations per minute (DPM-1) were measured. Media from 
wells with OE19 cells expressed 91 ± 2.4% of the disintegrations that media from empty 
wells expressed (fig 5.6 A, n=3, *p<0.001). Fig 5.6B demonstrates little background 
radioactivity in control cells but the OE19 cell pellet from the wells with haem55Fe had 
significantly greater radioactivity (n=3,** p<0.0001).  
 
5.5 Cellular iron loading of cells cultured in haem is inhibited by the addition of 
alginates to culture  
Oesophageal adenocarcinoma cells cultured in haem have elevated intracellular iron 
content. Alginate suppresses iron loading of cells cultured in supplemental iron 
sulphate and thus the effects of alginate to abrogate the haem loading of cell lines 
exposed to haem with or without supplemental alginate was explored. A 1% (w/v) 
solution of LFR 5/60 alginate or a 0.1% (v/v) solution of Gaviscon was added to the 
culture media with or without supplemental haem (for each regime n=6). A ferrozine 
assay was used to quantify intracellular iron content (fig 5.7A – OE33 and fig 5.7B – 
OE19). 
 
In OE33 cells, after 48 hours of cell culture with 50µM haem solution, there was a 1.6 
fold increase in iron content compared to control (2.52 ± 0.3 vs. 1.62 ± 0.17 nmol 
Fe/mg cell protein, p=0.014). Addition of alginate to control media reduced iron 
content (0.90 ± 0.2 vs. 1.62 ± 0.17 nmol Fe/mg cell protein, p=0.02) as did Gaviscon 
(1.19 ± 0.07 vs. 1.62 ± 0.17 nmol Fe/mg cell protein, p=0.0001). Addition of alginate to 
haem loaded media resulted in a non significant decrease in iron content (1.87 ± 0.18 
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vs. 2.52 ± 0.3 nmol Fe/mg cell protein, p=0.26) whilst the addition of Gaviscon reduced 
the iron content to that similar to control + Gaviscon (0.82 ± 0.18 vs 2.52 ± 0.3 nmol 
Fe/mg cell protein, p=0.0001).  
 
In OE19 cells, after 48 hours of cell culture with haem solution, there was a 5.5 fold 
increase in cellular iron content compared to cells grown in control media alone (14.6 ± 
0.31 vs. 2.67 ± 0.2 nmol Fe/mg cell protein, p=0.0001). Addition of alginate to control 
media resulted in a slight decrease in iron content (1.89 ± 0.34 vs. 2.67 ± 0.2 nmol 
Fe/mg cell protein, p=0.002) whilst Gavison had no significant effect (2.60 ± 0.13 vs. 
2.67 ± 0.2 nmol Fe/mg cell protein, p=0.4). The addition of alginate to haem loaded 
media resulted in a significant decrease in iron content compared to cells culture in 
haem loaded media alone (12.39 ± 0.61 vs. 14.6 ± 0.31 nmol Fe/mg cell protein, 
p=0.001) as did Gaviscon (10.81 ± 0.31 vs. 14.6 ± 0.31 nmol Fe/mg cell protein, 
p=0.0001).  
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Figure 5. 7.  Addition of alginate or Gaviscon to haem loaded media decreases 
cellular iron content in OE33 cells (fig 5.7A) and OE19 cells (fig 5.7B) 
Cells were cultured for 48 hours in the presence of control media or a 1% alginate 
solution or 0.1% Gaviscon solution ± 50µM Haem (for each regime n=6). Addition of 
alginate to control media resulted in a significant decrease in iron content in both cell 
lines (p<0.05) whilst Gaviscon decreased the iron content in OE33 cells (p<0.05). Haem 
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significantly increased the iron content of both cell lines (p<0.0001), an effect 
significantly suppressed by the addition of Gaviscon to either cell line (p<0.001). The 
addition of alginate to haem media decreased the iron content of OE19 cells (p<0.001) 
but not in OE33 cells. 
* p<0.05, ** p<0.01, *** p<0.001 vs. control cells; ‡ p <0.001 vs haem loaded cells 
Ctl: control; Alg: 1% w/v alginate; Gav: 1% Gaviscon; Haem: 50µM haem solution 
 
 
5.6 Haem loading oesophageal adenocarcinoma cell lines increases the cell viability 
an effect suppressed by the addition of alginate 
Culturing oesophageal adenocarcinoma cell lines with supplemental iron increased cell 
viability. To explore whether haem exposure would produce similar effects an MTT (3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was performed to 
quantify the viable cells following 48 hours of culture with and without haem added to 
culture media. Given that the addition of alginates to media decreases the cellular iron 
content of cells cultured in the presence of iron the effect of adding alginate (1% w/v) 
or Gaviscon (0.1% v/v) to control and haem loaded media was also explored (fig 5.8) 
(for each regime n=12). 
 
In OE33 cells, following 48 hours of cell culture, significantly greater numbers of viable 
cells were present when cultured in the presence of media supplemented with 50µM 
haem (1.55 ± 0.02 vs 1.0 ± 0.07, p=0.0001). The addition of alginate to control media 
significantly decreased the cell viability relative to control (0.57 ± 0.09 vs. 1 ± 0.07, 
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p=0.001) as did Gaviscon (0.68 ± 0.11 vs. 1 ± 0.07, p=0.0009). Supplementing haem 
loaded media with alginate decreased the cell viability relative to haem loaded media 
alone (0.95 ± 0.16 vs. 1.55 ± 0.02, p=0.0003) with Gaviscon having a similar effect (1.1 ± 
0.1 vs. 1.55 ± 0.02, p=0.0003), fig 5.8A.  
 
In OE19 cells haem also increased the population of viable cells following 48 hours of 
cell culture compared to control (1.47 ± 0.19 vs 1.0 ± 0.12, p=0.01). The addition of 
alginate to control media non-significantly decreased cell viability relative to control 
(0.83 ± 0.12 vs. 1 ± 0.12, p=0.15) as did Gaviscon (0.78 ± 0.19 vs. 1 ± 0.12, p=0.06). 
Supplementing haem loaded media with alginate non-significantly decreased cell 
viability relative to haem loaded media alone (1.20 ± 0.13 vs. 1.47 ± 0.19, p=0.1) with 
Gaviscon having a more marked and significant effect (0.82 ± 0.13 vs. 1.47 ± 0.19, 
p=0.002), fig 5.8B.  
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Figure 5. 8.  Haem increases the viable cell population, an effect which is inhibited by 
the addition of alginate or Gaviscon in OE33 cells (fig 5.8A) and OE19 cells (fig 5.8B) 
Cells were cultured for 48 hours in the presence of control media or a 1% alginate 
solution or 0.1% Gaviscon solution ± 50µM Haem (for each regime n=12). Haem 
significantly increased cell population in both cell lines. The addition of Gaviscon to 
cells cultured in the presence of haem decreased the cell population significantly in 
both lines whilst the addition of alginate led to a significant decrease in OE33 and non 
significant decrease in OE19 cells lines. Alginate and Gaviscon led to significant 
decreases in viable cells compared to a control cell population in OE33 cells and non 
significant differences in OE19 cells. 
* p=0.01, ** p=0.001 vs. control cells; ‡ p=0.01,  ‡‡ p=0.003 vs haem loaded cells 
Ctl: control; Alg: 1% w/v alginate; Gav: 1% Gaviscon; Haem: 50µM haem solution 
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5.7 Haem loading oesophageal adenocarcinoma cell lines increases BrdU 
incorporation an effect suppressed by the addition of alginate 
To further explore the effects of haem upon oesophageal adenocarcinoma cell 
phenotype a  bromodeoxyuradine (BrdU) assay was used as an indicator of cell 
proliferation following culture with or without haem (fig 5.9). To further explore the 
effects of alginate and Gaviscon the experiment included the addition of these agents 
to control and haem loaded media (for each regime n=12).  
 
In OE33 cells the addition of haem significantly increased cellular BrdU incorporation 
relative to control (2.06 ± 0.08 vs. 1 ± 0.04; p=0.001). The addition of alginate resulted 
in non significant decreases in BrdU incorporation when added to control (0.96 ± 0.03 
vs. 1 ± 0.04; p=0.2) and haem loaded media (1.84 ± 0.16 vs. 2.06 ± 0.08; p=0.55). 
Addition of Gaviscon reduced BrdU incorporation relative to control (0.88 ± 0.08 vs. 1 ± 
0.04; p=0.04) and when added to haem loaded media (1.02 ± 0.1 vs. 2.06 ± 0.08; 
p=0.004), fig 5.9A.  
 
In OE19 cells again haem significantly increased cell BrdU incorporation relative to 
control cells (1.60 ± 0.12 vs. 1 ± 0.07; p=0.0001) whilst Gaviscon was associated with no 
significant difference in BrdU uptake compared to control cells (1.05 ± 0.06 vs. 1 ± 0.07; 
p=ns). When added to haem loaded media Gaviscon resulted in a significant decrease 
in BrdU incorporation (1.17 ± 0.04 vs. 1.6 ± 0.12; p=0.0001). Addition of alginate 
decreased BrdU incorporation compared to control (0.59 ± 0.12 vs. 1 ± 0.07; p=0.001) 
and to haem loaded media (0.73 ± 0.09 vs. 1.6 ± 0.12; p=0.00001), fig 5.9B.   
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Figure 5. 9.  Haem increases BrdU incorporation in OE33 cells (A) and OE19 cells (B), 
an effect largely inhibited by the addition of alginate or Gaviscon  
Cells were cultured for 48 hours in the presence of control media or a 1% alginate 
solution or 0.1% Gaviscon solution ± 50µM Haem (for each regime n=12). Haem 
significantly increased BrdU incorporation in both cell lines. The addition of Gaviscon to 
cells cultured in the presence of haem decreased BrdU incorporation significantly in 
both lines whilst the addition of alginate led to a significant decrease in OE19 and non 
significant decrease in OE33 cells lines.  
* p=0.04, ** p=0.001 vs. control cells; ‡‡ p<0.0001 vs haem loaded cells 
Ctl: control; Alg: 1% w/v alginate; Gav: 1% Gaviscon; Haem: 50µM haem solution 
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5.8 The effect of haem exposure upon the rate of cellular migration in oesophageal 
adenocarcinoma cell lines 
Elevated intracellular iron stimulates oesophageal adenocarcinoma cell proliferation, 
cell cycling and migration. We have observed that oesophageal adenocarcinoma cells 
import haem increasing cellular iron content. To further explore effects of haem upon 
cell phenotype migration was assessed by utilising a wound healing assay (fig 5.10). 
 
OE33 cells that were cultured in the presence of supplemental haem rapidly closed a 
large wound (fig 5.10A) at a significantly greater rate than control. There was no 
difference in the initial wound size (p=0.07). After 12 hours of culture 56.9 ± 8.9% of 
the control wound surface area remained vs. 29.9 ± 5.3% of wound surface area 
exposed to haem (p=0.007). After 24 hours of culture 26.0 ± 3.4% of control wound 
surface area remained vs. 3.0 ± 5.3% of wound surface area  cultured in haem 
(p=0.002).  
 
In OE19 cells again the addition of haem resulted in significantly greater cell migration 
(fig 5.10B). There was no difference in the initial wound surface area between groups 
(p=0.28). After 24 hours of culture 68.0 ± 5.0% of control wound surface area remained 
vs. 45.5 ± 8.5% of wound surface area exposed to haem (p=0.04). After 48 hours 52.1 ± 
5.5% of control wound surface area remained vs. 33.8 ± 8.8% of wound surface area  
cultured in haem (p=0.03). After 96 hours 23.1 ± 8.5% of control wound surface area 
remained vs. 8.6 ± 2.4% of wound surface area  cultured in haem (p=0.03). All wounds 
had closed after 120 hours. 
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Figure 5. 10.  Haem increases migration in oesophageal adenocarcinoma cells  
Confluent monolayers of OE33 (fig A) and OE19 (fig B) were wounded and cultured in 
control media (control) or media supplemented with 50µM haem. Cell migration and 
the rate of wound closure in both cell lines was greater when exposed to haem (* 
p<0.05, ** p<0.01; N = 6 for each regime)  
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5.9 The effect of haem exposure upon cell migration is inhibited by addition of 
alginate or Gaviscon 
Exposure of oesophageal adenocarcinoma cell lines to haem induces a greater rate of 
cell migration. To assess whether alginate or Gaviscon can affect this observation the 
wound healing assay was performed with cells grown in media stimulated with 50µM 
haem ± alginate (1% w/v LFR5/60 alginate) or Gaviscon (0.1% v/v) (fig 5.11).   
 
In OE33 cells the addition of alginate or Gaviscon to media supplemented with haem 
had no significant effect upon the rate of wound closure relative to cells cultured in 
media with supplemental haem alone (fig 5.11A). After 12 hours of culture 29.9 ± 4.8% 
of wounds exposed to haem remained vs 36.0 ± 5.4% haem + alginate (p=0.3) and vs. 
42.8 ± 9.8% haem + Gaviscon (p=0.27). After 24 hours of culture 3.1 ± 5.3% of wounds 
cultured in haem remained vs 9.6 ± 4.5% haem + alginate (p=0.78) and vs. 5.1 ± 6.4% 
haem + Gaviscon (p=0.37). After 36 hours all wounds cultured in the presence of haem 
alone had closed. At this point 2.4 ± 2.4% of haem + alginate wounds remained as did 
2.5 ± 4.6% of haem + Gaviscon; fig 5.11A. 
 
In OE19 cells the addition of either alginate or Gaviscon to culture media with haem 
resulted in a reduced rate of wound closure (fig 5.11B and fig 5.12). There was no 
difference in the initial wound size (haem vs haem + alginate p=0.27, vs. haem + 
Gaviscon p=0.24). After 24 hours of culture 45.5 ± 4.3% of wounds exposed to haem 
remained vs. 70.9 ± 4.3% haem + alginate (p=0.04) and vs. 76.1 ± 10.5% haem + 
Gaviscon (p=0.002). After 48 hours of culture 33.9 ± 8.5% of wounds cultured in haem 
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remained vs 55.4 ± 6.9% haem + alginate (p=0.08) and vs. 62.7 ± 4.6 haem + Gaviscon 
(p=0.006). After 72 hours of culture 19.1 ± 6.8% of wounds exposed to haem remained 
vs. 33.7 ± 7.6% haem + alginate (p=0.03) and vs. 46.9 ± 1.3% haem + Gaviscon 
(p=0.001). After 96 hours of culture 8.6 ± 2.4% of wounds cultured in haem remained 
vs 33.7 ± 5.5% haem + alginate (p=0.003) and vs. 20.9 ± 5.6 haem + Gaviscon (p=0.03). 
After 120 hours of culture all wounds cultured in haem had closed whilst 15.9 ± 8.0% 
haem + alginate remained (p=0.04) and vs. 6.15 ± 3.7% haem + Gaviscon (p=0.07); fig 
5.11B. 
 
 
Figure 5. 11.  The effect of adding alginate or Gaviscon to haem loaded media upon 
cell migration of oesophageal adenocarcinoma cells 
Confluent monolayers of OE33 (fig 5.11A) and OE19 (fig 5.11B) were cultured and 
subsequently wounded in media supplemented with 50µM haem or with supplemental 
LFR 50 alginate (1%w/v) or Gaviscon (0.1%v/v). The addition of alginate or Gaviscon 
reduced the rate of cell migration and thus wound closure in OE19 cells but not in OE33 
cells (*/‡ p<0.05, ** p<0.01; */** = haem + Gaviscon vs. haem; ‡ = haem + alginate vs. 
haem; N = 6 for each regime).  
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Figure 5. 12.  Representative images of wound healing in a confluent monolayer of 
OE19 cells with haem +/- supplemental alginate or Gaviscon  
Cells were cultured in media supplemented with 50µM haem or with supplemental 
LFR50 alginate (1% w/v) or Gaviscon (0.1% v/v).  
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5.10 The effect of elevated haem exposure upon anchorage independent growth of 
oesophageal adenocarcinoma cells 
To further explore effects of haem upon cell phenotype a colony forming assay was 
performed (figs 5.13 and 5.14). Single cell agar suspension (1x105/ml) was seeded in 6 
well plates (N=6 each regime) and cultured for 14 days. 3 photographs at random were 
taken of each well and the surface area of colonies measured within each photograph. 
Results are expressed as the mean surface area ± 2SEM. 
 
In OE33 cells haem exposure increased the average size of colonies compared to 
control (12084 ± 3329 vs. 5564 ± 1038 µM 2, p=0.05). The addition of alginate or 
Gaviscon decreased colony size relative to control (2514 ± 1014 and 2250 ± 840 vs. 
5564 ± 1038 µM2 respectively, both p<0.0001). The addition of alginate or Gaviscon to 
haem loaded media decreased colony size relative to both haem loaded and control 
media (2526 ± 1699 and 2594 ± 1798 µM 2 for haem + alginate and haem and Gaviscon 
vs. haem [12084 ± 3329 µM 2] both p<0.00001 and vs control [5564 ± 1038 µM2] both 
p<0.0001. Fig 5.13 A and B. 
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In OE19 cells haem exposure increased the average surface area of colonies compared 
to control (13481 ± 1745 vs. 5556 ± 1413 µM2, p=0.000005). The addition of alginate or 
Gaviscon had no significant effect upon the size of colonies relative to control (5281 ± 
2180 and 6241 ± 2457 respectively vs. 5556 ± 1413 µM2, both p=NS). The addition of 
alginate or Gaviscon to haem loaded media resulted in a decrease in colony size 
relative to haem loaded media (5978 ± 2169 and 5013 ± 2598 µM2 for haem + alginate 
and haem + Gaviscon vs. 14179 ± 2878 µM2 both p<0.0001). This was comparable to 
colonies grown in control media ± alginate or Gaviscon (both p=NS). Fig 5.14 A and B. 
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Figure 5. 13.  Colony forming assay with OE33 adenocarcinoma cells 
Cells were cultured in control media or media supplemented with 50µM haem ± 
additional alginate (1% W/V) or Gaviscon (0.1% V/V). Colonies were measured (fig 
5.13A) and photographed (fig 5.13B, representative colonies demonstrated by arrows) 
14 days after seeding a single cell suspension.  
* p<0.01; ** p<0.00001 vs. control; ‡ p<0.00001 vs. haem.
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Figure 5. 14.  Colony forming assay OE19 adenocarcinoma cell line 
Cells were cultured in control media or media supplemented with 50µM haem ± 
additional alginate (1% w/v) or Gaviscon (0.1% v/v). Colony surface areas were 
measured (fig 5.14A) photographed (fig 5.14B, representative colonies demonstrated 
by arrows) 14 days after seeding a single cell suspension. 
* p=0.00005 vs control. 
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5.11 The effect of haem exposure upon haem and iron transport proteins in 
oesophageal adenocarcinoma cell lines 
Since haem appears to alter cellular iron metabolism and cell phenotype, the effect of 
haem on the expression of the pertinent cellular iron and haem transport proteins was 
assessed by qRT-PCR in the cell lines OE19 and OE33. (N=3 for each regime and then 
run in triplicate. Results are expressed as the mean fold change ± 2SEM). 
 
5.11.1 Expression of haem transport proteins following exposure to haem 
A significant reduction in LRP-1 mRNA expression was observed in both cell lines 
following culture with haem supplemented media compared to cells cultured in control 
media. There was a significant reduction in the expression of HCP-1 mRNA in OE33 but 
a non-significant decrease was seen in OE19 cells (data expressed in table 5.1 and as a 
figure in 5.15A). 
 
5.11.2 Expression of pertinent iron transport proteins following exposure to haem 
Significant increases in both TfR and DMT1 mRNA expression was observed in both 
OE33 and OE19 cell lines. There was no significant difference in ferritin expression 
between either line. A significant decrease in ferroportin expression was observed in 
OE19 cells though there was no significant decrease in OE33 cells (data expressed in 
table 5.1 and as a figure in 5.15B). 
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5.11.3 c-myc expression in oesophageal adenocarcinoma cells following exposure to 
haem 
Induction of c-myc mRNA expression was observed when cell lines were cultured in 
media with supplemental iron. To explore whether haem exposure would alter c-myc 
expression qRT-PCR was performed on OE19 and OE33 cells following culture with 
haem. Significant increase in c-myc mRNA expression was observed in both cell lines 
following culture with haem (data expressed in table 5.1 and as a figure in 5.15C). 
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 OE33  OE19  
 CONTROL 
HAEM 
LOAD 
P CONTROL 
HAEM 
LOAD 
P 
LRP-1 1±0.18 0.27±0.13 <0.001 1±0.15 0.6±0.20 0.01 
HCP-1 1±0.18 0.64±0.11 0.02 1±0.07 0.7±0.22 ns 
TfR 1±0.03 1.9±0.19 <0.01 1±0.12 2.28±0.31 <0.01 
DMT1 1±0.36 1.75±0.23 0.02 1±0.26 1.76±0.18 0.01 
Ferritin 1±0.24 0.65±0.28 ns 1±0.14 1.33±0.57 ns 
Ferroportin 1±0.20 0.82±0.05 ns 1±0.12 0.37±0.22 0.02 
c-Myc 1±0.32 2.25±0.11 <0.01 1±0.32 4.12±0.58 <0.001 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. 1 and Figure 5. 15. mRNA expression of pertinent iron and haem transport 
proteins and c-myc in OE33 and OE19 cell lines following culture with haem 
Cells were cultured in control media or media supplemented with 50µM haem for 3 
hours. Significant repression of LRP-1 (OE33, OE19), HCP-1 (OE33) and ferroportin 
(OE19) and induction of TfR, DMT1 and c-myc (OE33, OE19) mRNA was observed. 
Values are mean expression ± 2SEM * p<0.05, ‡ p<0.01  
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5.12 Modulating LRP-1 expression affects haem and iron metabolism and cell 
phenotype in oesophageal adenocarcinoma 
Having observed the novel expression of LRP-1 in OAC tissue and cell lines suppression 
of the functional protein was performed to identify effects upon haem transport, 
cellular iron storage and cell behaviour. Suppression of expression was achieved by 
transfection with shRNA. The OE33 line would not transfect using conventional 
transfection reagent kits or with electroporation techniques and thus OE19 cells were 
used for the majority of the following experiments. Knockdown of LRP-1 expression 
was performed by transiently transfecting cells with shRNA plasmids (3 potential 
plasmids were assessed and the plasmid producing the most effective knockdown was 
used in subsequent experiments). As the OE19 cell populations typically achieved a 
maximum transfection efficiency of 5-10% the population was first passed through a 
sterile cell sorting process using FACS assessment of GFP expression with subsequent 
selection of only cells that had been successfully transfected with plasmid. Control cells 
were transfected with a plasmid encoding expression of GFP in addition to a scrambled 
non-functional LRP-1 sequence. 
 
5.12.1 Evidence of successful LRP-1 knockdown 
OE19 cells transfected with LRP-1 shRNA or scrambled LRP-1 shRNA were analysed for 
LRP-1 expression. Haem oxygenase-1 mRNA expression was also quantified as a 
measure of haem import and subsequent metabolism. qRT-PCR analysis demonstrated 
no significant effect upon LRP-1 mRNA expression (1 ± 0.06 vs 1.20 ± 0.12, p=ns) but a 
significant reduction of HO-1 mRNA expression (1 ± 0.07 vs 0.43 ± 0.05, p=0.006) (fig 
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5.16). Assessment of LRP-1 protein expression by western blotting demonstrated 
successful knockdown of LRP-1 protein (table 5.2 and fig 5.17).  
Further analysis of LRP-1 function was assessed by zinc protoporphyrin uptake. A mixed 
population of non-transfected cells and cells transfected and with LRP-1 shRNA were 
exposed to zinc protoporphyrin (ZnPP) for 1 hour. Images were taken of the cells 
demonstrating transfection (with successfully transfected cells demonstrating green 
fluorescent protein expression). This was followed by images of the same field of view 
demonstrating ZnPP uptake (with cells internalising ZnPP demonstrating red 
fluorescence) and compared (fig 5.18). Transfected cells with LRP-1 knockdown 
imported less ZnPP than non-transfected cells. 
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Figure 5. 16. mRNA expression following LRP-1 knockdown in OE19 cells 
OE19 cells were transiently transfected with a plasmid to knockdown LRP-1 expression. 
No significant effect upon LRP-1 mRNA expression was observed but a significant 
repression of HO-1 was observed (*p =0.006).  
 
 
 
Normalised 
protein 
expression 
p 
value 
Control 1 ± 0.23 
0.002 
LRP-1 
knockdown 
0.42 ± 0.17 
 
Table 5. 2 and Figure 5. 17. LRP-1 western blot analysis following LRP-1 shRNA 
knockdown in OE19 cells 
A significant repression of LRP-1 protein expression was observed following LRP-1 
knockdown (n=3, p=0.002).  
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Figure 5. 18. Images of a mixed population of LRP-1 knockdown and untransfected 
OE19 cells following exposure to the haem analogue ZnPP 
Images were taken under light microscopy (x40). Successfully transfected cells are 
observed fluorescing green (white dots) (fig 5.18 A). Cells that had not been 
successfully transfected with LRP-1 knockdown would not fluoresce green. Figure 5.18 
B demonstrates ZnPP fluorescence and it can be observed that the successfully 
transfected cells demonstrate little ZnPP fluorescence whilst non-transfected cells 
(white arrows) demonstrate marked ZnPP fluorescence. 
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5.12.2 LRP-1 knockdown inhibits cellular uptake of haem55Fe 
 Successfully transfected control and LRP-1 shRNA OE19 cells were passed through a 
sterile cell sorter and, reserving only those strongly expressing GFP (top 5% of cells 
expressing GFP), placed into a 12 well plate. After 24 hours of cell culture a 50µM haem 
solution containing 1% haem55Fe was added to the wells. After 2 hours the media was 
aspirated and kept. The cells were washed, trypsinised and the cell pellet resuspended 
in scintillant. Both media and cells were independently analysed by radiation 
scintigraphy. 
 
Within the cell pellets of LRP-1 knockdown cells there was significantly lower 
radioisotope activity relative to sham knockdown cells (mean sum of disintegrations 
per minute (DPM-1) was 1201 ± 51 vs. 1755 ± 48 DPM-1 respectively, p=0.001) (fig 
5.19A). This data was normalised to the protein content of the wells as assessed by BCA 
protein assay. Correspondingly media aspirated from wells containing LRP-1 
knockdown cells had a significantly higher DPM-1 count than media taken from control 
cells (28045 ± 2563 vs. 20600 ± 364 DPM-1, p=0.001) (fig 5.19B). 
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Figure 5. 19.  Knockdown of LRP-1 in OE19 cells inhibits uptake of haem55Fe 
LRP-1 shRNA knockdown resulted in a significant reduction of radiolabelled haem 
uptake by cells (fig A) and correspondingly a significantly greater level of haem55Fe in 
aspirated culture media (fig B) compared to cells transfected with sham shRNA.  
DPM-1 - disintegrations per minute * p=0.001 
 
5.12.3 LRP-1 knockdown decreases cellular iron content and proliferation in 
oesophageal adenocarcinoma cells 
To identify effects of repressing LRP-1 expression upon cellular iron content and 
proliferation ferrozine and BrdU assays were performed respectively. Due to the 
numbers of cells required for these experiments it was necessary to use alternative cell 
lines as OE33 cells would not transfect and the highest yield of transfection using OE19 
cells was 10%. It was not financially viable to pass such a volume of cells through a cell 
sorter. These experiments were performed upon the mixed populations of non-
transfected and transfected OE19 cells but demonstrated no significant difference, 
presumably, due to the majority of untransfected cells. 
The oesophageal squamous cancer cell line OE21 and the line Seg-1 were used in the 
following experiments. At the time of writing this thesis it was reported that the cell 
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line Seg-1 is in fact a lung cancer derived cell line[349] and not derived from 
oesophageal adenocarcinoma as was previously thought. Following transient 
transfection successful repression of LRP-1 was demonstrated by western blotting 
(data not shown). 
 
5.12.3.1 LRP-1 knockdown decreases cell iron content in oesophageal 
adenocarcinoma cells 
24 hours following cell transfection media was supplemented with a 50µM solution of 
haem. After a further 24 hours of cell culture a ferrozine assay demonstrated a 
significant reduction in iron content in both cell lines (Seg-1: LRP-1 knockdown 1563 ± 
70 vs control 2245 ± 121 ng Fe/µg protein, N=6, p<0.0001; OE21: LRP-1 knockdown 420 
± 7 vs control 848 ± 97 ng Fe/µg protein, N=6, p=0.001) (fig 5.20 A). 
 
5.12.3.2 LRP-1 knockdown decreases cell proliferation in oesophageal 
adenocarcinoma cells 
24 hours following cell transfection media was supplemented with a 50µM solution of 
haem. After a further 6 hours of cell culture a BrdU assay demonstrated a significant 
reduction in proliferation in both cell lines (Seg-1: LRP-1 knockdown 0.82 ± 0.06 vs 
control 1 ± 0.09, N=6, p=0.05; OE21: LRP-1 knockdown 0.52 ± 0.08 vs control 1 ± 0.13, 
N=6, p<0.0001) (fig 5.20 B). 
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Figure 5. 20.  Knockdown of LRP-1 in tumour cell lines decreases cellular iron content 
and inhibits proliferation 
OE21 and Seg-1 cell lines were transiently transfected with LRP-1 shRNA resulting in a 
significant decrease in cell iron content (31 ± 4% vs control in Seg-1 cells, p=0.001 and 
51 ± 2% vs control in OE21 cells, p<0.0001; fig 5.20 A). 
A significant reduction in cell proliferation was also observed (18 ± 6% vs control in Seg-
1 cells, p=0.05 and 48 ± 8% vs control in OE21 cells, p<0.0001; fig 5.20 B). *p=0.05, 
**P≤0.001 
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5.13 Conclusions 
The finding that oesophageal adenocarcinoma tissue expresses haem import proteins 
HCP-1 and LRP-1 is novel. There is little background expression of these proteins in 
native squamous oesophagus or Barrett’s metaplasia from samples of non-dysplastic 
tissue. There appears to be a stage in the progression of early Barrett’s metaplasia to 
Barrett’s tissue associated with oesophageal adenocarcinoma where the expression of 
these proteins increases. The occurrence of this observed increase in expression is 
interesting as the triggers for stable Barrett’s epithelium to become dysplastic and give 
rise to adenocarcinoma are not known. In oesophageal adenocarcinoma expression of 
the import proteins is strongest and it is likely they mediate haem import which could 
provide an alternative source of iron[228;242] to inorganic iron captured by transferrin 
receptor overexpression. Iron can be utilised by cancer cells for energy production, cell 
cycle control and DNA synthesis[160;250]. Presumably liberated iron is also 
responsible, directly or indirectly, for the increased rates of proliferation, migration 
and anchorage independent growth that have been observed in this body of work. 
There are other potential candidates that may mediate this effect following haem 
exposure. Culturing oesophageal adenocarcinoma cells with haem induces haem 
oxygenase 1 (HO-1) expression to metabolise the degradation of haem to liberate free 
iron. HO-1 induction has been identified in various tumours where overexpression of 
the protein is associated with increased tumour burden[380-382] and conversely 
repression decreases tumour growth[381;383-385]. HO-1 levels influence cell 
proliferation directly in animal and in-vitro models and may represent an alternative 
mechanism of inducing a malignant phenotype following haem exposure. In pancreatic 
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adenocarcinoma inhibiting HO-1 via siRNA decreases tumour cell proliferation[383] 
whilst overexpressing HO-1 mRNA increases proliferation[382]. HO-1 can repress the 
function of the cyclin dependent kinase inhibitor p21[382;386;387] and is associated 
with an increased production of epidermal growth factor[382]. HO-1 expression is 
associated with angiogensis in-vitro and in-vivo. HO-1 knockout is associated with 
decreased expression of vascular endothelial growth factor (VEGF) compared to wild 
type endothelial cells[388]. Overexpression of HO-1 however is associated with 
increased VEGF expression and enhanced capillary formation in collagen gel[389]. In a 
rat ischaemic limb model HO-1 gene transfer was associated with augmented levels of 
VEGF, angiogenesis and improved muscle blood flow[99]. 
The LRP-1 receptor has diverse ligands[243] but from the experiments presented here 
including shRNA knockdown of protein expression it is clearly demonstrated that LRP-1 
has an important role in oesophageal adenocarcinoma cells acquiring haem. It is 
important to appreciate the complex activity of the LRP-1 receptor given that it 
captures up to 30 other ligands[243]. Thus the relevance of LRP-1 overexpression in 
oesophageal adenocarcinoma is complex but one might hypothesise that it represents 
a mechanism of cellular haem capture and aids progression of malignant disease. More 
broadly speaking the role of LRP-1 in cancer is unclear with evidence that LRP-1 
expression has pro- or anti-tumour activity. LRP-1 regulates extracellular proteolysis 
via its actions upon serine proteases and matrix metalloproteinases[390]. Increased 
expression of LRP-1 has been associated with a less invasive phenotype[391] whilst 
anti-LRP-1 IgG increases levels of matrix metalloproteinase-2[392]. Others, however, 
have associated LRP-1 repression with decreased tumour invasiveness[393;394]. LRP-1 
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silencing in thyroid follicular cells prevented invasion despite increases in proteolytic 
enzymes[395] suggesting LRP-1 mediated affects tumour invasion are in part due to as 
yet uncharacterised mechanisms. Haem could be a candidate having observed 
increased expression of LRP-1 in oesophageal adenocarcinoma and increased 
migration and anchorage independent growth. What is clear is that the role of LRP-1 
had diverse functions, many of which remain to be fully understood.  
The role of HCP-1 is also unclear. Initial evidence pointed to a role in haem import by 
intestinal cells[230]. However knockout studies had little effect upon haem import 
suggesting alternative pathways of uptake[230], presumably via LRP-1, and further 
work demonstrates a more likely role as a folate transporter[396]. For these reasons 
LRP-1 is considered the most important haem import protein and thus the focus of 
attention of knockout studies performed here. Knockout of HCP-1 expression would 
have been desirable but was not performed due to a lack of time and financial 
resource.  
 
It is interesting to observe an increase in transferrin receptor and divalent metal 
transport protein mRNA expression following exposure to haem. Intracellular haem 
binds to iron regulatory proteins marking the complex for degradation. This would 
result in repression of iron import protein expression and thus an alternative 
mechanism of control over their expression must be present.  
 
It is interesting that alginates inhibit haem mediated effects upon cell phenotype. The 
ability of alginates to bind divalent metals[335] is described as is the binding of toxins 
  
201 
 
including dioxins, heterocyclic amines and bile acids to fibres[319-323]. Prevention of 
haem mediated effects via presumed binding with alginate provides further evidence 
of the potential therapeutic platform of this compound. 
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CHAPTER 6: DISCUSSION 
 
6.1 Conclusions  
From results presented in this thesis it is clear that the expression of iron transport 
proteins and requirements for iron by oesophageal adenocarcinoma differs to that of 
native benign tissue. This is an exciting though not surprising observation as iron is 
essential for cell cycling, enzyme production, energy generation, proliferation and 
growth[160-162]. The observation of transferrin receptor overexpression in 
oesophageal adenocarcinoma has not been published previously though authors have 
observed this in other tumours (breast[166;250], colorectal adenocarcinoma[251], 
glioma[252], non-Hodgkins lymphoma[253], chronic lymphoid leukaemia[254], lung 
adenocarcinoma[255], gynaecological tumours[256], renal transitional cell 
carcinoma[257], cervical carcinoma[258], melanoma[259], hepatocellular 
carcinoma[260] and hepatoblastoma[261]).  
A more complete description of the remaining iron transport machinery given here 
allows greater insight into how tumour cells acquire and utilise iron. In addition to 
changes in the expression of transferrin receptor it is apparent that several of the 
other iron transport proteins are also altered in the process of tumorigenesis. Most 
notably our studies have suggested that ferroportin, which is normally located at the 
basal cell border (for its appropriate export function), is relocalised to a cytoplasmic 
location. This is likely to render the protein inactive. The process of ferroportin 
relocalisation has previously been reported in colorectal adenocarcinoma[251]. 
However the exact trigger for this event remains elusive. The most likely candidate for 
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mediating this relocalisation is the anti-microbial peptide hepcidin[213;357]. The 
finding that oesophageal adenocarcinoma cells express hepcidin is exciting. In health 
hepcidin is produced by the liver and controls systemic levels of iron. Local production 
of hecidin by tumour cells may be an autrocrine mechanism of cellular iron loading by 
preventing cellular efflux on the background of trasnferrin receptor and LRP-1 
overexpression.  
A further interesting observation is the paradoxical increased expression of transferrin 
receptor and divalent metal transport protein-1 following culture in the presence of 
supplemental iron or haem. This contradicts how cells should respond to an iron load 
via an appropriate IRE/IRP response. Following iron loading IRP2 levels would be 
expected to decrease with a subsequent decrease in TfR1 and DMT1 mRNA expression 
through increased degradation[204;397] which was not observed. In these 
experiments this is associated with an increased expression of the oncogene c-myc. In 
an elegant series of experiments[366;397] my laboratory co-workers were able to 
demonstrate that overexpressing c-myc reproduces the expression profile of elevated 
TfR1 and DMT1 seen following iron exposure in colorectal adenocarcinoma. 
Furthermore they associated c-myc overexpression with loss of APC function. Using an 
inducible APC plasmid in a colorectal cell line with truncated APC (SW480), elevated 
levels of TOPFLASH reporter assay indicated activation of the β-catenin/TCF signalling 
pathway following exposure to iron or haem. This occurred only in the native cell type 
but no activation was observed following restoration of APC function. An associated 
increase in expression of c-myc was observed within mutant APC cells but not those 
with reinstated APC function. In this work we have observed that both OE33 and OE19 
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cell lines possess inactive APC and thus it seems plausible that iron and haem 
mediated effects in oesophageal adenocarcinoma may be in part via β-catenin/TCF 
signalling. 
 
The expression of HCP-1 and LRP-1 in Barrett’s metaplasia and oesophageal 
adenocarcinoma is a novel finding. This is a complex issue given the paucity of clear 
evidence as to how cells handle haem in health[191;228-230;242] let alone in 
malignant disease. By acquiring iron through haem import pathways cells can access a 
significant pool of circulating iron[242].  Characterising their expression in malignant 
disease and identifying that oesophageal adenocarcinoma cells can metabolise haem 
adds to the plethora of evidence implicating iron with carcinogenesis but also brings 
many unanswered questions. What is the functional significance and relative 
contribution of iron acquired via haem pathways rather than conventional transferrin 
bound iron? Is haem transport overexpression a feature of other tumour types? Are 
there other roles of HCP-1 and LRP-1? HCP-1 takes up folate with great affinity from 
the intestine and may play a more important role in folate, rather than haem, 
transport. LRP-1 has many ligands and functions. By knockdown studies we have 
observed that it does play an important role in haem transport but does LRP-1 
overexpression mediate other, non iron, pathways in oesophageal adenocarcinoma? 
 
The trigger for HCP-1 and LRP-1 expression is not clear. There appears to be a stage 
between non-dysplastic Barrett’s epithelium and Barrett’s epithelium associated with 
oesophageal adenocarcinoma where expression of both transporters becomes 
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apparent. Very little background expression of either transporter was evident in 
samples of benign BM whilst samples of BM adjacent to OAC demonstrated strong 
expression whilst OAC cells themselves express most strongly. There appears to be a 
similar change in expression profile of inorganic iron transport proteins at the same 
stage in the metaplasia-adenocarcinoma sequence. Key genetic events known to occur 
with high frequency at this stage in the progression of BM to OAC include APC 
methylation[69;70], loss of p53 function[80;83], p16 methylation[63-65;398], loss of 
p27 function[86] and overexpression of cyclin D1[71;72]. Loss of APC function would 
be a good candidate. Inactivation of tumour suppressor genes p53, p27 and p16 are 
less likely candidates. They perform house-keeping of the cells genome triggering 
apoptosis[81] or control progression of cell cycle inhibiting clonal expansion of stem 
cells or by acting as a CDK inhibitor[65;86] . APC inactivation, however, is known to 
have downstream effects mediated via dysregulation of β-catenin/TCF signalling 
pathway resulting in overexpression of oncogenes such cyclin D1 and the oncogene c-
myc. Cyclin D1 regulates the cell cycle by inactivating the retinoblastoma protein and is 
thus an unlikely candidate. Overexpression of c-myc is however a possible downstream 
candidate and has been discussed above.  
 
Although imported via independent routes exposure to transferrin bound iron or haem 
iron yield remarkably similar responses by the cells. In epidemiological studies haem 
iron is more strongly associated with oesophageal adenocarcinoma[282] in addition to 
other epithelial tumours such as colorectal[282] and breast[284;285]. Furthermore 
recent evidence suggests that organic iron is absorbed more avidly from the 
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gastrointestinal tract than inorganic iron[228]. There is also an inherent protective 
effect with some foods high in inorganic iron; vegetables are relatively high in 
antioxidants which would counteract the actions of reactive oxygen species and the 
associated fibre could bind iron within the intestinal lumen and increase transit 
time[312;318]. Alginates are an example of a polysaccharide which can strongly bind 
iron within the GI tract and result in its excretion[347]. Diets high in alginate are 
associated with decreased incidence of colorectal[336], oesophageal[337] and breast 
cancers[338]. Furthermore being natural products, cheap and readily available they 
have commercial value. We have observed that alginate or Gaviscon inhibit both iron 
and haem mediated effects upon proliferation, migration and anchorage independent 
growth. This lends weight to the rational for iron chelation as a therapy against 
malignant disease. However in what form or at which stage of disease alginates could 
provide benefit in treating oesophageal adenocarcinoma is less clear. We have 
observed that iron mediates increased proliferation and oncogene expression in 
oesophageal adenocarcinoma. It would seem likely that the addition of dietary alginate 
at this stage of disease would provide little clinical benefit as patients have advanced 
disease and a poor prognosis. Systemic chelation may provide a temporary benefit for 
example using desferroxamine but it is difficult to hypothesise that alginate would 
have a beneficial effect such as that seen in the epidemiological studies above. 
Perhaps alginates can provide protection at an earlier stage in the progression of 
oesophageal adenocarcinoma. In rat models of oesophageal adenocarcinoma 
gastroesophageal reflux alone did not result in metaplastic change and subsequent 
development of OAC. Only when animals were given supplemental iron did this 
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occur[147-149]. Thus in patients with reflux disease a potential therapeutic study 
could involve the randomised administration of dietary alginate or placebo and an 
observation of the rates of progression to Barrett’s epithelium and oesophageal 
adenocarcinoma. 
 
Oesophageal adenocarcinoma incidence is increasing at a rate greater than any other 
malignant disease in Western populations. Obesity and gastroesophageal reflux 
disease are strongly linked. Accumulating evidence defines the genetic defects 
associated with the disease but oesophageal adenocarcarinoma remains a challenge to 
science and modern medicine. Understanding the differential expression of iron and 
haem transporters allows an appreciation of the importance iron metabolism plays in 
oesophageal adenocarcinoma. Utilising the differential expression of these 
transporters between malignant and benign tissue may pave the way for novel 
therapeutic strategies to deliver chemotherapeutic agents. A more simple approach 
would be to bind iron within the gastrointestinal tract by the use of alginates. This 
strategy may benefit subjects with high risk lifestyle factors. 
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6.2 Future work 
6.2.1 Laboratory experimental work 
To clearly understand the role of iron and aberrant β-catenin/TCF signalling in 
oesophageal adenocarcinoma cells it would be desirable to overexpress c-myc, IRP2 or 
to restore APC function in appropriate cell lineages. This would require an oesophageal 
adenocarcinoma cell line whose population would successfully undergo a high rate of 
transient transfection or to develop an alternative strategy for transfection of either 
OE19 or OE33 cell lines.  
Utilising singly or in combination the overexpression of the transferrin, HCP-1 and or 
LRP-1 receptors to deliver targeted chemotherapeutic agents to OAC cells and 
populations of benign cells to calculate the IC50 and LD50 would provide evidence to 
support the wider application of agents to include human phase 1 and 2 clinical trials.  
 
6.2.2 Clinical experimental work 
A randomised trial of alginate use in subjects with risk factors for developing Barrett’s 
metaplasia and oesophageal adenocarcinoma would be exciting. Being naturally 
occurring compounds they would not need to undergo as extensive testing prior to 
use. Furthermore they are cheap and readily available. If benefit could be proven they 
would likely be well tolerated by people who prefer natural compounds to 
pharmaceutical ones. 
There is no reason to limit the focus of iron to oesophageal adenocarcinoma. 
Increasing evidence associates iron with breast and hepatocellular cancer.  
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